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Psoriasis drug failure rates of biologics compared to conventional systemic therapies
S Au,1 AA Levin1,2 and AB Gottlieb1,3 1 Tufts Medical Center, Boston, MA, 2 Boston University 
School of Medicine, Boston, MA and 3 Tufts University School of Medicine, Boston, MA
The purpose of this study is to compare drug survival time and reasons for discontinuation of 
biologics and traditional systemic therapies for chronic plaque psoriasis. All patient visits with a 
code for psoriasis (ICD-9 696.1) for two dermatologists in a clinical practice from Jan 1, 2008 to 
Jan 4, 2012 were included in this retrospective data analysis. Patients were divided by treatment 
type (biologic or conventional systemic) and history of previous treatments. Treatment failure was 
defined as treatment discontinuation. Patient time to failure for each therapy was calculated, as 
well as the treatments failed, concomitant therapy, age and gender. Reasons for failure were col-
lected from the chart and clinical data. Kaplan–Meier estimates and Cox regression analysis of the 
cumulative probability of withdrawal from treatment were obtained. 162 patients with 340 courses 
of treatment were studied. 107 biological courses and 74 conventional systemic courses ended in 
treatment failure. Treatment failure rates were: Infliximab, 61% failed after an average of 292 days; 
Etanercept, 58% failed after an average of 237 days; Adalimumab, 43% failed after an average of 
256 days; Ustekinumab, 26% failed after an average of 177 days; Golimumab, 100% failed after 
an average of 210 days; Methotrexate, 68% failed after an average of 129 days. Overall, 48% of all 
biologics courses were terminated due to loss of efficacy after an average of 242 days, versus 64% 
of all conventional systemic courses were terminated after an average of 143 days. In conclusion, 
biologics are shown to have superior drug survival in clinical practice as compared to conventional 
systemic therapies. Within the biologics, golimumab had the highest failure rate, while ustekinumab 
had the lowest failure rate but the shortest time to loss of response. The most common reason for 
failure was loss of efficacy, and time until failure was influenced by number of previous failures.   
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Oxidative stress-induced CXCL16 production mediated CD8+ T cells trafficking in vitiligo
S Li, S Guo, Q Shi, R Ge, J Ma, G Wang, T Gao and C Li Dermatology, Xijing Hospital, Xi, 
China
Background: Reactive oxygen species (ROS) and autoimmunity interact synergistically, leading to the 
final destruction of melanocytes in vitiligo. However, how ROS induce the production of chemok-
ines and recruit CD8+ T cells to the skin, eventully destroy the melanocyte by cellular autoimmunity 
to is not clear. Objective: We tested the hypothesis that oxidative stress might induce CXCL16 pro-
duction, causing skin recruitment of CXCR6+ CD8+ T cells, which results in melanocytes destruction 
in vitiligo and halo nevus. Methods: The CXCR6+ CD8+ T cells, CXCL16 expression, and hydrogen 
peroxide (H2O2) concentration was detected in patients. Primary keratinocytes were cultured with 
H2O2, and/or various other cytokines, or a short interfering RNA (siRNA) for NF-κB to analyze the 
expression of CXCL16. Moreover, the functional effect of H2O2- induced CXCL16 was investigated. 
Results: We found the peripheral blood and skin CD8+ T cells expressing CXCR6, and the CXCR6 
ligand CXCL16 were higher in vitiligo and halo nevus patients than in healthy individuals. In addi-
tion, the increased CXCL16 levels in lesion correlated with epidermal H2O2 concentration in both 
vitiligo and halo nevus. In cultured keratinocytes, H2O2 induces the gene and protein expression 
of CXCL16, and augmented the IFN-γ and/or TNF-α–induced CXCL16 production. Furthermore, the 
siRNA against nuclear factor kB (NF-κB) significantly inhibited its production, suggesting NF-κB as 
important signaling molecules of H2O2. Furthermore, H2O2- induced CXCL16 promoted chemo-
tactic migration of vitiligo blood-derived CD8+ T cells in vitro. Conclusion: H2O2 is a potent inducer 
of CXCL16 in keratinocytes via NF-κB, supporting its regulatory role in CD8+T cells trafficking, and 
thereby contribute to melanocyte aotoimmune destruction in vitiligo and halo nevus.    
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CCR6 antagonist confers protection against psoriasiform-like disease in mice by limiting the 
infiltration of CCR6-positive leukocytes into the epidermis
J Tan, K Ebsworth, R Berahovich, M Leleti, P Zhang, DJ Dairaghi, TS Schall and MJ Walters 
Chemocentryx, Mountain View, CA
Dysregulated IL17 expression is well characterized in several autoimmune diseases including psori-
asis. Several reports indicate that the majority of IL17-secreting cells in human and mice co-express 
the chemokine receptor CCR6, thereby making it an attractive drug target. We have generated 
an orally bioavailable CCR6 antagonist, CCX9664 that inhibited CCL20-mediated chemotaxis of 
both human and mouse CCR6-positive cells. The utility of CCR6 blockade was tested in the IL-23 
mediated preclinical model of psoriasis where CCX9664 conferred protection against ear thickening 
in both prophylactic and therapeutic dosing regimens. CCR6 inhibition also dampened inflamma-
tory signatures associated with psoriasis in this model. Mechanistic studies were performed using 
imiquimod-induced psoriasiform-like disease where CCX9664 also provided protection against skin 
thickening and scaling. Here we showed that administration of our CCR6 antagonist significantly 
decreased the number of CCR6-positive leukocytes in the epidermis (Vehicle: 3.7x105±3.8x104 
versus CCX9664: 1.2x105±1.6x104) but not dermis (Vehicle: 9.4x105±9.2x104 versus CCX9664: 
8.9x105±1.7x105) including both αβ and γδ T cell subsets. Decrease in the γδ T cell subset was 
limited to the motile Vγ3-negative population that was thought to contain IL17-secreting T cells. 
Consistent with this observation, we detected fewer IL17-positive cells in the epidermis via immu-
nofluorescence staining. Thus, rather than prevent IL-17 signaling, CCX9664 disrupts the movement 
of infiltrating leukocytes into the epidermis thereby limiting psoriasis-like changes in the mouse 
skin. Cumulatively, these studies provide validation for CCR6 inhibition as a potential therapy 
against psoriasis.    
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Unique miRNAs appear at different times during the course of a delayed-type hypersensitivity 
(DTH) reaction in human skin
N Gulati,1 M Løvendorf,2,3 JR Zibert,2 WR Levis,4 N Renwick1 and JG Krueger1 1 The 
Rockefeller University, New York, NY, 2 LEO Pharma A/S, Ballerup, Denmark, 3 University 
of Copenhagen, Hellerup, Denmark and 4 New York University, New York, NY
Diphencyprone (DPCP) is a hapten that induces DTH reactions in human skin. miRNAs are short, 
endogenous non-protein coding RNAs that regulate gene expression and have been implicated in 
various inflammatory skin diseases such as psoriasis and atopic dermatitis, but their role in DTH reac-
tions is not well understood. To determine how DPCP activates the immune system, we generated 
global miRNA profiles (via sequencing, with validation by quantitative RT-PCR) of DPCP challenge 
reactions in skin of 7 healthy volunteers (open label design) at 3 (classic DTH peak response), 14, 
and 120 days after challenge. Compared to placebo-treated sites, DPCP-challenged skin at 3 days 
had a distinct miRNA signature with 127 miRNAs being significantly deregulated (false discovery 
rate<0.05). At 14 days (during resolution of clinical inflammation), 43 miRNAs were deregulated 
and, surprisingly, at 120 days (when clinical inflammation had completely resolved), there were 
6 miRNAs upregulated. Some of the top upregulated miRNAs at both days 3 and 14 (but not day 
120), such as miR-21, -142-3p, -142-5p, and -223, are known to be related to T cells and T cell 
activation, in agreement with the presumed pathogenesis of DTH reactions. While some miRNAs 
have also been found in psoriasis, most of the deregulated miRNAs have not yet been studied in 
the context of skin biology or immunology. Across the three timepoints studied, many but not all 
miRNAs were uniquely expressed at certain timepoints, and one miRNA in particular (-140-5p) 
progressively increased expression over time. As numerous miRNAs map to regulation of mRNAs 
activated/repressed by DPCP, this may indicate that the miRNAs exclusively expressed at different 
timepoints function to promote or resolve skin inflammation, and therefore may inform on the 
paradoxical ability of DPCP to treat both autoimmune conditions (alopecia areata) and conditions 
of ineffective immunity (melanoma).    
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Physiological modeling offers a valuable tool in early drug development for acne targets
EG Kang,1 S Frey,1 K Kudrycki,3 R Kumar,3 M Dalessandro,1 A Gupta,1 X Wang,1 V Damian-
Iordache,2 T Wilde,2 C Friedrich3 and EK Hussey1 1 Stiefel, a GSK company, Research 
Triangle Park, NC, 2 GlaxoSmithKline, Philadelphia, PA and 3 Rosa&Co, San Carlos, CA
Combining molecular biology, clinical data and informatics technologies with computational mod-
eling can aid comprehensive understanding of complex diseases such as acne. We have developed 
a quantitative physiological model depicting acne pathophysiology to enable effective evaluation 
of targets and pathways via systematic integration and analysis of existing data and knowledge. 
We created a mechanistic disease map of acne describing relevant biological pathways and their 
interactions. The mechanisms of action of current standard of care (SOC) therapies were included to 
support model qualification. This map was converted to a quantitative pharmacodynamic model, the 
Acne PhysioPD™ platform, using proprietary and published data. The contributions of sebum pro-
duction, P. acnes growth, hyperkeratinization of infundibulum and inflammation were integrated to 
represent an acne lesion of moderate severity and allow evaluation of target effects at the biological 
and clinical outcome level. Rosa’s Model Qualification Method was used to document the design, 
testing criteria, uncertainties, and patient variability. Integration of existing data and knowledge 
into a mechanistic model facilitated new insights into the pathophysiology and SOC therapies of 
acne and identified knowledge gaps. The model-simulated responses to SOC therapies were in 
agreement with published data. Analysis of the mechanistic pathways driving clinical benefits of oral 
isotretinoin therapy indicated that reduction in sebum production is a key driver of efficacy, while 
effects on keratinocyte lifecycle were immaterial to clinical efficacy. Subsequent literature analysis 
confirmed these findings. Simulations also suggested a potential role for IL-17 in the sebaceous 
follicle hyperkeratinization process. Use of quantitative modeling improved mechanistic understand-
ing of acne and provided a novel tool for evaluation of therapeutic potential of new drug targets.   
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In vivo treatment with RORγt antagonist attenuated psoriasis-like skin lesions in mouse 
through inhibition of pathogenic IL-17
M Takaishi,1 M Ishizaki,2 K Suzuki,3 T Isobe,2 T Shimozato2 and S Sano1 1 Dermatology, 
Kochi University, Nankoku, Japan, 2 Frontier Research Laboratories, Daiichi Sankyo Co., 
Ltd., Tokyo, Japan and 3 Medicinal Chemistry Research Laboratories, Daiichi Sankyo Co., 
Ltd., Tokyo, Japan
Intrerleukin-17 (IL-17) is thought to be one of the critical cytokines in the pathogenesis of psoriasis. 
This has been supported by successful efficacy of anti-IL-17A or anti-IL-17RA antibody for the 
treatment of patients with psoriasis. An alternative strategy to suppress the IL-17 signaling might be 
targeting retinoic acid receptor-related orphan receptor (ROR) γt, which is the master regulator of 
differentiation and activation of IL-17-producing cells, including Th17 cells or IL-17-producing γδ T 
cells. Previous study revealed that digoxin, a commonly used drug for the treatment of heart failure, 
inhibited IL-17 production by its binding to the ligand binding domain (LBD) of RORγt in CD4+ 
T cells (Fujita-Sato S et al., JBC, 2011). We recently synthesized a novel compound (designated 
as compX), which competitively binds to the RORγt LBD in a cell-free condition with a 250-fold 
higher affinity than digoxin. Accordingly, the compX could inhibit CD4+ T cells to differentiate to 
Th17 cells, but not Th1, with a 400-fold higher efficiency than digoxin. To examine whether compX 
inhibits Th17-mediated disease in vivo, the drug was orally administrated to K5.Stat3C transgenic 
mice, which exhibit psoriasis-like lesions associated with up-regulation of the IL-23/Th17 signaling 
similar to psoriasis (Nakajima K, et al., J Immunol, 2011). Development of skin lesions induced by 
topical TPA was significantly attenuated by treatment with compX. At the same time, IL-17A gene 
expression showed a significant reduction in lesions or skin-draining lymph nodes. These results 
strongly suggest that in vivo treatment with compX attenuated IL-17-mediated psoriasis-like lesions. 
Therefore, targeting RORγt may be a promising strategy for the treatment of psoriasis.    
ABSTRACTS | Auto-Immunity & Inflammation
S10   Journal of Investigative Dermatology (2014), Volume 134
053
Propionibacterium acnes activates the NLRP3 inflammasome in human SZ95 sebocytes
M Im,1 Z Li,1 I Chang,1 Y Lee,1 Y Seo,1 C Kim,1 J Lee1 and C Zouboulis2 1 Dermatology, 
Chungnam National University, Daejeon, Republic of Korea and 2 Dermatology, 
Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany
Propionibacterium acne (P. acnes) and sebaceous glands are considered to play an important role 
in the development of acne. However, information regarding the activation of innate immunity by 
P. acnes in the sebaceous gland is limited. In this study, we investigated whether P. acnes activates 
the inflammasome in human sebaceous glands in vivo and in vitro. We found that IL-1β expression 
was upregulated in sebaceous glands of acne lesions. After stimulation of human SZ95 sebocytes 
with P. acnes, the activation of caspase-1 and secretion of IL-1β were enhanced significantly. 
Moreover, knocking down the expression of NLRP3 (but not AIM2) abolished P. acnes-induced 
IL-1β production in SZ95 sebocytes. The activation of the NLRP3 inflammasome by P. acnes was 
dependent on protease activity and ROS generation. Finally, we found that NALP3-deficient mice 
display an impaired inflammatory response to P. acnes. These results suggest that human sebo-
cytes are important immunocompetent cells that induce the NLRP3 inflammasome, and that P. 
acnes-induced IL-1β activation in sebaceous glands plays an important role in acne pathogenesis.   
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Pemphigus vulgaris clusters with autoimmune thyroid disease, rheumatoid arthritis, and 
type I diabetes
A Parameswaran,1 K Attwood,2 R Sato,1 K Seiffert-Sinha1 and AA Sinha1 1 Dermatology, 
University at Buffalo, Buffalo, NY and 2 Biostatistics and Bioinformatics, Roswell Park Cancer 
Institute, Buffalo, NY
It is well known that individuals with one autoimmune disease as well as their family members are at 
increased risk of developing another autoimmune disease. We analyzed patient data from 3 sources: 
i) our own laboratory patient database (n=230), ii) an anonymous online survey conducted by our 
group (n=171), and iii) the International Pemphigus Pemphigoid Foundation patient registry (n=393) 
to address whether there are specific autoimmune diseases that cluster with Pemphigus vulgaris 
(PV). Autoimmune thyroid disease, rheumatoid arthritis, and psoriasis were revealed to be the most 
frequent concomitant autoimmune diseases in PV patients by all 3 sources. Review of our laboratory 
database and our anonymous online survey found autoimmune thyroid disease, rheumatoid arthritis, 
type 1 diabetes, psoriasis and inflammatory bowel disease among the most frequent autoimmune 
diseases in family members of PV patients. The frequency of 3 of these diseases was significantly 
increased in PV patients as compared to prevalence in the general population: autoimmune thyroid 
disease (OR: 6.03, 95% CI: 3.53-10.31, p-value <0.0001), rheumatoid arthritis (OR: 2.82, 95% 
CI: 1.33-6.00, p-value 0.007), and type 1 diabetes (OR: 5.07, 95% CI: 1.07-23.98, p-value 0.04). 
Furthermore, descriptive cluster analysis of comorbid autoimmune disease within PV patients and 
family members using basic principle components methods revealed that PV forms a distinct cluster 
with thyroid disease, rheumatoid arthritis, and type 1 diabetes, and another cluster with systemic 
lupus erythematosus, rheumatoid arthritis, and thyroid disease. These clusters suggest there may be 
shared genetic elements across clinically distinct diseases that underlie autoimmune susceptibility. 
Increased awareness of autoimmune disease clusters within PV patients and their families may also 
allow for earlier and more effective screening methods to identify individuals at risk.    
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Anti-desmoglein 1 and -3 profiles as predictors of disease variation in pemphigus vulgaris
SY Naseer, K Seiffert-Sinha and AA Sinha Dermatology, University at Buffalo, Buffalo, NY
The desmoglein (Dsg) compensation hypothesis postulates a clear relationship between anti-Dsg 
autoantibodies and clinical phenotype in Pemphigus vulgaris (PV). Recent studies question the 
accuracy of this hypothesis as a predictor of lesion morphology and severity. However, few studies 
address the association of anti-Dsg antibodies to other clinical parameters, e.g. disease phase. In 
order to ascertain the relationship of autoantibody profiles to broader fluctuations in clinical expres-
sion, we systematically and comprehensively analyzed anti-Dsg ELISA levels in 200 PV patients 
and 128 healthy controls in relation to several variable (disease phase, duration, therapy, lesion 
morphology) and constant (gender, age at onset) clinical parameters. We confirm that anti-Dsg1 
and anti-Dsg3 levels peak in the active phase but stay moderately elevated in remittent patients vs. 
controls (p<0.03). About half of patients in complete remission (47/78) remain positive for anti-Dsg 
antibodies. Of these antibody positive (Ab+) remittent patients, those in early remission (< 6 months) 
have mean anti-Dsg3 levels comparable to active patients but significantly lower anti-Dsg1 levels 
(58.1 ± 21 U/ml, p=0.02). Whereas, in long-term remittent patients (>6 months, LTR), both anti-Dsg1 
and –Dsg3 levels are significantly lower than active patients (p<0.001, p=0.03), suggesting that 
downward trends in anti-Dsg1 specifically may serve as a useful tool to assess therapeutic response 
and progress towards remission. Of note, we identified a subset of LTR patients who continue to 
experience periodic disease activity in the form of chronic transient lesions (lasting < 1 week), i.e. 
partial LTR. These patients have anti-Dsg3 levels (127 ± 50 U/mL) comparable to active Ab+ patients 
(123 ± 47 U/ml) and significantly higher than patients in complete LTR (p<0.01). These findings 
suggest that physiologic mechanisms underlying chronic partial remission more closely resemble 
an active disease state than a remittent state. We propose to broaden the consensus definition of 
active phase to include patients with transient lesions.    
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Ethnic variations in HLA DR14 alleles predispose to differential clinical phenotypes in pem-
phigus vulgaris
SY Naseer, K Seiffert-Sinha and AA Sinha Dermatology, University at Buffalo, Buffalo, NY
Pemphigus vulgaris (PV) is a life-threatening blistering disorder mediated by autoantibodies to the 
desmosomal proteins, desmoglein (Dsg) 3 and Dsg1. Although the etiology of PV remains unknown, 
there is a strong genetic component to disease susceptibility. Polymorphisms in the HLA class II 
genes, specifically the DRB1*0402 and DQB1*0503 alleles, have been associated with increased 
risk of PV. However, the clinical outcomes of carrying one disease-mediating HLA allele over 
another are not well characterized. In order to explore the link between distinct HLA alleles and 
heterogeneity in clinical expression, we set out to analyze the relationship between HLA type and 
a subset of demographic (gender, ethnicity) and clinical (age at onset, lesion morphology, anti-Dsg 
antibody profiles) parameters in 180 PV patients. We confirm that most PV patients (154/180, 
85.6%) carry either or both of the HLA alleles DRB1*0402 and DQB1*0503, depending on their 
ethnic origin. DRB1*0402 is the predominant allele in the Ashkenazi Jewish population (56/59 or 
91.5%), whereas the major allele in Asian patients is DQB1*0503 (12/14, 85.7%). Patients with 
DQB1*0503 are further subdivided by differential expression of DR14 alleles: Caucasian patients 
carry either DRB1*1401 (n=13) or -1404 (n=9) in near equivalent ratios, while all (7/7) South 
Asian patients co-express the DRB1*1404 allele and East Asian patients expressed neither. Clini-
cally, patients with the DRB1*1404/DQB1*0503 haplotype had an earlier age of onset compared 
to patients with the DRB1*1401/DQB1*0503 haplotype (38.6 years and 47.6 years respectively, 
p=0.04.) Moreover, there was a trend for increased anti-desmoglein 1 ELISA levels (p=0.06), as well 
as increased cutaneous involvement (p=0.096), in active patients with the DRB1*1404/DQB1*0503 
haplotype compared to the DRB1*1401/DQB1*0503 haplotype. The data suggest that patients 
with the DRB1*1404/DQB1*0503 haplotype may have a genetic predisposition towards molecu-
lar recognition of Dsg1 peptide fragments and development of a distinct cutaneous-predominant 
clinical profile.    
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The natural history of pediatric chronic cutaneous lupus
LM Arkin,1 L Ansell,3 M Curran,2 A Wagner,4 A Rademaker,5 M Klein-Gitelman2 and 
AS Paller3,4 1 Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, 2 Pediatrics, 
Division of Rheumatology, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, 
IL, 3 Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 
4 Pediatrics, Division of Dermatology, Ann and Robert H. Lurie Children’s Hospital of 
Chicago, Chicago, IL and 5 Preventive Medicine, Northwestern University Feinberg School 
of Medicine, Chicago, IL
Adult chronic cutaneous lupus (CCLE) transforms to systemic lupus (SLE) in <5-10% of cases and is 
associated with a more benign disease course. Previous studies have suggested that pediatric CCLE 
transforms more frequently to SLE, with uncertain disease-modifying effects. We hypothesized a 
higher rate of systemic transformation in children relative to adults and sought to investigate the time 
of greatest risk for the development of SLE. Using a single-center cohort of 45 patients with CCLE 
we explored: a) transformation to criteria-based SLE; b) development of laboratory abnormalities 
associated with SLE without full SLE criteria; and c) persistence as skin-limited CCLE alone. To better 
elucidate the modifying effect of CCLE in SLE, a cohort of patients with rheumatologist confirmed 
SLE without CCLE was identified and bivariate analysis was performed to investigate for associations 
between CCLE and each ACR criteria for SLE. Seven (16%) of the original 45 patients presented 
with both SLE and CCLE. Of the 38 children with CCLE without evidence of SLE on presentation, 
9 (24%) eventually met criteria for SLE, and 17 (45%) developed laboratory abnormalities without 
SLE. Only 12 (32%) maintained skin-limited CCLE. The average age of transformation to SLE was 
11 years, with greatest risk in the first year after CCLE diagnosis. CCLE in SLE was significantly 
associated with photosensitivity and a reduced risk of arthritis. We have confirmed a high rate 
of transformation of CCLE to SLE in children. We now show that this transformation most often 
occurs within the first year after diagnosis of CCLE, suggesting that early aggressive intervention 
may decrease the risk of SLE transformation.    
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A role for ST18 in the pathogenesis of pemphigus vulgaris
D Vodo,1 S Geller,1 E Ben-Asher,2 T Olender,2 I Goldberg,1 J Nosgorodsky,1 A Alkelai,2 
P Tatarsky,2 S Baum,4 A Barzilai,4 S Ibrahim,3 D Zillikens,3 D Lancet,2 E Sprecher1 and 
O Sarig1 1 Tel Aviv Medical Center, Tel Aviv, Israel, 2 Weizmann Institute, Rehovot, Israel, 3 
Luebeck University, Luebeck, Germany and 4 Sheba Medical Center, Sheba, Israel
A steadily growing body of evidence suggests that factors other than anti-desmosomal antibodies also 
play a role in the pathogenesis of the disease. Polymorphic variants within the ST18 transcription 
factor gene have recently been found to be associated with a 6-fold increased risk for PV in the 
Jewish population. In the present study, we aimed at delineating the possibility that ST18 may be 
causally associated with PV. In an attempt to identify causative variants, we performed targeted 
deep sequencing of the ST18 locus (0.47Mb) in 16 patients. A case-control association analysis of 
789 individuals revealed a large genomic haplotype block strongly associated with the propensity 
to develop PV (p= 0.003). The risk haplotype has a frequency of 50% in the sequenced cohort and 
only 8% in 1000 genome sequences and is located within an intron of the ST18 gene that harbors 
a lncRNA. A known SNP in this lncRNA, that modifies its secondary structure, is enriched in the 
PV cohort (p=8.83x10-6) and may be implicated in regulation of ST18 expression. Accordingly, 
ST18 was found to be overexpressed in the skin of PV patients. To investigate the consequences of 
abnormal ST18 expression on keratinocyte susceptibility to PV IgG antibodies, we overexpressed 
this gene in HaCaT cells exposed to normal or PV serum. We found that while ST18 affected neither 
the extent of PV serum-induced DSG3 endocytosis nor the expression of pro-inflammatory medi-
ators, it resulted in increased TNF alpha-induced cell apoptosis in the presence of PV serum. This 
suggested that ST18 may contribute to PV pathogenesis by augmenting keratinocyte susceptibility 
to PV IgG-induced apoptosis. Corroborating this possibility, an ST18-associated variant (rs2304365) 
was found to confer an increased risk for a more extensive phenotype in a cohort of PV patients 
(p=0.01). Taken together, these results support a direct contributory role for ST18 in PV pathogenesis.   
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Desmoglein-specific IgA in pemphigus vulgaris are clonally distinct from IgG4 and can 
cross-react with human pathogens
C Ellebrecht, EM Mukherjee, E Choi and AS Payne Dermatology, University of Pennsylvania, 
Philadelphia, PA
Pemphigus vulgaris (PV) is a chronic and potentially fatal autoimmune disease of the skin and 
mucous membranes characterized by autoantibodies (autoAbs) against desmoglein (Dsg) 3. During 
active disease, the majority of serum autoAbs in PV belong to the IgG4 and less so the IgG1 isotype. 
However, >50% of patients have serum anti-Dsg3 IgA, the role of which in PV has not been charac-
terized. To better understand IgA autoAbs in PV and their relationship to pathogenically dominant 
IgG4 autoAbs, we cloned the anti-Dsg3 IgA1, IgA2, and IgG4 repertoires from a mucocutaneously 
affected PV patient. We identified 5 unique Dsg3-reactive IgA1 clones (defined by heavy chain 
CDR3 sequence), 4 unique IgA2 clones, and 10 unique IgG4 clones. One clonal family was shared 
between the IgA1 and IgA2 repertoire. None were shared between IgA1/2 and IgG4. Furthermore, 
by CDR3-specific RT-PCR, we found no evidence of the IgA1/2 clones in the IgG4 repertoire. Inter-
estingly, a clonally expanded IgA1 family was identified that used the VH3-15 gene segment, the 
predominant VH gene used in the natural and vaccine induced response to Haemophilus influenzae 
type B capsular polysaccharide (HIB PRP). The VH3-15 anti-Dsg3 mAb specifically crossreacted 
to HIB PRP, but not other self-antigens such as RNA polymerase II or BP180 glycoprotein. This 
crossreactivity was encoded by the heavy chain and was lost after reversion of somatic mutations 
to the germline VDJ sequence. Conversely, a VH3-15 anti-HIB PRP IgA1 clone isolated by hetero-
hybridoma from an immune adult after infection showed weak crossreactivity with Dsg3 by ELISA 
and immunofluorescence. In summary, our results suggest that Dsg3-specific IgA, which do not 
comprise the majority of autoAbs in PV, are clonally distinct from the IgG4 autoAb repertoire, can 
harbor pathogen crossreactivity, and may contribute to the origins of autoimmunity in PV.    
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Transcriptional analysis reveals different immune regulation between scalp and skin psoriasis 
with potential therapeutic implications
J Ruano,1 M Suarez-Farinas,2 A Shemer,3 J Marcusson,4 E Guttman2,5 and J Krueger2 1 
Department of Dermatology, Reina Sofia University, Córdoba, Spain, 2 Laboratory of 
Investigative Dermatology, Rockefeller University, New York, NY, 3 Department of 
Dermatology, Tel Hashomer Hospital, Tel Hashomer, Israel, 4 Department of Dermatology, 
Haukelands Sykehus, Bergen, Norway and 5 Department of Dermatology, Icahn School of 
Medicine at Mount Sinai Medical Center, New York, NY
The scalp is frequently involved in psoriasis and it often constitutes the only manifestation of 
the disease. Scalp psoriasis shows a variable clinical spectrum and in many cases poses a great 
therapeutic challenge. We assessed the transcriptomic profile (by microarrays) of lesional and 
non-lesional psoriatic scalp tissue as compared with psoriatic skin. Clustering, principal component 
analysis, manually curated-gene set enrichment analysis, and co-differential expression gene set 
network analyses were performed. Our data suggest that the immune mechanisms that mediate 
scalp psoriasis are similar with those involved in psoriasis skin lesions. However, the magnitude of 
dysregulation [log2(FCH)], number of differentially expressed genes, and enrichment of the psoriatic 
genomic fingerprinting were higher for skin versus scalp lesions. Furthermore, the scalp transcrip-
tome showed increased modulation of several gene sets, particularly those induced in keratinocytes 
by interferon-gamma, as compared with skin psoriasis samples that were mainly associated with 
a a significant higher activation of genes involved in TNF-alpha/IL-17/IL-22-induced keratinocyte 
response genes. We also detected differences in expression of sets of genes involving negative 
regulation processes, psoriasis epigenetic regulation, epidermal differentiation, and dendritic cell 
or Th1/Th17/Th22-related T-cell function processes. These data help to understand the differences 
between skin and scalp psoriasis and may be valuable in selecting novel targets to specifically treat 
scalp psoriasis that still has a large unmet medical need.    
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Role of plasmacytoid dendritic cells in psoriasiform skin inflammation
D Popkin Dermatology, Case Western Reserve University, Cleveland, OH
Psoriasis is a common chronic immune-mediated disease of unknown origin. However, there is 
competing evidence that plasmacytoid dendritic cells (pDC) may be central to disease development 
and therefore a target for treatment. pDC are notable for producing ~1000x more type I interferon 
(IFN-I) than any other cell type. Thus, despite being only ~1% of the rare DC population, pDC 
account for ~50% of all circulating IFN-I following infection. Our lab and others have studied the 
mechanisms whereby pDC direct T cell function. Here we demonstrate a requirement for toll like 
receptor (TLR) sensing in pDC in a non-xenograft psoriasiform mouse model. pDC activation requires 
environmental sensing of “danger” via innate sensors, e.g. toll-like receptors (TLRs). pDC uniquely 
express high levels of TLR7 & TLR9 which requires the solute-like channel slc15a4, a gene expressed 
predominantly in pDC. These findings identify slc15a4 as an ideal target to isolate pDC function. 
Additionally, polymorphisms in the slc15a4 locus are found in autoimmune diseases (e.g. systemic 
lupus erythematosus and type I diabetes mellitum. Taken together, we hypothesized that slc15a4 
may be required for pDC mediated psoriasis. Congruent with our hypothesis, we observed that in 
the imiquimod (IMQ) model of psoriasiform dermatitis, acanthosis, recruitment of inflammatory 
cells and weight loss, was indeed largely dependent on pDC sensing. We are currently comparing 
the role of slc15a4 in IMQ-induced versus IL-23-induced psoriasiform inflammation.    
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Psoriasis, psoriatic arthritis, and risk of gout in U.S. men and women
JF Merola,1,5 S Wu,1 J Han,1,2,3 HK Choi4 and AA Qureshi1,2 1 Dermatology, Brigham and 
Women’s Hospital, Harvard Medical School, Boston, MA, 2 Channing Division of Network 
Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 3 
Epidemiology, Fairbanks School of Public Health, Indiana University, Indianapolis, IN, 4 
Rheumatology, Clinical Epidemiology, Boston University School of Medicine, Boston, MA 
and 5 Medicine, Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, 
Boston, MA
Objective: Individuals with psoriasis have been found to have increased blood levels of uric acid. 
However, there is no prospective data on the association between psoriasis and uric acid levels and 
subsequent development of gout. In this study, we examined the risk of gout among individuals with 
psoriasis and psoriatic arthritis (PsA) in two cohorts of men and women, the Health Professionals 
Follow-up Study (HPFS) (1986-2010) and Nurses’ Health Study (NHS) (1998-2010). Methods: A total 
of 27,751 men and 71,059 women were included in the analysis. Lifetime history of physician-di-
agnosed incident psoriasis and PsA was confirmed by validated supplementary questionnaires. 
Incident gout diagnoses were confirmed based on the American College of Rheumatology survey 
criteria. We used Cox proportional hazards models controlling for potential risk factors to calculate 
the hazard ratios (HRs) with 95% confidence intervals (CIs) of incident gout while simultaneously 
adjusting for several common risk factors. Results: We documented 2,217 incident cases of gout 
during the follow-up. Psoriasis was associated with an increased risk of subsequent gout with a 
multivariate HR of 1.71 [95% confidence interval (CI), 1.35-2.15] in the pooled analysis. Risk 
of gout was substantially augmented among those with psoriasis and concomitant PsA [pooled 
multivariate HR: 4.93, (95% CI, 2.71 to 8.96)] when compared to participants without psoriasis. 
Conclusions: In this prospective study of US women and men, psoriasis and PsA were associated 
with an increased risk of gout.    
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Increased expression of interferon regulatory factor-8 in psoriasis
T Watanabe,1 Y Yamaguchi,1 T Tamura2 and M Aihara1 1 Department of Environmental 
Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, 
Japan and 2 Department of Immunology, Yokohama City University Graduate School of 
Medicine, Yokohama, Japan
Background: Psoriasis is a chronic inflammatory skin disease, in which IL-23/IL-17 axis is critical in 
the immunopathogenesis. In particular, it has been considered that dendritic cells, such as TNF-α 
and iNOS producing dendritic cells (Tip-DCs) and plasmacytoid dendritic cells (pDCs) play a key 
role in the pathogenesis of psoriasis. Interferon Regulatory Factor-8 (IRF8) is a transcription factor 
essential for the development of immune cells including dendritic cells (DCs), monocytes, and mac-
ropahges. The role of its function regarding DCs has been widely studied in mouse, yet association 
of IRF8 and psoriasis has not been reported. In this study, we determined IRF8 expression levels in 
patients with psoriasis and imiquimod (IMQ)-induced mouse psoriasis model. Methods: Expression 
levels of IRF8 were examined in the skin obtained from psoriasis patients and IMQ-induced mouse 
model by using qRT-PCR and immunohistochemistry. Psoriasis-like dermatitis was developed by 
daily application of IMQ to the back skin for 7 days using CB57B6 (WT) mice and IRF8 knockout 
mice. The skin was evaluated by measuring the epidermal thickness, the severity index (PASI) 
score, and the phenotype of infiltrated cells. Results: IRF8 mRNA and protein levels in dermis were 
significantly elevated in patients with psoriasis and psoriasis mouse model compared to that in 
healthy controls and non-treated WT mice, respectively. Immunohistochemical analysis revealed 
that IRF8 positive cells in dermis were positive for CD11c or CD11b, indicating those cells were 
DCs or macrophages. Further, IMQ-induced mouse model in IRF8 knockout mice suppressed PASI 
score and epidermal thickening compared to that in WT mice.    
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Phosphorylation of Stat3 involved in the pathogenesis of dysfunctional regulatory T cells 
in psoriasis
L Yang, B Li and G Wang Xijing Hospital, Fourth Military Medical University, Xi, China
Regulatory T cells (Treg) are characterized by their immunosuppressive functions to maintain the 
immune balance. In psoriatic patients, the T effector cells are poorly restrained by regulatory T cells. 
Studies suggested abnormal proportional and dysfunctional Treg cells trigger the unrestrained patho-
genic activation of T effector cells in psoriasis. But the mechanism involved in the pathogenesis of 
dysfunctional Treg in psoriasis is not clarified. By comparison of Treg proportions in normal (n=35) 
and psoriatic blood (n=44), we show that the proportion of Treg cells are decreased in psoriatic 
patients. Microarray of Treg cells from normal and psoriatic blood revealed 1919 psoriasis-increased 
DEG (differentially expressed genes) and 1206 psoriasis-decreased DEG. Consistent with Microar-
ray analysis, we found by real-time PCR that the potential Stat3 target genes such as TCF4, Nrp1, 
MAP3K8, ITGB8, IL7 belonged to the upregulated genes, CD28 belonged to the downregulated 
genes. We also observed that Treg cells from psoriatic patients display higher Stat3 phosphorylation 
and Stat3 nuclear translocation. We next confirmed that the inhibition of Stat3 phosphorylation 
could partly restore the functional Treg immunosuppression, without affecting the proliferation of 
CD4+CD25- T effector cells. These findings show that Stat3 phosphorylation is a pivotal mechanism 
contributing to the dysfunctional regulatory T cells in psoriasis.    
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Keratinocytes drive depigmentation in a mouse model of vitiligo via recruitment and activa-
tion of CD8+ T cells in the skin
J Richmond,1 K Essien,1 J Groom,2 A Luster3 and J Harris1 1 University of Massachusetts 
Medical School, Worcester, MA, 2 Walter and Eliza Hall Institute of Medical Research, 
University of Melbourne, Melbourne, VIC, Australia and 3 Massachusetts General Hospital, 
Harvard Medical School, Boston, MA
Vitiligo is an autoimmune disease of the skin that results in disfiguring depigmentation. The disease 
is caused by autoreactive CD8+ T lymphocyte-mediated killing of melanocytes. We previously 
reported that depigmentation in a mouse model of vitiligo is dependent upon IFNγ and the IFN-in-
ducible chemokine CXCL10, which is responsible for the recruitment and activation of autoreactive 
CD8+ T cells in the skin. It is not known which populations of cells in the skin produce CXCL10 
during vitiligo, and therefore we set out to determine this by inducing vitiligo in a novel CXCL10 
reporter mouse strain (REX3). We found that Langerhans cells produced the most CXCL10, fol-
lowed by keratinocytes. To determine if these cell types were functionally required for vitiligo, we 
tested genetically modified strains in our model. Hu-Lang-DTA mice, which lack Langerhans cells, 
developed vitiligo, indicating that Langerhans cells are dispensable for disease induction. We then 
sought to address the functional role of keratinocytes. IFNγ signals through the IFNγR via STAT1 to 
induce chemokine production. We crossed STAT1-floxed mice to keratinocyte-specific Cre mice 
(STAT1-flox-K5-Cre) to render the keratinocytes unable to respond to IFNγ. Keratinocyte-specific 
STAT1-deficiency significantly protected mice from vitiligo (p<0.01), revealing that non-immune 
cells can drive autoimmune processes in the skin by amplifying chemokine signals. Understanding 
how different cell types contribute to vitiligo will ultimately allow for the design of novel, targeted 
treatment strategies.    
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Dupilumab, a fully human anti-hIL4Rα mAb: Efficacy evaluation in a novel murine model 
with human IL-4 and IL4Rα gene replacements
L Wang, X Liu, W Zhang, Y Tang, F Luo, T Huang, C Lin, J Martin, D Valenzuela, 
N Papadopoulos, N Graham and A Murphy Regeneron, Tarrytown, NY
Common allergic disorders, such as atopic dermatitis, asthma, and allergic rhinitis, are linked with 
abnormal type II T cell polarization including increased IL-4 and IL-13 signaling. Two distinct 
heterodimeric receptors incorporating IL4Rα mediate biological actions of IL-4 and IL-13; type I 
receptor (IL4Rα with common gamma receptor) that transduces IL-4-dependent signaling, including 
IgE class switching in B cells; type II receptor (IL4Rα/IL13Rα1) provides signaling functions for 
both IL-4 and IL-13 in hematopoietic and non-hematopoietic cells. Dupilumab, a fully human 
anti-hIL4Rα monocloncal antibody generated by VelocImmune® technology, binds human IL4Rα 
specifically. Genetically engineered mice were created by replacing the full-length murine IL4 locus 
with 8.8 kb of human IL4 genomic sequences and extracellular domain of murine IL4Rα (CD124) 
gene with 15.6 kb human IL4Rα genomic DNA fragment. Double gene replacement was needed 
as mouse IL-4 does not cross activate human IL4Rα. Functionality of substituted human IL-4/IL4Rα 
genes was demonstrated using mouse derived primary cells in vitro and in vivo. These “human-
ized” mice enabled evaluation of dupilumab in preclinical animal models. Humanized IL4Rα 
mice respond to human IL-4 specifically. Human and mouse IL-13 activate biological responses 
similarly. Human IL-4 induced IgE production by primary B cells from humanized IL4Rα mice 
and dupilumab prevented IgE class switch. In an IL-25-induced acute lung inflammation model, 
dupilumab prophylactic dosing at 10 mg/kg (every other day) and above demonstrated efficacy in 
reducing lung pathology in a dose-dependent manner; 25 mg/kg reduced mucus pathology >90%. 
These results demonstrate the pharmacological activity of dupilumab in a genetically modified 
acute inflammation mouse model. Generation of genetically engineered mice with human gene 
replacements provides a powerful tool to evaluate function of gene orthologs and in vivo efficacy 
of antibody candidates with limited cross-species reactivity.    
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Importance of SIRT6 in supporting human dermal fibroblasts health
EC Goyarts, K Dong, E Pelle, N Pernodet and D Yarosh Estee Lauder Companies, Melville, 
NY
Sirt6 is a member of the Sirtuin family and thus considered a longevity gene. SIRT6 is an ADP-ribo-
sylase as well as a histone deacetylase. Its functions are involved in many different pathways. SIRT6 
has been linked to genomic stability through its role in base excision repair (BER) and double strand 
break (DSB) repair. SIRT6 has also been shown to be a regulator of two key transcription factors, 
NFKB and Hif-1alpha. Here, we used SIRT6 siRNA to decrease SIRT6 levels and followed its effects 
on human dermal fibroblasts. Sirt6 mRNA levels were followed as a function of time to determine 
the best conditions. Based on these results, we then measured NFKB levels as a function of time 
with or without UVA/B exposure. DNA lesions generated by UVA/B exposure were evaluated by 
the comet assay. Our results show that NFKB was increased significantly (up to 400%) due to SIRT6 
silencing in the absence of UVA/B, illustrating the master regulation of SIRT6 in inflammation. We 
also found a significant increase in DNA damage after UVA/B with SIRT6 silencing, indicating its 
importance in DNA repair pathways in human dermal fibroblasts. Taken together, these results 
emphasize the importance of SIRT6 in skin cellular health and aging.    
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Serum autoantibodies and cutaneous autoimmunity in chronic graft-versus-host disease
RC Zuo,1 Z Kuzmina,2 HB Naik,1 SZ Pavletic2 and EW Cowen1 1 Dermatology, NCI CCR, 
NIH, Bethesda, MD and 2 Experimental Transplantation and Immunology, NCI CCR, NIH, 
Bethesda, MD
The manifestations of chronic graft-versus-host disease (cGVHD) are highly variable and may 
recapitulate well-characterized autoimmune diseases, including systemic sclerosis and Sjögren’s 
syndrome. However, other cutaneous autoimmune conditions including vitiligo and alopecia areata 
(AA) have not been well characterized in the cGVHD setting. This cross-sectional retrospective 
study assessed demographic characteristics and prevalence of serum autoantibodies in cGVHD 
patients with concomitant signs of cutaneous autoimmunity. 15 individuals aged 9-69 with vitiligo 
(14) and/or AA (2) were identified from a group of 282 patients with cGVHD seen at the NIH from 
2004 to 2013. One patient was diagnosed with both vitiligo and AA. 67% (n=10) of the patients 
were male. Sera were tested for ANA, anti-ENA, RF, anti-parietal, anti-CCP, IgG and IgM ACA, 
anti-TPO, anti-smith, anti-RNP, anti-centromere, and anti-proteinase-3 antibodies. The prevalence 
of one or more elevated autoantibodies was higher in patients with AA or vitiligo (9/15; 60%) 
compared with cGVHD patients without cutaneous autoimmunity (114/267; 43%). A higher pro-
portion of cGVHD patients with AA or vitiligo had increased RF (27% vs. 12%), IgG-ACA (27% 
vs. 7%), anti-parietal (13% vs. 2%), anti-CCP (13% vs. 7%), anti-ENA (13% vs. 8%), anti-TPO (7% 
vs. 1%), anti-centromere (7% vs 3%), anti-smith (7% vs. 1%) and anti-proteinase-3 (7% vs. 0.4%) 
antibodies. Although autoantibody formation is found frequently in the cGVHD setting, the clinical 
significance of these autoantibodies remains uncertain. Our data suggests that AA and vitiligo occur 
in a relatively small subset of cGVHD patients but is associated with the presence of a number of 
non-specific autoantibodies.    
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A novel 6-hour method to study IL-17A and IL-22 in unstimulated cells from fresh biopsies 
of psoriatic patients
M Sarfati,1 S Mashiko,1 M Rubio,1 N Baba,1 C Jack3,2 and R Bissonnette2 1 Immunoregulation 
Laboratory, CRCHUM, Montreal, QC, Canada, 2 Innovaderm Research, Montreal, QC, 
Canada and 3 Division of Dermatology, McGill University, Montreal, QC, Canada
In psoriasis, Th17 cells that produce IL-17A and IL-22 appear to play a central role in disease 
pathogenesis. However, evidence suggests that IL-17A and IL-22 might be expressed by cells of the 
immune system other than Th17 cells in skin lesions. We developed a novel, rapid (6 hours) and 
reproducible experimental approach combining enzymatic digestion and mechanical dissociation 
for skin cell isolation followed by multi-color flow cytometry analysis in the absence of in vitro 
expansion and re-stimulation. Using this method, we examined the cellular source of IL-17A and 
IL-22 on a small number (20x103) of viable CD45+ cells that are freshly isolated from 4 mm punch 
skin biopsies (n=22 patients with psoriasis). Our data indicate that in psoriatic skin, IL-17A positive 
cells are mostly T cells (CD3+c-kit-; T cells versus non-T cells 3/1 ratio, p=0.008). In contrast, T 
cells represent only a minor source of IL-22, which is predominantly produced by mast cells in 
psoriatic plaques (c-kit+ FcεR+Lin-) (T cells versus mast cells 1/3 ratio, p=0.0014). In conclusion, 
our novel method enables characterization of inflammatory cells from psoriatic skin biopsies in 
less than 6 hours with minimal enzymatic digestion, no expansion and no stimulation. Using this 
method we found that mast cells are the main source of IL-22 in psoriasis whereas T cells appear 
to be the main source of IL-17A.    
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The effects of different inducer on angiogenesis and the Chinese herbs interventions
X Liu and P Li Pathophysiology Laboratory, Beijing Institute of Traditional Chinese Medicine, 
Beijing, China
Psoriasis is a chronic inflammatory disease of skin and joints in the genetic and environmental 
backgrounds. T lymphocytes (especially Th1 and Th17 cells) play central roles in the pathogenesis 
of psoriasis. However, angiogenesis is also a very important pathological processe in psoriasis. 
Angiogenesis stars with early psoriatic changes and disappears with disease clearance. It is closely 
associated with occurrence, development, persistence and recurrence of disease. In this study, 
human dermal microvascular endothelial cells(HDMEC) are induced by phorbol myristate acetate 
(PMA)/basic fibroblast growth factor(bFGF)/vascular endothelial growth factor(VEGF), to simulate the 
pathological angiogenesis in psoriasis. We aim to observe and compare the differences of prolifera-
tion, migration, tube formation and mRNA expression of related signal pathway (such as Raf, MEK, 
ERK, PI3K, AKT, FAK) between different cells stimulated by different inducers, and the intervention 
of Chinese herbs. In conclusion, we show that three kinds of inducers can promote angiogenesis, 
mediated by the different signal pathways. In addition, Chinese herbs can inhibit endothelial cell 
proliferation, migration, tube formation and the related mRNA expression, in different degrees. 
These findings provide novel approaches in psoriasis treatment.    
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Psoriasiform eruptions in the setting of Kawasaki disease: A unique phenotype?
W Tom,1,2 J Burns,1,2 A Tremoulet,1,2 A Calame3 and E Haddock1 1 University of California, 
San Diego, San Diego, CA, 2 Rady Children’s Hospital, San Diego, CA and 3 Compass 
Dermatopathology, San Diego, CA
Kawasaki disease (KD) is an acute systemic inflammatory illness that produces vasculitis and 
potentially fatal coronary artery aneurysms, particularly in untreated children. A subset develops a 
psoriasiform eruption during the acute or subacute phase. This study is a retrospective case-control 
study that systematically compared such eruptions in the setting of KD versus classic psoriasis and 
additionally examined whether the course of KD accompanied by psoriasiform eruptions differed 
from that without. Eleven pediatric cases were matched 1:2 with controls of the same age, gender, 
and ethnicity for each disorder. Median age was 1.9 years (0.3-15.2) for cases, 2.0 years (0.2-14.9) 
for psoriasis controls, and 1.5 years (0.08-15.5) for KD controls. Most striking was >90% of KD 
psoriasiform eruptions resolved within 13 months and without recurrence (range of follow-up: 0.1-
13.4 years), vs. only 23% of classic psoriasis controls had resolution. Diaper, neck, and scalp lesions 
were less frequent in the setting of KD. On histologic exam, psoriasiform lesions during KD were 
distinct in that they showed more serum and crusting and had presence of bacteria at the epidermis. 
KD patients who developed psoriasiform lesions were found to have more dilated coronary arteries 
than those without the lesions (median maximal z score 2.8 vs. 1.8, p= 0.034), and required more 
time for platelets and GGT to normalize (p = 0.044 and p = 0.003, respectively). Our comparison 
suggests that psoriasiform lesions during KD are distinct in terms of tendency to go into remission, 
cutaneous distribution, lack of association with obesity, and degree of serum, crusting, and epi-
dermal bacteria. The possibility for a poorer prognosis for associated KD warrants further study.   
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Ruxolitinib prevents cutaneous lupus erythematosus in MRL/lpr mice
ES Chan,1 LC Herlitz2 and A Jabbari1 1 Dermatology, Columbia University Medical Center, 
New York, NY and 2 Pathology and Cell Biology, Columbia University Medical Center, 
New York, NY
Discoid lupus erythematosus (DLE) is a cutaneous manifestation of lupus erythematosus (LE) char-
acterized by scaly plaques, often on the face and scalp, that can lead to scarring, alopecia, and 
disfigurement. Autoantibody production, deposition of immune complexes and complement, and 
leukocytic infiltration are hallmark immunopathologic events in LE. We previously reported results 
from expression profiling of affected skin from DLE patients demonstrating strong type I and II 
interferon signatures. Using the MRL/lpr mouse model of lupus, we examined the effects of orally-ad-
ministered ruxolitinib, a protein tyrosine kinase inhibitor with relative selectivity for the proximal 
interferon signaling molecules JAK1 and JAK2, on the development of DLE lesions. Preliminary 
analyses show that ruxolitinib prevented the development of DLE lesions. On gross examination, 
the number of lesions and area affected were improved with ruxolitinib versus vehicle treatment. 
On histopathologic grading, epidermal hyperplasia, inflammatory infiltrate, and dermal thicken-
ing were significantly reduced with ruxolitinib. Skin sections were stained for CD3+ and CD4+ 
cells, and numbers of CD3+ and CD4+ cells were increased in lesional skin in ruxolitinib versus 
vehicle-treated mice and in lesional versus non-lesional skin in vehicle-treated mice. These data 
show that JAK inhibition attenuates autoimmunity and inflammation in mouse models of cutaneous 
disease. We are currently investigating the effect of ruxolitinib on extracutaneous LE manifestations 
in the MRL/lpr mice. Further elucidation of the role of JAK inhibition in cutaneous and systemic LE 
will help support ruxolitinib as a promising new therapy for human LE.    
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Proinflammatory microvesicles in patients with cutaneous lupus erythematosus
M Liu,1,2 H Xu,1,2 M Bashir,1,2 M Sharma,1,2 K Williams,3 C Anyanwu,1,2 J Okawa1,2 
and V Werth1,2 1 University of Pennsylvania, Philadelphia, PA, 2 Philadelphia VAMC, 
Philadelphia, PA and 3 Temple University, Philadelphia, PA
Cutaneous lupus erythematosus (CLE), an autoimmune disease, is associated with the accumulation 
of autoantibodies and inflammatory cell infiltration in the skin. Apoptosis, which generates apoptotic 
blebs or membrane microvesicles (MVs), has been proposed to play a central role in autoimmune 
diseases. We have shown that apoptotic MVs have pro-inflammatory properties, however, the role 
of MVs in CLE has not been studied. In addition, tobacco smoking has emerged as a risk factor for 
CLE, but the underlying mechanisms are unclear. We recently reported that exposure of human 
monocyte/macrophages to tobacco smoke extract (TSE) provokes the release of MVs. In the cur-
rent study, we seek to investigate the potential proinflammatory role of MVs in CLE. Using flow 
cytometry, we found that skin lesions of CLE patients contain MVs that carry LL-37, an antimicrobial 
peptide with proinflammatory property and is involved in autoimmune diseases. Interestingly, these 
LL-37-positive MVs are largely of neutrophil origin (CD66-positive). In the plasma, we found the 
increased concentrations of circulating total- and LL-37-positive MVs, again largely neutrophil 
origin, in CLE patients as compared to those in healthy controls. Most importantly, we found that 
MVs isolated from the plasma of CLE patients who smoke can stimulate TNFα release from the 
homologous PBMCs (231±75 with MVs vs 4±3 pg/ml with MV-free plasma, p<0.05). In vitro, expo-
sure of human HL-60 neutrophils to TSE induced LL-37 display on cell surface and their budding 
with MVs. Similarly, treatment of PBMCs from healthy donors with TSE-induced MVs can stimulate 
TNFα release in a dose-dependent manner. In conclusion, our studies indicate for the first time 
that extracellular LL-37 carried by MVs can be found in skin lesions and in the circulation of CLE 
patients. These microvesicles can stimulate cytokine release from nearby inflammatory cells. Thus, 
the proinflammatory MVs may contribute to cutaneous inflammation in CLE, particularly in smokers.   
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Autoantibodies directed against thyroid peroxidase may contribute to blister formation in 
pemphigus vulgaris
T Sajda, K Seiffert-Sinha and AA Sinha Dermatology, University at Buffalo, Buffalo, NY
The pathogenicity of antibodies directed against desmoglein (Dsg)1 and 3, desmosomal proteins that 
function in maintaining cell-cell adhesion, has been well established in Pemphigus vulgaris (PV). 
Recent studies have demonstrated that PV patients also harbor antibodies directed against additional 
self-antigens. Utilizing protein microarray technology, our lab identified significantly increased 
levels of autoantibodies directed at the muscarinic acetylcholine receptors M3, M4, and M5, as 
well as pemphaxin and thyroid peroxidase (TPO) in PV sera when compared to healthy controls, in 
addition to anti-Dsg1 and 3. The extent to which these autoantibodies contribute to blister formation 
in PV is unclear. We performed standard keratinocyte dissociation assays to assess if antibodies 
directed towards the non-desmosomal antigens could weaken keratinocyte cell-cell adhesion by 
themselves or in concert with anti-Dsg antibodies. Confluent HaCaT cells were incubated with the 
respective antibodies at concentrations of 1ug/ml, mechanically stressed by repeated pipetting, and 
the resulting fragmentation was analyzed by ImageJ software. Cell sheets exposed to anti-TPO anti-
bodies, but not its isotype control, exhibited significantly greater fragmentation than untreated cells 
(p<0.001). Furthermore, the combination of Ak23 (a known pathogenic murine anti-Dsg3 antibody) 
with anti-TPO antibody produced significantly more fragmentation than Ak23 alone (p<0.001). 
Preliminary studies using antibodies directed at pemphaxin, and the muscarinic acetylcholine 
receptors M3, 4, and 5 indicate that these antibodies may not induce keratinocyte dissociation by 
themselves. Our data suggests that ant-TPO antibodies may contribute to blister formation in PV, 
and warrant further investigation into the mechanisms of cell dissociation induced by this antibody.   
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Interleukin-36α is the dominant source of interleukin-36 receptor dependent psoriasis-like 
phenotypes in the imiquimod induced skin inflammation model
KA Milora, H Fu, J Fang, O Dubaz and LE Jensen Microbiology and Immunology, Temple 
Autoimmunity Center, Temple University School of Medicine, Philadelphia, PA
The interleukin-36 system comprises three related cytokines, IL-36α, IL-36β and IL-36γ, a receptor, 
IL-36R, and a receptor antagonist, IL-36Ra. The physiological function(s) of the IL-36 system remains 
largely unknown. Exacerbated IL-36R signaling has recently been linked to generalized pustular 
psoriasis and IL-36R knockout (KO) mice develop less severe disease in the imiquimod-induced 
skin inflammation model. However, it has not been established which IL-36 cytokines are respon-
sible for driving the IL-36R dependent phenotypes. Using knockout mice for each individual IL-36 
cytokine we examined psoriasis-like phenotypes induced by imiquimod. Expression of each IL-36 
mRNA was induced by imiquimod (20-50-fold, p<0.05). Disease development in IL-36γ KO mice 
was indistinguishable from that observed in wild type mice. IL-36β KO mice had fewer Munro’s 
microabscesses and exhibited a trend (p>0.05) towards thinner epidermis. Immunohistochemical 
analyses of PCNA revealed reduced acanthosis. The most dramatic effect of gene ablation was 
observed in IL-36α KO mice. After four imiquimod applications the skin was noticeably less red, 
stiff and scaly. Histological analyses revealed that IL-36α KO mice, compared to wild type, had 
thinner epidermis (48 versus 81 μm, p<0.01) and reduced dermal edema and inflammation. Mun-
ro’s microabscesses were absent from IL-36α KO skin. We previously documented IL-1α induced 
Munro’s microabscess formation via CXCL1 and CXCL2. In IL-36α and IL-36β KO mice expression 
of CXCL1 was reduced compared to wild type (39 and 51 ng/ml, respectively, versus 84 ng/ml 
in wild type, p<0.05). Interestingly, CXCL2 expression was not affected in IL-36α and IL-36β KO 
mice. This indicates that IL-36α and IL-36β regulate neutrophil recruitment through CXCL1 and 
not CXCL2. It is noteworthy that this bias towards CXCL1 is also observed in psoriasis in humans. 
Overall, our data document that not all IL-36 cytokines are created equal.    
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IL-6 plays a critical role in melanocyte destruction in autologous transplantation
F Lin,1 M Zhou,1 Y Wan2 and A Xu1 1 Dermatology, The 3rd Hospital of Hangzhou, 
Hangzhou, China and 2 Biology, Providence College, Providence, RI
Vitiligo is an acquired skin depigmentation disorder characterized by the progressive development 
of skin areas deficient in melanocytes. Although the precise etiology of vitiligo is still not fully 
addressed, the autoimmune pathogenesis has been proposed as one of the main causes. Our in 
vivo and in vitro data have demonstrated that CD8+ T cells and IL-6 play important roles in the 
destruction of melanocytes in the perilesional area of vitiligo patients. However, the mechanisms 
through which IL-6 induces melanocyte apoptosis remain still unclear. This study aimed to explore 
the pathogenesis of melanocyte destruction of vitiligo, and to investigate the potential effects of IL-6 
on the apoptosis of autologous melanocytes and the underlying cell signaling mechanisms. Our 
results showed that IL-6 induces melanocyte apoptosis in a dose dependent manner. Further, we 
found that IL-6-induced melanocyte apoptosis is mediated by BCL-2 family and caspase cascade. 
Depending on the concentration, IL-6 induces NFκB phosphorylation and nuclear translocation that 
are associated with cell survival, or inhibition of melanocyte apoptosis. Collectively, we conclude 
that IL-6 induces melanocyte apoptosis via BCL-2 and caspase cascade with NFκB acting as a unique 
regulator in autologous transplantation.    
ABSTRACTS | Auto-Immunity & Inflammation
S14   Journal of Investigative Dermatology (2014), Volume 134
077
Novel approaches to vitiligo treatment via modulation of mTORC1 and NF-κB pathways in 
human skin melanocytes
J Wan,1 F Lin,2 A Xu,2 J DeGiorgis1 and Y Wan1 1 Biology, Providence College, Providence, 
RI and 2 Dermatology, The 3rd Hospital of Hangzhou, Hangzhou, China
Vitiligo is a skin depigmentation disorder with an increasing prevalence. Among recognized mech-
anisms is the oxidative stress that affects melanocytes which are responsible for skin pigmentation. 
Studies have shown that high concentration of hydrogen peroxide, or H2O2, induces apoptotic 
activities. Few studies have been done with lower doses of H2O2. Using human skin melanocytes, 
we investigated the effect of moderate concentration of H2O2 on melanocyte dendrites. Confocal 
data show that H2O2 at 250 μM induces loss of dendrites, as indicated by cytoskeletal proteins. 
α-melanocyte stimulating hormone or α-MSH pretreatment protects against H2O2-induced loss 
of dendrites, while α-MSH alone enhances dendrites. PI3K/AKT inhibitor LY294002 and mTORC1 
inhibitor Rapamycin inhibit α-MSH-induced dendrites. In this study, we also investigated the effect 
of TNFα on cultured human skin melanocytes, since TNFα plays important roles in vitiligo. Confocal 
data demonstrate that TNFα induces NF-κB activation. Western blot analysis shows that TNFα 
induces IκB phosphorylation and degradation. Interestingly, α-MSH does not have any effect of 
TNFα-induced IκB degradation and NF-κB activation. α-MSH, however, activates mTORC1 path-
way. TNFα induces p38 but not AMPKα activation. Collectively, our data suggest that modulation of 
mTORC1 and NF-κB pathways may be a novel approach for better clinical management of vitiligo.   
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The retinoid-related orphan receptor RORα promotes semaphorin 3A expression in human 
keratinocytes
Y Kamata,1 M Tominaga,1 Y Umehara1 and K Takamori1,2 1 Institute for Environmental and 
Gender-Specific Medicine, Juntendo University Graduate School of Medicine, Urayasu, 
Japan and 2 Department of Dermatology, Juntendo University Urayasu Hospital, Urayasu, 
Japan
Increased epidermal nerve density is considered as one cause of itch sensitization in the periphery. 
Previously, we reported a potential contribution of keratinocyte-derived semaphorin 3A (Sema3A) to 
modulation of epidermal innervation in dry skin-based skin diseases such as atopic dermatitis (AD). 
However, the regulatory mechanism of endogenous Sema3A is currently unknown. In this study, 
we investigated the promoter region of the Sema3A gene in normal human epidermal keratinocytes 
(NHEK). The 5’-flanking region of the Sema3A gene (approx. 1.4 kb) was cloned and a number of 
putative transcription factor binding sites were identified by using BIOBASE P-Match-Public v1.0. A 
critical region for Sema3A promoter activity within -134 bp from the transcription start site was iden-
tified in deletion analyses. In this region, some consensus sequences recognized by RORα, Sox and 
GABP were found. Site-directed mutagenesis of RORα site showed significantly lower activity (4.3%, 
p<0.001) than in an intact case. Furthermore, RORα siRNA effectively reduced Sema3A expres-
sion (24%, p<0.001) compared with control siRNA. Sema3A expression was dose-dependently 
promoted by SR1078 (3.4-fold, p<0.001) and cholesterol sulfate (6.3-fold, p<0.001), which are 
RORα agonists. Expression levels of Sema3A (3.6-fold, p<0.001) and RORα (13-fold, p<0.001) 
were enhanced in NHEK cultured in 1.4 mM calcium compared with 0.15 mM calcium. These 
results suggest that RORα plays a key role in regulating Sema3A expression during keratinocyte 
differentiation. RORα was also expressed in both nuclei and cytosol of spinous and granular layers 
in healthy skin, whereas it was hardly detectable in nuclei in the AD skin. Thus, RORα agonists 
may be useful for the topical antipruritic treatment of skin diseases with itch sensitization involving 
epidermal hyperinnervation, such as AD.    
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CD4+Bcl-6+ T follicular helper cells in skin lesions of patients with bullous pemphigoid
E Dang and G Wang Dermatology, Xijing Hospital, the Fourth Military Medical University, 
Xi’an, China
T follicular helper (Tfh) cells, which assist B cells and are crucial to humoral immunity, also play 
crucial roles in the pathogenesis of bullous pemphigoid (BP). Elevated levels of circulating Tfh cells 
are observed in BP, which is positively correlated with disease severity. However, the characteristics 
of Tfh cell infiltration into the lesions of BP patients have not been well defined. The aim of this study 
is to characterize Tfh cell infiltration in lesional skin of BP patients and to evaluate the correlations 
of those cells with disease severity of BP. Immunohistochemical study showed that both CD4+ cells 
and Bcl-6+ cells were present in higher numbers in BP lesions than in control skin (P<0.01 and 
P<0.01), and they tend to accumulated and co-localize in the bases of the blisters and superficial 
derma in the skin lesions of BP patients. The presence of double-stained CD4+Bcl-6+ Tfh cells was 
confirmed in the lesions of BP patients by confocal microscopy. Moreover, Tfh cells in the lesional 
skin were positively correlated with anti-BP180-NC16A autoantibody titers (R=0.8667, p< 0.01). 
These results indicate that the infiltration of numerous Tfh cells into the lesions play an important 
role in the pathogenesis and progression of BP.    
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N-linked glycosylation on laminin γ1 influences recognition of anti-laminin γ1 pemphigoid 
autoantibodies
X Li,1 H Qian,1 H Koga,1 A Tsuchisaka,1 N Ishii,1 T Hayakawa,1 Y Hirako2 and T Hashimoto1 
1 Department of Dermatology, Kurume University School of Medicine, and Kurume 
University Institute of Cutaneous Cell Biology, Fukuoka, Japan and 2 Division of Biological 
Science, Nagoya University, Nagoya, Japan
Anti-laminin (LM) γ1 pemphigoid is an autoimmune blistering disease with IgG antibodies to LMγ1. 
Reactivity of patient sera with LMγ1 in various antigen sources has not been well addressed. In this 
study, we performed immunoblotting of various antigen sources; i.e., normal human dermal extract 
(NHDE), lysates and supernatants of five different keratinocyte cell lines, and recombinant proteins 
of LM521 and LM411 trimers. Immunoblotting using anti-LMγ1 monoclonal antibody showed that 
various antigen sources produced LMγ1 with different molecular weights, resulting from different 
N-linked glycosylation levels. Patient sera showed different reactivity with LMγ1 among various 
antigen sources with best reactivity to LMγ1 in NHDE. Patient sera reacted significantly more 
strongly with deglycosylated LMγ1 than glycosylated LMγ1 in LM521 recombinant proteins, while 
patient sera reacted significantly more strongly with glycosylated LMγ1 than deglycosylated LMγ1 
in NHDE. Patient sera showed no positive reactivity with either glycosylated or deglycosylated 
LMγ1 in lysates and supernatants of all cell lines. This was the first study, which revealed LMγ1 
with different molecular weights. This study also showed that anti-LMγ1 antibodies in patient sera 
are heterogeneous and N-linked glycosylation influences LMγ1 recognition of patient sera. These 
findings should facilitate future studies of pathomechanisms in anti-LMγ1 pemphigoid.    
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Anti-inflammatory activity of alkylamides from Echinacea purpurea in keratinocytes in vitro 
and in mouse models of inflammatory skin diseases
M Soeberdt,1 A Oláh,2 U Knie,1 D Metze,3 T Biro2 and C Abels1 1 Dr. August Wolff GmbH 
& Co. KG Arzneimittel, Bielefeld, Germany, 2 DE-MTA “Lendület” Cellular Physiology 
Research Group, University of Debrecen, Debrecen, Hungary and 3 Department of 
Dermatology, University of Münster, Münster, Germany
Echinacea purpurea extracts (purple coneflower) are known to have immunomodulatory effects. 
Several alkamides, major lipophilic constituents, bind to cannabinoid receptors 1 and 2 (CB1-R 
and CB2-R). N-Isobutyl dodeca-2E,4E-diene amide (15) binds to CB2-R (Ki = 60 nM) and CB1-R 
(Ki = 1.94 μM). Since the endocannabinoid system is of importance in inflammatory skin diseases, 
anti-inflammatory activity of alkamides was investigated. An alkamide mixture and substance 15 
were tested in cultured human keratinocytes. A significant (p<0.05) reduction of lipoteichoic acid-in-
duced mRNA expression of IL-1α, IL-1β, and IL-6 was observed for the mixture and 15. Moreover, 
the mixture was also able to reduce expression of IL-8. In addition, effects of the mixture or 15 
were assessed in a DTH mouse model. Mice (n = 5) were sensitized with oxazolone, challenged 
4 to 6 times and treated daily for 12 or 5 days with the mixture (1%) or 15 (1%) or betamethasone 
dipropionate (0.05%). Histology of treated ears showed anti-inflammatory effects on ear thickness, 
epidermal thickness and dermal infiltrate. Moreover, 15 (1%) was tested in NC/Nga mice for 30 d 
(n = 8-9). Substance 15 exhibited a significant reduction of symptoms (61%; p<0.01) comparable 
to tacrolimus (0.1%) (78%; p<0.01) in this model. A mixture of alkamides from Echinacea showed 
significant anti-inflammatory effects in vitro and in vivo. Most interestingly, a single alkamide 15, a 
CB2-R agonist, exhibited significant anti-inflammatory effects in vitro and in two dermatitis models. 
The low molecular weight and reduced cLogP make 15 a potential therapeutic option for the topical 
treatment of inflammatory skin diseases like atopic dermatitis.    
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A role of IRF7 in the pathogenesis of SLE
F Miyagawa and H Asada Dermatology, Nara Medical University, Kashihara, Japan
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs and is 
characterized by the production of autoantibodies specific for nuclear components. Recent genetic 
studies of SLE patients have revealed that interferon regulatory factor (IRF) 7 gene polymorphisms 
are associated with an increased risk of SLE but the precise role of IRF7 in SLE development is not 
fully understood. IRF7 is a member of the IRF family of transcription factors that induce transcription 
of IFN-α and the expression of IFN-responsive genes. Many lines of investigation support IFN- α as 
a causal agent in human lupus, and high levels of serum IFN- α are a heritable risk factor for SLE. 
In order to examine the role of IRF7 in the pathogenesis of SLE, a murine model of SLE induced by 
2,6,10,14-tetramethylpentadecane (TMPD) was used. IRF7 deficient mice and wild-type (WT) con-
trol mice were treated intraperitoneally with TMPD and spleens, kidneys and blood were harvested 
9-10 months later. Sera from WT or IRF7 deficient mice treated with TMPD as well as sera from 
PBS treated mice were tested for anti-nuclear antibodies (ANAs) by indirect immunofluorescence. 
Sera from TMPD-treated WT mice were strongly ANAs positive while TMPD-treated IRF7 deficient 
mice and PBS-treated mice were negative. However, direct immunofluorescence of the kidneys 
revealed glomerular IgG deposits in both TMPD-treated WT mice and IRF7 deficient mice. We 
also examined cytokine production from CD4 T cells in TMPD-treated WT and IRF7 deficient 
mice since recent evidence suggests that IL-17-mediated inflammation might play a role in the 
pathogenesis of SLE. Production of IFN-γ, IL-4, and IL-17 from CD4 T cells was not detected in 
both TMPD-treated WT and IRF7 deficient mice suggesting that Th differentiation is not involved 
in this murine model. Further studies have been in progress to explore the actual contribution of 
IRF7 to the development of lupus.    
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The role of magnetic resonance imaging in the diagnosis of early eosinophilic fasciitis prior 
to the development of cutaneous findings
L Gorcey,1 AN Femia,1,2 AB Eastham,2 G Gaviola3 and RA Vleugels2 1 Ronald O. Perelman 
Dept of Dermatology, NYU School of Medicine, New York, NY, 2 Dept of Dermatology, 
Brigham & Women, Harvard Medical School, Boston, MA and 3 Dept of Radiology, Brigham 
& Women, Harvard Medical School, Boston, MA
Eosinophilic fasciitis (EF) is a rare fibrosing condition, typically presenting with abrupt-onset sym-
metric thickening and induration of the distal extremities. Diagnosis can be challenging and is 
often delayed, potentially leading to permanent functional impairment. We report a case of EF in 
which MRI enabled early diagnosis prior to the development of characteristic cutaneous findings. 
A 56-year-old woman presented with a 5-month history of atrophic, indurated plaques on her 
abdomen, breast, and inguinal fold, with 3 biopsies supportive of morphea. In addition, she had 
an indurated plaque on the left forearm associated with tightness and persistent tenderness of the 
bilateral quadriceps without associated skin findings, which led to substantial functional limitation 
and the requirement of a cane for ambulation. Although the abdominal plaques were consistent 
with morphea, the thigh tenderness and arm tightness raised suspicion for deeper inflammation, 
which prompted MRI, revealing fascial enhancement in the forearm and thighs. Incisional biopsy 
confirmed the diagnosis of EF. Differentiating EF and morphea can be challenging as both condi-
tions share clinical features and overlap occurs in up to 30% of cases. Histopathologic findings 
can be identical without adequate fascial sampling. Identifying fascial inflammation is imperative, 
as systemic corticosteroids are indicated in EF to prevent irreversible fibrosis, but are typically not 
required in plaque morphea. In this case, MRI allowed for early diagnosis and initiation of systemic 
corticosteroids prior to the development of cutaneous findings on the thighs. The patient improved 
within 3 weeks and returned to baseline functioning. We propose that MRI may allow for early 
diagnosis of EF even in the absence of cutaneous findings, enabling early institution of therapy and 
prevention of permanent fibrosis.    
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A direct role for ΔNp63 in regulating the pruritogenic cytokine IL-31 and alarmin IL-33, in 
the pathogenesis of atopic dermatitis
R Romano and S Sinha Biochemistry, State University of New York at Buffalo, Buffalo, NY
Atopic Dermatitis (AD) is a chronic relapsing inflammatory skin disease with complex etiology. AD 
is associated with reactive immune responses and defective skin barrier but to what extent these two 
mechanisms contribute to AD is debatable. Recent genomic profiling experiments on skin lesions 
of AD patients have revealed a dramatic up-regulation of the transcription factor p63. p63, specif-
ically ΔNp63, plays an indispensable role in epidermal development and homeostasis. However, 
the role of ΔNp63 in AD has not been examined. To investigate the contribution of ΔNp63 in the 
pathogenesis of AD, we have utilized a transgenic mouse model with overexpression of ΔNp63 in 
the epidermis (ΔNp63TG). Expression of ΔNp63 in adult mice results in a skin phenotype that shares 
many of the key features associated with human AD skin lesions. Specifically these animals develop 
epidermal hyperplasia, altered terminal differentiation/barrier function defects and a chronic and 
reactive inflammatory microenvironment marked by macrophage and mast cell infiltrations and 
the polarization Th2 cells. Additionally, ΔNp63TG animals develop severe pruritic skin lesions, a 
predominant symptom of AD. Consistent with these pathological changes, ΔNp63TG epidermis 
shows a marked increase in many cytokines/chemokines that include predominant activation of 
the IL-33 signaling pathway. Moreover, IL-31 signaling is elevated in the ΔNp63 transgenic mouse 
skin, which might be the underlying cause for the severe pruritic skin phenotype. Interestingly, 
ChIP experiments demonstrate that a large number of AD related cytokines/chemokines, including 
IL-33 and IL-31, as well as genes involved in terminal differentiation/barrier function, are under the 
direct transcriptional control of ΔNp63 in keratinocytes. Together, our data suggests that high levels 
of ΔNp63 may function as an initiating event for AD by functioning through both an inside-out 
(immune) and outside-in (barrier) mechanism. A better understanding of the ΔNp63-driven events 
can thus be harnessed for effective treatment of AD.    
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RNA-Seq profiling increases the atopic dermatitis transcriptome and identifies pro-inflam-
matory genes with potential therapeutic implications
M Suarez-Farinas,1 M Rozenblit,1,2 H Mitsui,1 JM Correa da Rosa,1 J Krueger1 and E Guttman-
Yassky1,2 1 Investigative Dermatology, Rockefeller University, New York, NY and 2 
Department of Dermatology, Icahn School of Medicine, New York, NY
Genomic profiling of lesional and non-lesional atopic dermatitis (AD) skin using microarrays has led 
to increased understanding of immune and barrier abnormalities that contribute to disease patho-
genesis, leading to identification of therapeutic targets. However, microarrays have limitations that 
might result in below reliable detection levels of potentially important AD genes. High throughput 
parallel sequencing/RNA-Seq does not harbor these limitations, is not dependent on probe design, 
and covers a larger dynamic range. In this study, RNA-seq and microarrays were used to identify the 
AD transcriptome, defined by differentially expressed genes/DEGs in lesional versus non-lesional 
skin in 18 adults with severe AD. Both methods correlated well with RT-PCR (r=0.64 vs 0.63), the 
gold standard in detecting low abundance genes. In terms of detecting DEGs, RNA-seq achieved the 
highest sensitivity (0.53 vs 0.47). Using the classical cutoff (FCH>2, FDR<0.05), RNA-seq detected 
an AD transcriptome of 1109 DEGs (519 up and 590 down-regulated) while only 886 (511 up and 
375 down-regulated) were identified on arrays, of which 209 were also identified by RNA-seq. 
Among the up-regulated DEGs uniquely identified by RNA-Seq we found TREM-1 and related genes 
(CCL2/3, TNF, ITGAX/CD11c, and SIGIRR which regulates IL-1 and TLR-mediated inflammation). 
Using RNA-seq profiling for the first time in AD, we enlarged the AD transcriptome, and identified 
increased expression of genes previously unreported in AD. TREM-1 signaling has been shown to 
amplify inflammatory responses to microbial infections. Since AD is characterized by excessive 
immune responses to staph infections, TREM-1 might constitute a potential therapeutic target.   
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Circulating central and effector memory T-cells in atopic dermatitis display pathologic, high 
level activation irrespective of IgE levels
T Czarnowicki,1 J Krueger,1 J Gonzalez1 and E Guttman1,2 1 Rockefeller University, New 
York, NY and 2 Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
The extent to which T cell activation extends beyond the skin in atopic dermatitis (AD) is largely 
unexplored. Flow cytometry was used to measure a sequence of T-cell activation steps in central 
memory (Tcm) and effector memory (Tem) of both CLA+ and CLA- subsets from 16 adult severe 
AD patients and 16 controls. T-cells that displayed early (CD25), mid (ICOS), and late (HLA-DR) 
activation molecules were quantified in Tcm (CCR7+CD45Ro+) and Tem (CCR7-CD45Ro+) pop-
ulations using CLA to separate skin homing (CLA+) vs. other T-cell subsets. Interestingly, CLA+ 
Tcm and Tem cells in normal controls had higher levels of CD25+ and ICOS+ T-cells, but only 
CLA+ Tem had higher HLA-DR frequency (p < 0.05). This suggests that skin homing T-cells are 
generally more activated than other populations. In comparison, skin homing T-cells displaying 
early and mid activation markers were ~2-fold higher in both Tcm and Tem populations from AD, 
while persistently activated (HLA-DR+) were 8.6% in AD vs. 1.4% in controls for Tcm and 16% 
vs. 6% for Tem subsets (p<0.05). These data suggest that skin homing T-cells of AD patients are 
persistently activated in both central and effector memory subsets and are not related to IgE levels. 
In addition, CLA- Tcm (“systemic T-cells”) displayed higher CD25, ICOS, and HLA-DR frequencies 
in AD patients vs. controls (p < 0.05), but overall activation was reduced compared to respective 
CLA+ subsets. Pathologic T-cell activation in AD extends into skin homing central memory subsets 
and to “systemic” central memory populations. Having a large reservoir of chronically activated, 
circulating central and effector memory CLA+ T-cells helps to explain frequent disease exacerbations 
across different skin regions. It also provides a potential explanation for short disease remissions 
produced by treatments that deplete T-cells from skin lesions. Conversely, non-cutaneous features 
of AD may be regulated by pathologic activation within CLA- T-cells.    
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Development of a novel animal model to study the role of eosinophils in autoimmune blis-
tering disease bullous pemphigoid
L Lin,1 K Messingham,2 P Geng,1 L Lin,1 B Hwang,1 N Li,1 J Fairley,2 J Lee,3 RP Hall,4 
LA Diaz,1 B Koller1 and Z Liu1 1 University of North Carolina, Chapel Hill, NC, 2 University 
of Iowa, Iowa City, IA, 3 Mayo Clinic Scottsdale, Scottsdale, AZ and 4 Duke University, 
Durham, NC
Bullous pemphigoid (BP) is an autoimmune inflammatory subepidermal blistering disease associated 
with autoantibodies against two hemidesmosomal components, the BP230 and BP180 and an 
inflammatory infiltrate including eosinophils and neutrophils. BP180-specific IgG autoantibodies 
from BP patients induce BP-like skin lesions in BP180 humanized mice (hBP180 mice). Subepider-
mal blistering induced by anti-BP180 IgG depends on complement, mast cells, and neutrophils. 
Eosinophils as dominant infiltrating cells in BP have long been suspected to be pathogenically rele-
vant; but, it still remains unknown whether eosinophils participate in BP. Here, we test if anti-BP180 
IgE induce an eosinophil-dependent BP disease in mice. Knowing that mouse eosinophils lack IgE 
receptors for human IgE, we generated a humanized IgE receptor FceRI mouse strain (hFceRI) and 
crossed hFceRI mice onto hBP180 mice to generate hFceRI/hBP180 mice. Anti-BP180 IgE, when 
injected i.d. into hFceRI/hBP180 mice, trigger eosinophil infiltration and subsequent subepidermal 
blistering 48 h post IgE injection. In contrast, the pathogenic anti-BP180 IgE failed to induce BP in 
hBP180 mice deficient of eosinophils or lacking hFceRI. Furthermore, eosinophil-deficient hBP180 
mice reconstituted with eosinophils from hFceRI+/+ but not hFceRI-/- mice became susceptible to 
anti-BP180 IgE-induced BP. These data suggest that BP180-specific IgE and eosinophils are involved 
in BP. This novel animal model should be an ideal in vivo system for dissecting the role of IgE 
autoantibodies and eosinophils in the disease pathogenesis    
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TNF-α and IL-17 can induce inflammatory changes in human aortic endothelial cells, poten-
tially promoting early stages of atherogenesis in psoriasis
M Cannizzaro,1,3 H Mitsui,1 J Gonzalez,2 J Fuentes-Duculan,1 M Suarez-Farinas1 and 
J Krueger1 1 Laboratory for Investigative Dermatology, Rockefeller University, New York, NY, 
2 Translational Technology Core Lab (CCTS), Rockefeller University, New York, NY and 3 
Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy
Atherosclerosis is one of the most frequent psoriasis comorbidities. Since psoriasis is an independent 
risk factor for development of cardiovascular diseases, we hypothesized that a mechanistic link 
between skin inflammation and atherogenesis could be high-levels of psoriasis related cytokines 
(IL-17, TNF, IFN-γ) in the circulation with attendant effects on aortic endothelial cells. Expression 
of IL-17 receptor on human aortic endothelial cells was demonstrated using double immunoflu-
orescence with CD31 and confirmed by RT-PCR. Hence we cultured Human Aortic Endothelial 
Cells (HAoECs) with IL-17, TNF-α and IFNγ, alone or in combination. We studied effects on gene 
expression using the new Affymetrix HTA 2.0 arrays. We detected up-regulation of several adhesion 
molecules (VCAM, ICAM, SEL-E) as well as chemokines (CX3CL/fractalkine and CXCL2) in cells 
treated with the combination of IL-17 and TNF-α. The results were confirmed by RT-PCR (p<0.005). 
We further confirmed protein expression of inflammatory cytokines and chemokines in the superna-
tant of cultured HAoECs by using ECL (MSD) and xMAP technology (Luminex). These results suggest 
that in a state of systemic inflammation driven by IL-17, TNF-α, and IFNγ, HAoECs express higher 
levels of adhesion molecules (p < 0.005) required for leukocyte trafficking to subendothelial space 
(early atheromas), and HAoECs synthesize chemokines such as fractalkine that stimulate migration 
of inflammatory macrophages associated with atheroma formation. These findings thus provide a 
possible mechanism by which skin inflammation in psoriasis could increase atheroma formation and 
thus help create the increased rate of cardiovascular disease in this patient population.    
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Environmental factors transmitted by the aryl hydrocarbon receptor influence the severity 
of psoriatic inflammation
P Di Meglio,1 JH Duarte,1 H Ahlfors,1 ND Owens,2 Y Li,1 F Villanova,3 I Tosi,3 K Hirota,1 
FO Nestle,3 U Mrowietz4 and B Stockinger1 1 Molecular Immunology, MRC NIMR, London, 
United Kingdom, 2 System Biology, MRC NIMR, London, United Kingdom, 3 St. John’s 
Institute of Dermatology, King, London, United Kingdom and 4 Dermatology, University 
Medical Center Schleswig-Holstein, Kiel, Germany
Psoriasis is a chronic inflammatory skin disease resulting from the interaction of genetic and envi-
ronmental factors. A pathogenic cross-talk between innate, adaptive and epithelial cells underpins 
this disease. Genome-wide association studies have identified more than 40 disease-associated loci. 
Environmental risk factors on the other hand remain less well-defined on a mechanistic basis. Here 
we show that the aryl hydrocarbon receptor (AhR), a transcription factor that senses environmental 
stimuli, modulates pathology in psoriasis. AhR-activating ligands reduced inflammation in the 
lesional skin of psoriasis patients, whereas AhR antagonists increased inflammation. Similarly, AhR 
signalling via the endogenous ligand FICZ reduced the inflammatory response in the imiquimod-in-
duced model of psoriasiforme skin inflammation and AhR deficient mice exhibited a substantial 
exacerbation of the disease, compared to AhR sufficient controls. Non-haematopoietic cells, in 
particular keratinocytes, were responsible for this hyper-inflammatory response, which involved 
increased reactivity to IL-1β and upregulation of AP-1 family members of transcription factors. Thus, 
our data suggest a critical role for AhR in the regulation of inflammatory responses and open the 
possibility for novel therapeutic strategies in chronic inflammatory disorders.    
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Neural recruitment and activation is required for the development of atopic dermatitis: Novel 
insights into disease pathogenesis revealed by in vivo imaging
S Elmariah, T Luo, E Azimi, VB Reddy and EA Lerner Dermatology, Massachusetts General 
Hospital, Boston, MA
Atopic dermatitis is a common and frequently disabling cutaneous disorder characterized by pruritus 
and inflammation. In addition to defective barrier function and immune dysregulation, alterations 
in neural innervation and neurogenic inflammation appear to play little recognized but important 
roles in atopic dermatitis pathogenesis. In this study, we report for the first time the use of in vivo 
imaging of fluorescently labeled peripheral sensory nerves in mice during epicutaneous sensitization 
to ovalbumin, an allergic mouse model that produces eczematous skin lesions. Visualization of 
the same cutaneous nerve branches sequentially over time revealed that specific subpopulations 
of peripheral sensory nerves are highly dynamic early in eczema development, eventually resulting 
in higher innervation density and arbor complexity in the skin. Neural sprouting and retraction 
occurred within hours to days of ovalbumin sensitization and continued throughout epicutaneous 
sensitization, preceding changes in vascularization, vascular permeability, and immune infiltration. 
Blocking neural activation during periods of sensitization prevented ovalbumin-induced changes 
in neural recruitment and pattern reorganization, inflammatory infiltrate, scratching behavior and 
the development of eczematous skin changes. These data demonstrate that neural changes are 
not merely a reaction to inflammation in eczematous skin, as previously thought. Rather, neural 
innervation changes and activation in response to epicutaneous antigen exposure are required for 
the development of the inflammatory cascade involved in the pathogenesis of allergic eczema.   
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Bullous pemphigoid eosinophils express surface FcεRI and exhibit BP180-specific 
degranulation
HM Holahan,2 K Messingham,2 C Fullenkamp,2 R Srikantha2 and JA Fairley1,2 1 Veterans 
Administration, Iowa City, IA and 2 Dermatology, University of Iowa, Iowa City, IA
Bullous pemphigoid (BP) is characterized by IgG and IgE autoantibodies targeting BP180 (type XVII 
collagen) resulting in loss of epidermal integrity. These patients exhibit systemic eosinophilia, though 
the pathologic role of eosinophils in BP is not well understood. Inhibition of IgE binding to its high 
affinity receptor, FcεRI, results in improvement of the disease, and a rapid decline in circulating 
eosinophils; however, the mechanism behind this remains unknown. Furthermore, the expression 
of FcεRI by BP eosinophils is not well defined. These studies evaluated eosinophils from BP patients 
for expression of FcεRI and explored its functional significance in disease pathogenesis. To achieve 
this, peripheral blood and biopsy tissue were obtained from BP patients or controls. RT-PCR con-
firmed expression of FcεRI by immunomagnetically purified (≥ 96%) peripheral eosinophils from 
BP patients. Flow cytometry on peripheral eosinophils (CD203c-/CD16-/CD49d+) revealed surface 
bound IgE and a low level of FcεRIα in subset of BP samples, but not controls, which was lost with 
disease remission. Using a proximity ligation assay and confocal microscopy to increase sensitivity, 
interaction of IgE with the alpha-chain of FcεRI was confirmed on the surface of eosinophils from 
peripheral blood or biopsy tissue of BP patients. IgE receptor function was evaluated using an ex 
vivo degranulation assay on purified eosinophils to eliminate involvement of other cell types. 
Eosinophils from active BP patients degranulated in response to the recombinant BP autoantigen 
(BP180), but not GST or NC1 control proteins. Eosinophils from patients in remission, or healthy 
controls, did not degranulate. Finally, eosinophil degranulation in BP was confirmed by the presence 
of eosinophil-derived neurotoxin (EDN) and eosinophil chemotactic protein (ECP), in BP sera and 
blister fluid by ELISA. Current studies are aimed at establishing whether eosinophil degranulation 
in BP is dependent on FcεRI as a possible mechanism of pathogenesis.    
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Profiling a vast natural collection for dermatological uses
W Kinney,1 M Goetz,1 J Fernandez,2 M Stock2 and E Perez2 1 Natural Product Discovery 
Institute, Blumberg Institute, Doylestown, PA and 2 Signum Dermalogix, Monmouth, NJ
The Natural Products Discovery Institute (NPDI) houses the former Merck U.S. natural product 
collection and makes it available to qualified researchers in both academic and industrial settings. 
This proven druggable collection amounts to over 100,000 extract samples (plants, fungi, and 
actinomycetes sourced), which are backed up with reserve materials and producing cultures, as 
well as extensive expertise in chemistry and microbiology garnered from decades of experience in a 
pharmaceutical setting. Early experience with the screening of the NPDI collection for pharmaceuti-
cal uses has yielded virgin hit extracts in 80% of cases (i.e. they had not been previously identified 
as biologically active nor explored for a bioactive component). The NPDI and Signum Dermalogix 
are collaborating to characterize components of this Natural Product collection for possible derma-
tological uses. Dermalogix develops cosmetic and drug candidates for skin care and have in-house 
screening capabilities to assess the activity and safety of potential cosmetic ingredients. Utilizing 
a cell-free radical scavenging assay, well-characterized natural extracts from the NPDI library are 
tested to identify those with the most potent radical scavenging capacities (antioxidant properties). 
Hits are then screened for anti-inflammatory in a dermal cell line. This work describes our recent 
screening results in profiling a pilot set of diverse samples and demonstrate the cosmetic product 
opportunities within this collection.    
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CD14+ HLA-DRlow myeloid derived suppressor cells are numerically increased yet func-
tionally impaired in psoriasis
DC Soler,1,2 A Young,1 L Fiessinger,1 T McCormick1,2 and KD Cooper1,2,3 1 Dermatology, 
Case Western Reserve University, Cleveland, OH, 2 The Murdough Family Center for 
Psoriasis, Case Western Reserve University, Cleveland, OH and 3 University Hospitals Case 
Medical Center and VA Medical Center, Cleveland, OH
The clinical extent of psoriasis pathology is regulated in part by defects in innate immune networks, 
particularly in the suppressive actions of regulatory T cells (Tregs). Recently, CD14+ HLA-DRlow 
monocytic myeloid-derived suppressor cells (M-MDSC) have been shown to induce Tregs as one 
of the mechanisms favoring oncogenic cell expansion, however little is known about the role of 
M-MDSC in benign chronic inflammatory conditions such as psoriasis. We found that M-MDSC were 
elevated in psoriatic patient peripheral blood (PBMC) compared to non-psoriatic healthy controls 
(19.1% vs. 9.7%, p=0.002). Interestingly, functional assays demonstrated that psoriatic M-MDSC 
converted fewer naïve T effector cells (Teff) into Tregs. Further, psoriatic M-MDSC suppress CD8 
proliferation less efficiently compared to M-MDSC from healthy controls (38% vs. 66%. Lack of 
suppression by psoriatic M-MDSC may be due to decreased levels of arginase production, PD-1 
expression (N=11, 11.4% vs. 26%, p=0.04) and PD-L1 expression (N=8, 4% vs. 13.25%, p=0.05) 
compared to healthy controls M-MDSC. Skin-homing chemokines CCR4 and CCR10 were increased 
in psoriatic M-MDSC (N=6 3 % vs. 19 %, p=0.04 and 6% vs. 16%, p=0.05 respectively). Taken 
together, these results suggest that functional defects in psoriatic M-MDSC prevent proper suppres-
sion of effector T cell expansion, interfere with proper Treg generation, and hamper the immune 
system’s ability to correctly self-regulate.    
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Treatment of blood monocytes with substance P may lead to an up-regulation of inflammatory 
cytokines in vitro: A mechanism underlying the pathogenesis of atopic dermatitis
V Yanofsky, AR Shalita and W Lee Dermatology, SUNY Downstate Medical Center, 
Brooklyn, NY
Atopic dermatitis (AD) is an extremely common inflammatory skin condition thought to affect up 
to 10% of the global population. Despite this high disease prevalence, the specific pathogenesis of 
AD remains largely unknown. Recent evidence suggests that neuropeptides such as substance P (SP) 
may be playing a key role in the onset and promotion of disease. In fact, cutaneous levels of SP have 
been shown to be up-regulated in both lesional and non-lesional skin of AD patients. The precise 
nature of this effect, however, has yet to be fully explored. Herein, we investigate the impact of SP 
on PBMCs derived from both healthy volunteers and AD patients treated with or without SP. We 
further evaluate the role of SP on inflammatory cytokine expression in vitro using RT-PCR. Finally, 
cytokine secretion from monocytes following incubation with SP was assessed using a cytokine 
ELISA assay. We found that treatment with SP (50nM, 24hr) resulted in a significant increase in 
the mRNA expression for the inflammatory cytokines IL-6, IFN-γ and TNF-α in PBMCs derived 
from healthy volunteers (p<0.05). Additionally, the mRNA expression for the anti-inflammatory 
cytokine IL-10 was also found to be significantly up-regulated, which is consistent with previous 
research (p<0.05). Furthermore, there was a marked and significant increase in the secretion of 
pro-inflammatory cytokines IL-1α and IL-1β from monocytes, as measured via ELISA assay of PBMC 
supernatants following culture with SP (p<0.05). Increased SP levels in atopic patients may therefore 
be directly stimulating the chronic inflammation seen in AD through the enhanced secretion of 
pro-inflammatory cytokines from monocytes. This suggests that targeting the SP axis may provide 
a novel means of both preventing and controlling severe atopic disease.    
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Differential cytokine profiles offer multi-dimensional view on immune pathways involved 
in pemphigus vulgaris
C Guo, K Seiffert-Sinha and AA Sinha Dermatology, University at Buffalo, Buffalo, NY
Cytokines and chemokines direct the inflammatory response and may serve as markers of immune 
dysregulation in Pemphigus vulgaris (PV), an autoimmune blistering skin disease. Previous studies 
on limited numbers of patients and cytokine profiles in PV have produced equivocal results. In this 
study, we examined a comprehensive set of cytokines and chemokines covering several functional 
categories using serum samples from 121 PV patients, 15 HLA-matched and 15 HLA-unmatched 
controls by multiplexed bead array assays (Luminex Platform). Cytokines and chemokines analyzed 
include: IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, IL-21, 
IL-22, IL-23, TNFα, INFγ, MCP-1, Eotaxin. Our results indicate that several proinflammatory (IL-1α, 
IL-1β, IL-6, TNFα), Th2 pathway (IL-5, IL-13), and Th17 pathway (IL-21, IL-22, IL-23) cytokines are 
significantly increased in PV patients compared to healthy HLA-unmatched controls. Cytokines 
involved in the Th9- and NK cell-, but also antiinflammatory pathways (IL-9, IL-10, IL15) are 
significantly increased in PV patients compared to healthy HLA-matched controls. Interestingly, in 
several instances, HLA-matched controls have elevated proinflammatory cytokines similar to PV 
patients, indicating that there is an elevated immune state in genetically susceptible, but disease free 
individuals. The chemokines eotaxin and MCP-1 show no differential regulation between patients 
and controls. To our knowledge, this study is the most extensive analysis of serum cytokines/
chemokines in PV to date, both in terms of the range of soluble mediators studied and the number 
of patient and control samples analyzed. These data are relevant to autoimmune mechanisms and 
may help reveal markers of disease and clinical progression, as well as potential targets for therapy.   
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Autoantibodies against BP180 (Collagen XVII) in Parkinson’s disease and dementia
J Helfenberger,1 K Messingham,1 N Narayanan,2 J McKillip1 and JA Fairley1,3 1 Dermatology, 
Univ of Iowa, Iowa City, IA, 2 Neurology, Univ of Iowa, Iowa City, IA and 3 Dermatology, 
VA Medical Center, Iowa City, IA
Dementia (DEM) and Parkinson’s disease (PD) are independent risk factors for bullous pemphigoid 
(BP), an autoimmune disease caused by autoantibodies against the hemidesmosomal protein BP180 
(collagen XVII). The aim of this study was to determine the incidence of autoantibodies directed 
against BP180 in PD and DEM patients with no evidence of BP. Sera from 50 patients with PD 
(n=25) and DEM (n=25) and controls (n=50) were tested for autoantibodies against: 1) the pathogenic 
NC16A domain, 2) the intracellular domain and 3) extracellular, non-NC16A regions of BP180. Only 
one DEM patient had reactivity to the NC16A domain as determined by ELISA (41U, nl <9). Further 
analysis of this patient’s autoantibodies showed they were of the IgG4 subclass and complement 
fixation assay was negative. Reactivity to other domains was determined by immunoblotting against 
recombinant proteins. Densitometry of positive bands was performed with ImageJ software and was 
compared to positive (BP patients) and negative controls (age and sex matched without neurologic 
disease). Reactivity to the intracellular domain was seen in 7/50 patients (5/25 DEM and 2/25 PD) 
including the patient with NC16A reactivity. Immunoreactivity to the extracellular domain was 
observed in 5/50 patients (1/25 DEM, 4/25 PD). Demographics and disease activity scores were 
available for 22/25 of the PD patients. The autoantibody positive patients were older at diagnosis 
than autoantibody negative patients (72.4y vs 62.8) but disease activity scores were similar (2.6 
vs 2.4). This study indicates that autoantibodies to the BP180 protein develop at a higher rate in 
DEM and PD patients than controls. Further study of this subset of PD and DEM patients may give 
additional clues to the mechanisms of autoantibody development and the relationship between 
neurologic disease and autoimmunity.    
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PCR array study of atopic dermatitis-relevant genes in IL-4 transgenic mice before and after 
onset of the skin lesion
L Bao,1 H Zhang,1 GC Mohan,1 K Shen1 and LS Chan1,2,3 1 Dermatology, University of 
Illinois, Chicago, IL, 2 Microbiology/Immunology, University of Illinois, Chicago, IL and 3 
Medical Service, Jesse Brown VA Med Center, Chicago, IL
IL-4 plays an important role in atopic dermatitis (AD). We have generated IL-4 transgenic (Tg) 
mice by over-expressing IL-4 in the epidermis. These mice spontaneously develop chronic pruritic 
inflammatory skin lesions, which meet the clinical and histological diagnostic criteria for human 
AD. Systemic survey of immune-related genes has not been performed. In this study, we utilize 
PCR array technique to examine hundreds of AD-relevant genes in the IL-4 Tg mice. We collected 
skin tissues from IL-4 Tg mice before and after onset of the skin lesion as well as from their wild 
type littermates. After mRNA extraction, DNase digestion, and reverse transcriptase reaction, we 
performed the 384 PCR Gene Array on Inflammation/Autoimmunity (Qiagen) on these samples. 
Those genes with at least 2-fold up-regulation or down-regulation and with a P-value of less than 
0.05 were identified and analyzed. In the skin lesion, chemokines, pro-inflammatory cytokines, 
and their receptors are up-regulated while factors involved in antimicrobial peptides production 
are down-regulated compared to the wild type mice. Particularly, CXCL5, FPR1, IL-1β, IL-24, IL-6, 
oncostatin M, COX2 and REG3G are up-regulated several hundred-fold. We have collected the 
serum and will test whether these factors also dramatically increase in the peripheral blood of IL-4 
Tg mice. In the “pre-lesion” group that show no skin abnormality, 47 dysregulated genes were 
nevertheless identified though the fold changes are much less than that of the “post-lesion” group. 
These factors include CCL6, CCL8, CCL11, CCL17, CXCL13, CXCL14 CXCR3, IL-12Rβ2 and IL-24. 
Taken together, our data have identified hundreds of dysregulated factors in the IL-4 Tg mice before 
and after onset of the skin lesion. Future detailed examination of these factors will shed light on our 
understanding of the development and progression of AD and help to discover important biomarkers 
for clinical AD diagnosis and treatment.    
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Treatment with anti-IFNγ and anti-CXCR3 antibodies prevent the onset of alopecia areata 
in mice
L Xing,2 Z Dai,1 A Jabbari,1 A Christiano1,3 and R Clynes1,2 1 Dermatology, Columbia 
University, New York, NY, 2 Pathology and Cell Biology, Columbia University, New York, 
NY and 3 Genetics and Development, Columbia University, New York, NY
Alopecia Areata (AA) is an autoimmune disease resulting in non-scarring hair loss. C3H/HeJ mice 
develop AA spontaneously with histopathological similarities to the human disease, including a 
dense peribulbar infiltrate of CD8 T cells. We performed Affymetrix profiling to characterize the 
transcriptional landscape of AA mouse lesional skin versus unaffected C3H/HeJ skin. We found 
that many of the upregulated genes in alopecic skin were IFN-response genes, including striking 
upregulation of the IFN-inducible chemokines CXCL9, CXCL10 and CXCL11. We administered 
anti-IFNγ antibody to AA skin-grafted mice, which effectively prevented AA development, and 
prevented the accumulation of activated CD8 T cells in the skin. Effector and memory T lymphocytes 
can express CXCR3, the chemokine receptor which binds the IFN-inducible chemokines CXCL9, 
-10, and -11 to recruit T cells to inflammatory tissue sites. To determine the importance of CXCR3 
in pathogenesis we treated grafted mice with an anti-CXCR3 antibody which blocks CXCL10 and 
11. The incidence of AA in anti-CXCR3 treated C3H/HeJ grafted mice was reduced by 60%, with a 
corresponding diminution in CD8 T cell dermal infiltration. These data demonstrate the importance 
of the IFNγ Type I cellular response to AA pathogenesis and suggests that blocking dermal homing 
with CXCR3 targeted approaches represents a rational therapeutic approach in AA.    
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IL-23 cytokine is induced by TNFα and IL-17A in psoriatic keratinocytes
Y Liu and B Ehst Dermatology, Oregon Health & Science University, Portland, OR
Psoriasis is a chronic inflammatory disease with a genetic predisposition. Th17 immunity is a host 
defense system that protects tissues from the invasion of foreign pathogens. The activation of Th17 
immunity plays a predominant role in the pathogenesis of psoriasis. Under normal conditions, 
Th17 activation against infection will subside upon healing. Under psoriatic conditions, however, 
Th17 immunity initially triggered by skin injury or infection becomes persistently activated. Despite 
successful improvement of psoriasis therapy by blocking Th17 signaling pathway, the molecu-
lar mechanism underlying constitutive Th17 activation in psoriasis has not yet been identified. 
In searching keratinocyte derived factors critical for Th17 activation, we have identified IL-23 
being induced by TNFα and IL-17A in psoriatic keratinocytes. Compared with the keratinocytes 
from non-psoriatic patients, keratinocytes from psoriasis patients showed significantly higher IL-23 
expression in response to TNFα and IL-17A stimulation. Immunostaining with anti–IL-23 antibody 
revealed intensive IL-23 staining in psoriatic epidermis. These data provide the first evidence that 
IL-23 is induced by TNFα and IL-17A in psoriatic keratinocytes. As IL-23 is an inflammatory cytokine 
essential for Th17 cell activation, IL-23 induction by TNFα and IL-17A in psoriatic keratinocytes 
thus provides a basis for forming a positive feedback loop of Th17 activation involving Th17 cell 
activation by IL-23 from keratinocytes and keratinocyte activation by TNFα and IL-17A from Th17 
cells. This feedback loop may explain how the chronic inflammation is maintained in psoriasis 
pathogenesis and provide novel strategy for psoriasis therapy.    
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Chronic spontaneous urticaria – The Saskatchewan experience and questionnaire survey
N Gattey, B Bahrani and P Hull University of Saskatchewan, Saskatoon, SK, Canada
Background: Chronic spontaneous urticaria (CSU) is defined as urticaria persisting for more than 
6 weeks with no inducible cause. An autoimmune basis is held responsible for more than half 
the cases. Many cases have no identifiable cause. Method: 173 patients with CSU had been seen 
between 2003 and 2013. There were significantly more females than males (130:43). The age range 
was 1 year to 81. The mean age was 36 years. The average duration was 9.3 years. An autologous 
serum skin test (ASST) was performed on 138 patients and was positive in 58 (42.02%). Results: A 
questionnaire and informed consent, approved by the Research Ethics Office, was sent to patients 
and replies were received from 101 participants. We were unable to contact 25 patients, and 2 
patients had died. Of the respondents, 40 were ASST positive and 49 were ASST negative partic-
ipants. 55.00% of ASST (+) participants and 46.80% of ASST (-) participants no longer had hives. 
21 ASST positive patients who had significant quality of life issues were treated with intravenous 
immunoglobulin (IVIG), and 85.0% of these patients had improved quality of life with 13 of these 
patients now free of urticaria and no longer receiving IVIG.Patients were most bothered by pruritus, 
disturbed sleep, anxiety and their physical appearance including facial swelling. Many (70.4%) 
had missed work or school because the urticaria. The majority of patients felt that over the counter 
antihistamines were useful in disease control although prednisone as prescribed by emergency room 
physicians and family practitioners were added in about a fifth of the patients. Conclusion: In this 
follow-up questionnaire study, 30% of patients found antihistamines gave effective control. About 
40% of patients may have chronic spontaneous urticaria caused by autoimmunity as assessed by 
the ASST. IVIG was an effective treatment for this group of patients.    
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Compound 48/80-treated keratinocytes mimics neurogenic inflammation of atopic dermatitis: 
A new role of compound 48/80 as an inducer of neurogenic inflammation
H Lee, J Choi and S Lee Dermatology, Chonnam National University Medical School, 
GwangJu, Republic of Korea
Subjective and objective symptoms of atopic dermatitis (AD) are known to be related with neu-
rogenic inflammation (NI). AD skin lesions are induced by orchestrated expression of cytokines, 
chemokines, neurotransmitters, and neuropeptides, which are mediated by a complex of cells 
including T lymphocytes, dendritic cells, macrophages, keratinocytes (KCs), mast cells, and eosin-
ophils. This study was aimed to test a new role of compound 48/80 in KCs, based on the following 
backgrounds: KCs play a crucial role by producing a set of neuropeptides or neurotransmitters; KCs 
express substance P (SP) receptors; and compound 48/80 plays a role as very similar way as SP. For 
experiments, primary cultured human KCs were treated with 1-10 μg/ml of compound 48/80 for 24 
h, and markers of NI, such as NGF, CGRP, and TSLP were checked by RT-PCR. In results, CGRP and 
TSLP were up-regulated, but NGF was down-regulated, by compound 48/80 in a dose-dependent 
manner. Interestingly, Dermatophagoides farinae or Dermatophagoides pteronyssinus modulated 
those markers as the same way as compound 48/80 did. The compound 48/80-induced modulation 
of markers was mediated by ROS from our antioxidant experiments. From these results, we propose 
that compound 48/80-treated KCs can be a novel experimental system to test NI of AD.    
102
Eccrine sweat contains IL-1α, IL-1β and IL-31 and activates epidermal keratinocytes as a 
danger signal
X Dai, H Okazaki, Y Hanakawa, M Murakami, M Tohyama, Y Shirakata and K Sayama Ehime 
University Graduate School of Medicine, Toon, Japan
Eccrine sweat is secreted onto the skin’s surface and is not harmful to normal skin, but can exacerbate 
eczematous lesions in atopic dermatitis. Although eccrine sweat contains a number of minerals, 
proteins, and proteolytic enzymes, how it causes skin inflammation is not clear. We hypothesized 
that it stimulates keratinocytes directly, as a danger signal. Eccrine sweat was collected from the 
arms of healthy volunteers after exercise, and levels of proinflammatory cytokines in the sweat were 
quantified by ELISA. We detected the presence of IL-1α, IL-1β, and high levels of IL-31 in sweat 
samples. To investigate whether sweat activates keratinocytes, normal human keratinocytes were 
stimulated with concentrated sweat. Western blot analysis demonstrated the activation of NF-κB, 
ERK, and JNK signaling in sweat-stimulated keratinocytes. Real-time PCR using total RNA and ELISA 
analysis of supernatants showed the upregulation of IL-8 and IL-1β by sweat. Furthermore, pretreat-
ment with IL-1R antagonist blocked sweat-stimulated cytokine production and signal activation, 
indicating that bioactive IL-1 is a major factor in the activation of keratinocytes by sweat. Moreover, 
IL-31 seems to be another sweat stimulator that activates keratinocytes to produce inflammatory 
cytokine, CCL2. Sweat is secreted onto the skin’s surface and does not come into contact with 
keratinocytes in normal skin. However, in skin with a defective cutaneous barrier, such as atopic 
dermatitis-affected skin, sweat cytokines can directly act on epidermal keratinocytes, resulting in 
their activation. In conclusion, eccrine sweat contains proinflammatory cytokines, IL-1 and IL-31, 
and activates epidermal keratinocytes as a danger signal.    
103
Epidermal Rac1 hyperactivation is a key feature of human psoriasis
MC Winge,1 B Ohyama,1 EA Waterman,1 C Dei,1 N Ehsani-Chimeh,1 W Li,1 A Truong,1 
D Wu,1 T Makino,3 M Davidson,1 D Starcevic,1 N Nguyen,1 A Kislat,4 B Homey,4 
AW Armstrong,5 T Hashimoto,3 E Engleman,1 M Bradley2 and MP Marinkovich1 1 Stanford 
Univ, STA, CA, 2 Karolinska Inst, STO, Sweden, 3 Kurume Univ, KUR, Japan, 4 Heinrich-
Heine Univ, DUS, Germany and 5 UC Denver, DV, CO
We show here that mice overexpressing a K14 driven hyperactive V12 Rac1 mutant displayed 
clinical-histologic features mimicking human psoriasis including hyperkeratosis, erythema, Koeb-
nerization, Auspitz sign, arthritis, onychodystrophy, marked psoriasiform hyperplasia, parakerato-
sis, Munro microabcesses, dilated rete ridge blood vessels and characteristic immune infiltrates. 
Rac1 mouse and human psoriasis skin showed similar epidermal thickness, suprabasilar Ki67, and 
increased expression of IL 1,6,17,23,36/CCL 2,5,17,20/TNFα/TGFα/CARD14/IFIH1/IRFs,NFKB, 
STAT3 activation/β defensins/Act1/IL17R. Transcriptional comparison of psoriasis susceptibility 
genes in Rac1 mouse and human psoriatic skin showed marked overlap of both epidermal and 
immune pathways. A panel of 6 human psoriasis lesional skin samples showed high epidermal 
Rac1 activation using Rac1-GTP mAb compared to age/location matched controls (p<0.001). GTP 
pulldown/IF analysis of a panel of 4 primary human psoriasis keratinocyte (HPKC) cultures showed 
markedly high Rac1 activation in response to inflammatory cytokines such as IL23 and EGF, com-
pared to control KCs. Both HPKC and Rac1 overexpressing normal human KCs (Rac1KC) showed 
increased TGFα/IFIH1/CARD14/IL17R expression and increased NFKB/STAT3/IRF1 nuclear local-
ization, in response to IL17 stimulation, but this response was abolished in HPKC overexpressing 
a dominant negative N17Rac1 mutant. Coculturing human PBMCs with HPKC or Rac1KCs upreg-
ulated a number of inflammatory cytokines including IL 1,6,17,23/IFN α,γ/CCL4/TNFα as seen by 
Luminex assay. However N17Rac1 overexpression in HPKC abolished this response. In summary, 
comparison of our novel mouse model with human psoriasis cells/tissue shows that epidermal Rac1 
hyperactivation is a key event in psoriasis pathogenesis, which drives psoriasis pathways through 
the promotion of an abnormal epidermal-immune feedback loop.    
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Identification of aa502-533 as bullous pemphigoid-specific T lymphocyte epitopes
J Zhang and G Wang Dermatology, Xijing Hospital, Fourth Military Medical University, 
Xi’an, China
Bullous pemphigoid (BP) is a common and intractable autoimmune blistering skin disease, in which 
the epidermal basal cell- proximal noncollagenous domain (NC16A) of BPAG2 has been proven to 
be the target of autoimmune T lymphocytes in BP patients. However, a more precise identification 
of the target epitopes is still of potential interest as immunotherapy target antigen. To identify the 
NC16A- specific T lymphocyte epitopes and analyze the epitope- specific T cell response during the 
progress of BP, we employed the ELISPOT assay to detect the cytokines secretion of PBMC samples 
from BP patients in response to the stimulation of mixed and individual overlapping 15-mer peptides 
spanning the amino acid sequence of NC16A respectively. All of the 21 patients had anti- BP 180 
autoantibodies. 8 cases showed positive NC16A ELISPOT results. Of note, PBMC samples from four 
patients in both convalescent and active stages recognized the same NC16A region (aa502-533). 
Yet the frequency of aa502-533-specific T cell showed no significant difference, which should be 
further confirmed by more cases. Our results identified aa502-533 as a major NC16A-specific T 
lymphocyte epitopes. This new findings can be of great help with defining the target epitopes in BP 
more precisely which may contribute to the understanding the pathogenesis of BP.    
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Novel skin microperfusion demonstrates that psoriasis lesional skin contains higher protein 
levels of IL-17A and IL-17AF, but not IL-17F compared to non-lesional skin
C Loesche,1 MA Valentin,1 B Aigner,2 M Bodenlenz,2 F Polus,1 G Bruin,1 F Kolbinger,1 
C Calonder1 and F Sinner2 1 Novartis, Basel, Switzerland and 2 Joanneum, Graz, Austria
Secukinumab (AIN457), a selective fully human IL-17A monoclonal antibody, has shown supe-
riority to standard of care in the treatment of moderate-to-severe plaque psoriasis. We sought to 
characterize IL-17 subtype proteins as well as pathway relevant biomarkers, such as β-defensin-2 in 
the skin of healthy volunteers and psoriasis patients before and after a single dose of secukinumab 
using the novel open flow microperfusion (OFM) methodology. In this single-center, open-label, 
exploratory study, 8 healthy volunteers and 8 psoriasis patients received one dose of 300 mg s.c. 
secukinumab. At baseline, one and two weeks later, skin catheters were placed in healthy skin or 
non-lesional and lesional skin of patients to collect a perfusate of dermal interstitial fluid (dISF) and 
protein levels were measured. Single dose treatment with secukinumab resulted in a significant 
decrease of disease scores from baseline to end of study. Baseline IL-17A protein in lesional dISF 
of psoriasis patients was significantly higher (geometric mean: 1.46 pg/mL) than in non-lesional 
skin or in skin of healthy volunteers (0.12 and <0.096 pg/mL resp.; p<0.0001). Similarly, IL-17A/F 
heterodimer proteins were measured and differed significantly between lesional and non-lesional 
dISF (p<0.0001), while IL-17F homodimer protein levels in skin did not achieve significant differ-
ences (p>0.05). Consistent with our IL-17A observations, baseline β-defensin-2 levels in lesional 
skin (410 pg/mL) were significantly higher compared to non-lesional and healthy volunteers (62.2 
and <32.5 pg/mL resp). Skin and serum levels of β-defensin-2 decreased dramatically already at 
week 1 after single dose treatment. Directly measured in skin with OFM, the role of IL-17A homo- 
(AA) and heterodimers(AF) in psoriasis could be confirmed. In addition, a single dose of a specific 
anti-IL-17A antibody, secukinumab, decreased rapidly and dramatically relevant IL-17A pathway 
markers such as β-defensin-2.    
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The anti IL-17A IgG1 antibody distributes in dermal interstitial fluid as demonstrated by 
using dermal open flow microperfusion after a single 300 mg subcutaneous administration; 
assessment in healthy volunteers and patients with moderate-to-severe plaque psoriasis
G Bruin,1 C Dragatin,2 B Aigner,3 F Polus,1 C Calonder,1 C Froeliger,1 K Tiffner,2 
M Bodenlenz,2 J Mader,3 S Korsatko,3 M Ratzer,2 T Pieber,2,3 C Loesche1 and F Sinner2 1 
Novartis, Basel, Switzerland, 2 Joanneum, Graz, Austria and 3 Medical University, Graz, 
Austria
This single-center, open-label study (NCT01539213) was conducted for the quantification of secuki-
numab, a fully human anti–interleukin-17A monoclonal antibody to treat moderate to severe plaque 
psoriasis, in dermal interstitial fluid (dISF) of healthy subjects and psoriasis patients. In Part 1, 8 
healthy volunteers received a single s.c. dose of secukinumab (300 mg) on Day 1. Secukinumab 
concentrations were measured in serum and dOFM samples obtained at baseline and on Days 8 
and 15, as well as in blister fluid and skin biopsy samples obtained on Day 15 in healthy volunteers. 
The dISF concentrations obtained from dOFM were compared with blister fluid concentrations and 
calculated concentrations in skin biopsy homogenates. In part 2, secukinumab levels were quantified 
in 8 patients with moderate-to-severe plaque psoriasis to investigate the distribution of secukinumab 
in lesional and non-lesional skin. Sinistrin was administered as calibrator for secukinumab in both 
parts of the study. Its relative recovery in dOFM samples was used to quantify secukinumab in dISF. 
Dermal ISF concentrations of secukinumab as determined in dOFM samples, blister fluid and skin 
biopsies were similar. The dermal interstitial concentration of secukinumab was 23.5% of the serum 
concentration in healthy individuals and between 28% and 39% in psoriasis patients on Day 15. 
In conclusion, our study demonstrated significant levels of secukinumab in the target tissue after a 
single s.c. secukinumab 300-mg dose.    
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Regulatory T cells dysfunction is due to decreased Foxo1 activity in psoriasis patients
B Li, L Jin, E Dang, C Gao, T LYang and G Wang Dermatology, Xi Jing Hospital, Xi an, China
Background: Psoriasis is recognized as a T lymphocyte driven systemic inflammatory disease. 
T regulatory cells (Treg cells) are essential for establishing and maintaining immune tolerance. 
Recent studies showed that Treg cells dysfunctions are crucial in psoriasis progression. However, 
the mechanism of its dysfunction was still largely unknown. Methods: We collected blood sam-
ples from 45 patients in the progressive stage of psoriasis and 30 healthy volunteers. After blood 
collection, CD4+CD25+Foxp3+ was defined as Treg cell, and its frequency was detected by FCM. 
Suppressive activities of Treg cells were evaluated by co-culture of CD4+CD25+CD127-Treg cells 
and CD4+CD25-T effect cells model. Gene expressions prolife of Treg cells were detected by 
microarray. Lentivirus was used for siRNA delivery. Result: We found that compare with healthy 
volunteers, the frequency of Treg cell was decreased and its suppressive activity was impaired in 
psoriasis patients. To further investigate the mechanism, we preformed mRNA array to study the gene 
expression profile of psoriatic Treg cells. Interestingly, the results showed that the gene expression 
of psoriatic Treg cells has the similar expression pattern with Foxo1-/-Treg cells, such as producing 
more pro-inflammatory cytokines. By using both western blotting and immunofluorescence, we 
found the ratio of pFoxo1/Foxo1 were increased and rather than in nucleus, Foxo1 located more in 
cytoplasm in psoriatic Treg cells compare with control Treg cells. By using siRNA to knockdown 
Foxo1 expression in Treg cell from healthy volunteers, we found the suppressive activity was also 
decreased in these Treg cells. Conclusion: Our findings reveal that the dis-regulation of Foxo1 may 
be a critical cause in the dysfunction of Treg in psoriasis, and Foxo1 may be a potential treating 
target for psoriasis.    
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Impaired function of CD19+CD24hiCD38hi regulatory B cells in pemphigus patients
H Zhu,1,2 R Xu,1 Y Chen,1 H Yuan,1 H Cao,1 X Zhao,1 J Zheng,1 Y Wang3 and M Pan1 1 
Department of Dermatology, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong 
University, Shanghai, China, 2 Department of Dermatology, Rui Jin Hospital North, School 
of Medicine, Shanghai Jiao Tong University, Shanghai, China and 3 Shanghai Institute of 
Immunology, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Pemphigus is an organ specific autoimmune bullous disease, in which pathogenic mechanism is 
complicated and not fully understood. To determine the role of Bregs in pemphigus, we examined 
the frequency and regulatory function of CD19+CD24hiCD38hi Bregs in the disease. The number 
of these Bregs was increased significantly in pemphigus than that in normal controls (13.3±4.4% 
vs 9.4±2.8%, p<0.001). But no statistical differences were found between the newly diagnosed 
patients and the treated group. To test whether the ability of IL-10 production by these B cells is 
intact, PBMCs were cultured with B cell stimulus. The percentage of IL-10-proucing B cells in the 
patients was higher than that in healthy controls after short-term stimulation but lower after long-term 
stimulation. Further studies revealed these Bregs in pemphigus lost their ability to down-regulate 
IFN-γ production by CD4+T cells. CD4+T cells co-cultured with autologous CD19+CD24hiCD38hi 
Bregs from healthy controls led to a significant decrease in the percentages of CD4+IFN-γ+T cells in 
contrast to cultured alone (13.1±6.3% vs 8.0±3.4%, p=0.049), and the inhibition rate was 38.1%. 
Strikingly, these Bregs from pemphigus did not significantly suppress IFN-γ production by autologous 
CD4+Th1 cells (8.9±3.6% vs 10.1±4.2%, p=0.5), and the inhibition rate was 11.9%. However, 
there was no difference in antibody response from PBMCs with or without Bregs after stimulation. 
Our results suggest that Bregs in pemphigus patients are elevated in the periphery but with defective 
regulatory function on Th1 cells.    
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Altered manifestations of skin disease in patients with nerve damage
E Azimi, EA Lerner and S Elmariah Dermatology, Massachusetts General Hospital, Boston, 
MA
Despite advances in our understanding of neural-immune interactions, the contribution of the 
nervous system to skin inflammation is currently underappreciated. We sought to identify reported 
cases of alterations in the manifestations or distribution of skin disorders in patients with acquired 
central or peripheral neural damage or dysfunction. We performed a systematic review of reports 
published in Pubmed (1966 to present) and Embase (1974 to present). We identified a total of 23 
cases described in 19 case reports, including 9 cases of eczema, 8 cases of psoriasis, 2 cases of 
scleroderma, and 1 case each of rosacea, contact dermatitis, bullous pemphigoid and a relapsing 
vesicular dermatitis. In 19 cases, near or complete resolution of skin lesions were reported in the 
areas innervated by the injured nerves. The cases highlighted in this review essentially represent 
conditional knockouts in people, providing definitive clinical evidence for the importance of neu-
ral-mediated signaling in inflammatory skin disease. We suggest that the clearance of inflammatory 
skin disease as a result of neural compromise requires further examination of the use of sensory 
neural blockade as a therapeutic option to treat common skin disorders.    
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Ficin, a plant protease, induces itch and edema by different mechanisms
E Azimi, VB Reddy, S Elmariah, T Luo and EA Lerner Dermatology, Massachusetts General 
Hospital, Boston, MA
Cysteine proteases derived from plants are known to cause itch in humans. Previously, we demon-
strated that proteases derived from fig, papaya and pineapple (ficin, papain and bromelain respec-
tively) cleave the extracellular N-terminus and thereby activate protease activated receptor (PAR) 
2, a member of the PAR family implicated in itch signaling. We decided to extend these in vitro 
findings with in vivo studies using wild type mice and mice in which PAR2 was knocked out (KO). 
Ficin elicits robust scratching in both wild type (WT) and PAR2 KO mice. Ficin also causes signif-
icant edema surrounding the injection site within minutes of delivery in WT mice, a reaction not 
observed in response to other plant proteases or control injections. We quantified the edema in both 
WT and PAR2 KO mice. Ficin induces significantly less edema in PAR2 KO mice but the scratching 
bouts are not significantly decreased compared to WT. PAR2 activation contributes to ficin-induced 
edema but does not seem to be the major mechanism underlying ficin induced itch. A separate 
class of receptors, termed Mas-related G-protein coupled receptors, or Mrgprs, are essential for itch 
signaling in humans and mice. We thus determined if Mrgprs contribute to ficin induced itch. We 
transfected HeLa cells with cDNAs encoding MrgprC11 and performed in vivo studies using mice 
in which a cluster of genes encoding Mrgprs had been knocked out. Plant proteases are surprisingly 
capable of activating Mrgprs and ficin induced itch is significantly decreased in Mrgpr KO mice. 
We conclude that ficin is a potent pruritogen that induces itch and edema by different mechanisms.   
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The role of Mas-related G-protein coupled receptors in substance P signaling
E Azimi, VB Reddy, T Luo, S Elmariah and EA Lerner Dermatology, Massachusetts General 
Hospital, Boston, MA
The release of Substance P (SP) from peripheral nerve fibers in the skin contributes to neurogenic 
inflammation. SP has been implicated in the itch of eczema, psoriasis, and cutaneous T-cell lym-
phoma. Neurokinin 1 (NK1), a G protein coupled receptor, is the classic receptor for SP. Drugs 
that target NK1 have been used to treat dermatologic and non-dermatologic conditions. A separate 
class of GPCRs, termed Mas-related G-protein coupled receptors, or Mrgprs, is essential for itch 
signaling in humans and mice. We thus asked if SP might also activate a Mrgpr. HeLa cells were 
transfected with a series of cDNAs encoding receptors involved in mediating itch. These receptors 
included human MrgX1, MrgX2, MrgX3, NK1 and mouse MrgC11 and MrgA3. As expected, SP 
activated NK1 transfected cells. In addition, SP specifically activated HeLa cells expressing the 
human MrgprX2 receptor, as determined by calcium imaging. This in vitro finding was extended 
with behavioral studies in vivo using wild type mice and mice in which a cluster of genes encoding 
Mrgprs had been knocked out. Behavioral studies of itch were performed using the mouse cheek 
model. Scratching induced by the intradermal injection of substance P was significantly decreased 
in the cluster knockout mice as compared to wild type mice. These findings suggest that SP may 
cause itching by activating specific Mrgprs in addition to activating NK1.    
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Anti-Dsg3 IgG autoantibodies from mucosal pemphigus vulgaris are pathogenic to oral 
mucosa of humanized Dsg3 mice
DA Culton,1 SK McCray,1 M Park,1 N Li,1 DC Zedek,1,2 GJ Anhalt,3 Z Liu1 and LA Diaz1 
1 Dermatology, University of North Carolina, Chapel Hill, NC, 2 Pathology, University of 
North Carolina, Chapel Hill, NC and 3 Dermatology, Johns Hopkins University, Baltimore, 
MD
We have previously described the existence of two clinical subsets of pemphigus vulgaris (PV), 
mucosal PV (mPV) and mucocutaneous PV (mcPV). The mPV subset typically exhibits exclusive 
anti-human Dsg3 autoantibodies that fail to recognize murine Dsg3; thus, passive transfer experi-
ments of mPV IgG into wildtype (WT) mice have been unsuccessful. We therefore generated a fully 
humanized Dsg3 (hDsg3) murine model utilizing a novel human Dsg3 transgenic animal crossed 
to the murine Dsg3 knockout line. The humanized Dsg3 mice express hDsg3 in the mucosa and 
skin, which rescues the murine Dsg3 knockout phenotype. Well characterized mPV sera (n=8) 
bind mucosal epithelia from the hDsg3 mice, but not mucosal tissues from WT mice by indirect 
immunofluorescence (IF). Submucosal injection of mPV IgG into adult hDsg3 mice, but not WT 
mice, induces suprabasilar acantholysis in mucosal tissues in a dose-dependent manner, thus con-
firming pathogenicity of mPV anti-hDsg3 IgG in vivo. Human anti-hDsg3 antibodies are detected in 
perilesional mucosa as well as in sera of recipient mice by IF. These findings suggest that the Dsg3 
epitope targeted by pathogenic mPV IgG is human specific. This novel hDsg3 mouse model will be 
invaluable in studying the disease mechanisms of mPV autoantibodies and the transition from mPV 
with mucosal disease alone to mcPV when the disease has spread to the skin.    
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Evaluating morbidity and association with autoimmune thyroiditis of chronic urticaria in 
children
E Netchiporouk1 and M Ben-Shoshan2 1 Dermatology, McGill University, Montreal, QC, 
Canada and 2 Allergy and Clinical Immunology, Montreal Children`s Hospital, Montreal, 
QC, Canada
Chronic urticaria (CU) is defined when hives occur for at least 6 weeks. Recent studies suggest that 
autoimmunity including targeting either the mast cell IgE receptor, the IgE molecule or auto-antigens 
(i.g. thyroid antigens) may account for almost 50 % of CU cases. The pathogenesis of CU and its 
effect on quality of life (QoL) are not well established in children. We aimed to establish a registry 
of CU in children to assess autoimmunity, QoL and factors affecting QoL. Between January 2013 
and 2014, we recruited 35 children from our urticaria clinic. Participants were queried on demo-
graphics, clinical history and QoL (CU-Q2oL) through a validated questionnaire that measures 6 
domains through a five-point Likert-type scale. In addition, participants filled the urticaria activity 
score (UAS). Blood tests were drawn to assess basophile activation, thyroid autoimmunity and 
confirmatory tests were performed when applicable to diagnose inducible forms. The Wilcoxon 
Rank Sum test and mulrivariate regression analysis were used to assess autoimmunity and factors 
associated with impaired QoL respectively. Our findings reveal that the majority of children were 
males (57%) presenting at a median age of 8 years (IQR: 3.75-12.0). Thyroiditis was reported in 
17.1% of family members, but TSH and anti-thyroid peroxidase were normal in all patients. Physical 
forms occurred in 17.1 % of patients (mostly cold induced CU). Mean CD63 expression was 5.3% 
and was comparable to CD63 levels in controls . The mean weekly quality of life (UAS) score over 
3 months was 6.5 on a scale of 42, which indicates a mild disease. Increased age at onset (odds 
ratio, OR=2.2, 95%CI,1.51,2.87) was associated with decreased QoL in the functionality domain 
and higher UAS (2.16, 0.48,3.85) with worse sleep domain. In conclusion, CU in children was 
not associated with thyroiditis or autoimmunity. Older age of onset and higher UAS may affect the 
quality of life in pediatric population.    
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Genetic deletion of S100A9 fails to abrogate psoriasiform inflammation in the KC-Tie2 mouse 
model due to IL-12/23 compensation
Y Fritz,1 S Dawes,1 D Diaconu,1 J Golden,1 Y Wang,2 D Simon,2 T McCormick1 and 
NL Ward1 1 Dermatology, University Hospitals Case Medical Center, Case Western Reserve 
University School of Medicine, Cleveland, OH and 2 Medicine, University Hospitals Case 
Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH
The proinflammatory proteins S100A8/9 are purported to play a pathogenic role in psoriasis, as 
S100A8/9 genes are located within the psoriasis PSORS4 susceptibility region and serum and skin 
S100A8/9 levels are upregulated in psoriasis patients. A recent report showed genetic deletion of 
S100A9 strongly attenuated ear skin inflammation in the K5-JunB:Jun KO mouse and imiquimod-in-
duced acute murine skin inflammation model, further supporting a role for S100A9 in psoriasis 
pathogenesis. We previously reported increased expression of S100A8/9 (>135-fold; P<0.05) in the 
KC-Tie2 psoriasiform mouse model, with expression downregulated following gene repression, CsA 
treatment, or APC depletion. We sought to confirm the importance of S100A9 in disease pathogene-
sis and mated KC-Tie2 mice with S100A9 KO mice. Surprisingly, and in contrast to the observations 
recently reported, KC-Tie2-S100A9 KO mice (n=11) had similar levels of dorsal skin inflammation 
(acanthosis), T cell and myeloid cell skin-infiltration as KC-Tie2 mice (n=9); despite significantly 
decreased levels of DefB4, IL-1α, IL-17C and TNFα (all P<0.05). Interestingly, KC-Tie2-S100A9 
KO animals had significantly elevated splenic and skin-draining CD11b+Ly-6C+ pro-inflammatory 
monocytes (27% and 86%, respectively; P<0.05) compared to KC-Tie2 animals, as well as increased 
expression of skin IL-12/23 and IL-17A/F, and sustained levels of skin IFNγ, IL-22, IL-6 and KLK6, 
potentially explaining the sustained presence of disease. Taken together, these results suggest that 
the IL-23-Th17 inflammatory axis may compensate for the genetic ablation of S100A9 and sustain 
psoriasiform skin inflammation in KC-Tie2 animals. Therefore, the role of S100A9 in skin inflam-
mation appears to be model dependent and further investigation is needed to establish S100A9 as 
a therapeutic target in psoriasis.    
115
CCL7 augments TNF-alpha-dependent inflammation in lesional psoriatic skin
PM Brunner,1 B Reininger,1 I Klein,1 P Uhrin2 and G Stingl1 1 Dpt. of Dermatology, Medical 
University of Vienna, Vienna, Austria and 2 Dpt. of Vascular Biology and Thrombosis 
Research, Medical University of Vienna, Vienna, Austria
Chemokines are small chemotactic proteins that have a crucial role in leukocyte recruitment into 
tissue. Targeting these mediators has been suggested as a potential therapeutic option in inflamma-
tory skin diseases. Using quantitative PCR, we searched for transcripts of proinflammatory mediators 
in psoriatic skin. We found that CCL7 (monocyte chemotactic protein-3, MCP-3), a chemokine 
ligand known to interact with a broad range of C-C chemokine receptors, was markedly increased 
in lesional as compared to nonlesional and normal control skin (40.2 and 63.6 fold increase, respec-
tively; p<0.001). Surprisingly, its expression outnumbered mRNA levels of other C-C chemokines 
known to be upregulated in lesional psoriatic skin, namely CCL2 (MCP-1), CCL3 (MIP-1A), CCL5 
(RANTES), CCL11 (Eotaxin-1), CCL19 (MIP-3B), CCL20 (MIP-3A) and CCL22. In contrast, we did 
not detect increased levels of CCL7 in other inflammatory skin diseases such as atopic dermatitis 
or lichen planus. Immunohistochemistry revealed that blood vessel, but not lymphatic endothelial 
cells are the cellular source of this cytokine. In cultured human blood vessel endothelial cells, 
CCL7 protein expression could be induced by TNF-alpha, a key cytokine for the development of 
psoriasis, but not by IL-4, IL-10, IL-13, or IL-6. In vivo, CCL7 mRNA expression of lesional skin of 
psoriasis patients was decreased to levels found in nonlesional skin already 16 hours after a single 
intravenous infusion of the TNF-alpha-blocker infliximab. In a mouse model of imiquimod-induced 
psoriasis-like skin inflammation, antibody-mediated blockade of CCL7 did not alter the Th17-pro-
moting cytokine milieu, but resulted in a significantly decreased ear swelling response. In sum, 
our data point to a pathophysiological role of CCL7 in the development of psoriatic skin disease, 
possibly as an amplifier of the TNF-alpha-dependent tissue response.    
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IL-33 deficiency exacerbates the atopic dermatitis-like phenotype in STAT6VT transgenic 
mice
SC DaSilva-Arnold,1 LJ Seymour,1 Q Yi,1 JR Bradish,3 MH Kaplan,2 JB Travers1 and MJ Turner1 
1 Dermatology, Indiana University, Indianapolis, IN, 2 Pediatrics, Indiana University, 
Indianapolis, IN and 3 Pathology, Indiana University, Indianapolis, IN
The Stat6VT transgenic mouse model develops an AD-like phenotype as a result of expressing a con-
stitutively active form of STAT6 (STAT6VT) in the T cell compartment. Early (<1 week old) and late 
(>1 month old) AD-like lesions reveal histologic findings and cytokine expression patterns similar to 
acute and chronic AD. Quantitative PCR demonstrated increased IL-33 transcripts in early and, to 
a lesser degree, late AD-like lesions from Stat6VT mice in comparison to nonlesional skin and skin 
from WT mice. Immunofluorescence revealed increased numbers of IL-33-positive keratinocyte in 
early and, more prominently, in late lesions and localized IL-33 expression to a subset of keratin 
5-positive cells. To investigate the function of IL-33 in this system, IL-33-deficient Stat6VT mice were 
generated. The onset and severity of the AD-like phenotype were analyzed in Stat6VT and IL-33 
deficient Stat6VT mice. IL-33 deficient Stat6VT mice developed disease earlier in life and exhibited 
a more severe AD-like phenotype compared to Stat6VT mice. The biology of IL-33 is complex as 
IL-33 has both intracellular (e.g. as nuclear factor regulating NF-κB-dependent gene expression) 
and extracellular (cytokine) functions. Moreover, a number of resident and infiltrating cell types 
produce and respond to IL-33 in the skin; thus, further investigation is required to understand the 
mechanism(s) by which global IL-33 deficiency exacerbates the AD phenotype in Stat6VT mice.   
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Proteomics identifies novel psoriasis-related proteins in a mouse model and translation to 
human disease
K Lundberg,1 Y Fritz,2 A Johnston,3 A Foster,3 J Baliwag,3 JE Gudjonsson,3 D Schlatzer,1 
T McCormick,2 MR Chance1 and NL Ward2 1 Proteomics, Case Western Reserve University, 
Cleveland, OH, 2 Dermatology, Case Western Reserve University, Cleveland, OH and 3 
Dermatology, University of Michigan, Ann Arbor, MI
We identified protein expression changes in the KC-Tie2 psoriasis mouse and validated these 
changes in human psoriasis to demonstrate efficacy of a proteomics approach, the utility of study-
ing preclinical mouse models and the translational significance and impact of combining the two 
approaches. KC-Tie2 mouse skin (n=3) was compared to littermate controls (n=3) using gel-based 
fractionation followed by label free protein expression analysis. 5482 peptides mapping to 1282 
proteins were identified and quantitated: 104 proteins exhibited fold-changes ≥2.0 (P<0.05) includ-
ing stefin-1 (342.4-fold change; cystatin A, human orthologue); slc25a5 (46.2-fold change); ser-
pinb3b (35.6-fold change; serpinB1, human orthologue); and kallikrein related peptidase 6 (4.7-fold 
change; KLK6). We independently validated gene expression-based increases in serpinb3b (17.4-
fold, P<0.0001), KLK6 (9.0-fold, P=0.002), stefin A1 (7.3-fold; P<0.001) and slc25A5 (1.5-fold; 
P=0.05) using qRT-PCR on a second cohort of animals (n=8). Parallel LC/MS/MS analyses vali-
dated protein-level increases of 1.3-fold (slc25a5), 29,000-fold (stefin-A1), 322-fold (KLK6) between 
KC-Tie2 and control mice. To underscore the utility and translatability of our combined approach, 
we analyzed gene and protein expression levels in psoriasis patient skin and primary keratinocytes 
vs normal controls. Increases in gene expression for slc25a5 (1.8-fold), cystatin A (3.0-fold), KLK6 
(5.8-fold) and serpinB1 (76-fold; all P<0.05) were observed between normal controls and involved 
lesional psoriasis skin and primary keratinocytes. Moreover slc25a5, cystatin A, KLK6 and serpinB1 
were all increased in lesional psoriasis skin compared to normal skin at the level of protein. These 
results demonstrate the usefulness of mouse models and proteomic approaches for identifying novel 
peptides/proteins that are differentially regulated in human psoriasis.    
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Histological analysis of acne samples reveals different macrophage populations within the 
pilosebaceous unit
D Torocsik,1 K Cseri,1 D Kovács,1 ÉVA Remenyik,1 R Ádány2 and D Töröcsik1 1 Department 
of Dermatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary and 
2 Department of Preventive Medicine, Faculty of Public Health, University of Debrecen, 
Debrecen, Hungary
Inflammation of the pilosebaceous unit is the characteristic feature in acne that involves different 
types of inflammatory cells. Detecting the expression of the macrophage marker CD163 in acne 
samples, a high number of positive cells were found. In order to gain information on their possible 
role in the pathogenesis of acne, we classified these macrophages upon their activation towards 
the alternative and classical pathways by using markers such as FXIII-A and CD206 or CD209 in 
double label immunohistochemical reactions. In our studies we showed that while macrophages 
surrounding the sebocytes in the unaffected regions were expressing the markers of alternative 
activation (CD163+/FXIII-A+), in contrast, macrophages in the necrotic foci were classically acti-
vated (CD163+/FXIII-A-). This was further confirmed by labeling for other markers of alternative 
activation, as both CD206 and CD209 showed co-expression with FXIII-A but were not detected 
within the necrotic parts. Our results show that macrophages are potential players in the patho-
genesis of acne. Depending on the activating stimuli they polarize and exert different functions 
within the lesions that could modulate the progression of acne. Identifying the stimuli behind their 
polarization could lead to the better understanding of acne pathogenesis and might serve also as 
a potential therapeutic target.    
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 CARD14 expression in dermal endothelial cells in psoriasis 
JL Harden,1 SM Lewis,1 KC Pierson,1 M Suarez-Farinas,1,2 T Lentini,1 F Ortenzio,1 LC Zaba,1 
R Goldbach-Mansky,3 AM Bowcock4 and MA Lowes1 1 Laboratory for Investigative 
Dermatology, The Rockefeller University, New York, NY, 2 Center for Clinical and 
Translational Science, The Rockefeller University, New York, NY, 3 Translational 
Autoinflammatory Disease Section, NIAMS/NIH, Bethesda, MD and 4 Genomic Medicine, 
Imperial College, London, United Kingdom
Mutations in the caspase recruitment domain, family member 14 (CARD14) gene have recently been 
described in psoriasis patients, and explain the psoriasis susceptibility locus 2 (PSORS2). CARD14 
is a scaffolding protein that regulates NF-κB activation, and psoriasis-associated CARD14 mutations 
lead to enhanced NF-κB signaling. CARD14 is expressed mainly in epidermal keratinocytes, but also 
in unidentified dermal cells. To determine which dermal cells express CARD14, psoriasis lesions 
were stained by two-color immunofluorescence. Dermal CARD14 expression did not co-localize 
with T-cells, dendritic cells, or macrophages. However, CARD14 highly co-localized with CD31+ 
endothelial cells (ECs). CARD14 was also expressed in aortic tissue, which may indicate a role in 
the systemic inflammation and cardiovascular comorbidities associated with psoriasis. Nuclear 
phosphorylated NF-κB was found in psoriatic CARD14+ CD31+ ECs. Skin biopsies of two patients 
with the CARD14 mutation had similar transcriptomic profiling to “classic” psoriasis skin. Transfec-
tion of dermal ECs with psoriasis-associated CARD14 mutations resulted in increased expression of 
several chemokines including CXCL10, IL-8, and CCL2. These results show that CARD14 expression 
in ECs may contribute to the psoriasis, through increased expression of chemokines and facilitating 
recruitment of immune cells into skin.    
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M1 macrophage genes are enriched in discoid lupus skin
BF Chong,1 L Tseng,1 S Zhang,2 N Olsen3 and C Mohan4 1 Dermatology, University of 
Texas Southwestern Medical Center, Dallas, TX, 2 Clinical Sciences, University of Texas 
Southwestern Medical Center, Dallas, TX, 3 Internal Medicine, Penn State Hershey Medical 
Center, Hershey, PA and 4 Biomedical Engineering, University of Houston, Houston, TX
Discoid lupus erythematosus (DLE) is a scarring form of cutaneous lupus whose genetic profiles 
are not completely characterized. Macrophages can easily morph from a pro-inflammatory M1 
subtype to an anti-inflammatory M2 subtype, and vice versa. Their plasticity makes macrophages 
ideal targets for future therapies. We previously found that immunostaining of DLE skin had marked 
up-regulation of CD163+ and CD68+ macrophages versus normal skin. As we postulate that DLE 
skin will enhance expression of genes and proteins associated with M1 macrophages, we carried 
out transcriptome analysis of DLE lesional skin (N=9) and age- and gender-matched normal skin 
(N=8) to determine macrophage polarization in DLE skin. DLE skin expressed 543 up-regulated 
and 273 down-regulated genes compared with normal skin (>2 fold change (FC), q<0.05). Gene 
set enrichment analysis comparing these genes with previously published gene sets associated with 
M1 and M2 macrophages showed strong overlap between up-regulated genes in DLE skin and M1 
macrophages (p=0.02). Confirmatory RT-PCR studies in DLE skin (N=17), normal skin (N=12), and 
psoriasis skin (N=9) showed that several M1 macrophage genes had amplified mRNA levels in DLE 
skin such as CXCL10 (DLE>normal: 47.2 FC, DLE>psoriasis: 21.3 FC), CCL5 (DLE>normal: 25.9 
FC, DLE>psoriasis: 21.8 FC), and IL-12 (DLE>normal: 1.5 FC, DLE>psoriasis: 5.42 FC) (p<0.01). 
mRNA from multiple M2 macrophage genes such as arginase 1 and CD206 were not differentially 
expressed in DLE, psoriasis, and normal skin. The M1 macrophage bias in DLE skin likely contributes 
to the dysregulated inflammatory response and scarring in DLE because M1 macrophages can cause 
tissue damage by producing cytokines and toxic radicals. Shifting polarization of macrophages 
from M1 to M2 through medications (e.g. PPARγ agonists) early in DLE disease course may avoid 
the scarring sequelae.    
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IL-17A regulates inflammation in Dlx3-deficient murine skin
J Kim,1 Y Ogawa,2 U Siebenlist,3 MC Udey2 and M Morasso1 1 Laboratory of Skin Biology, 
NIH, NIAMS, Bethesda, MD, 2 Dermatology Branch, Center for Cancer Research, NIH, NCI, 
Bethesda, MD and 3 Laboratory of Molecular Immunology, NIH, NIAID, Bethesda, MD
The homeobox transcription factor Dlx3 is involved in the terminal differentiation of keratinocytes 
(KCs), and mutations in Dlx3 are associated with Tricho-Dento-Osseous syndrome characterized 
by abnormal hair, teeth and bone. We previously reported that epidermal depletion of Dlx3 in vivo 
(K14cre;Dlx3kin/f mice; cKO) led to IL-17 predominant inflammation in skin. Recently, it has been 
reported that most IL-17A-producing cells in murine skin are Vγ4+ γδT cells, and these cells accu-
mulate in Imiquimod-induced psoriasis-like inflammation. We determined that Vγ4+ γδT cells are 
also a major source of IL-17A in cKO mice, and that their numbers are also dramatically increased. 
Neutralizing IL-17A in human psoriasis improves the outcome of disease, and we hypothesized that 
IL-17A produced from Vγ4+ γδT cells might drive inflammation in cKO mice. To address this, we 
generated IL-17A null/DLX3 cKO (dKO) mice, and analyzed skin inflammation via flow cytometric 
analysis using skin single cell suspensions from P21 mice. We found that dKO mouse skin harbored 
significantly more CD45+ cells, specifically CD3+, MHC class II+, and NK cells than control skin, 
and the skin phenotype was not attenuated. Interestingly, IL-17A depletion in cKO mice did not 
increase Th1 and IFN-γ-producing γδT cells. Among CD3+ cells, the number of Vγ4+ γδT cells was 
increased, but Vγ5 bearing dendritic epidermal T cells were similarly represented. Ki67 labeling 
was increased in Vγ4+ γδT cells in dKO mice, suggesting that numeric increases reflected enhanced 
cell proliferation. These data suggest that Dlx3 regulates IL-17A-associated skin inflammation and 
that IL-17A produced by Vγ4+ γδT cells can be anti-inflammatory rather than proinflammatory. 
Elucidation of cytokine networks that modulate skin inflammation in Dlx3 cKO mice may lead to 
insights into human inflammatory skin diseases such as psoriasis.    
122
Signal transducer and activator of transcription (STAT) 3 is a negative regulator of interleukin 
9 production by T cells
MR Olson, JB Travers and MH Kaplan Indiana University, Indianapolis, IN
Atopic dermatitis (AD) is characterized by dysregulated inflammation in the skin, leading to redness, 
swelling and itching. This type of inflammatory response was originally thought to be initiated by 
classic TH2 cytokines, including interleukins (IL)-4, 5, and 13. However, our group, along with 
others, has demonstrated an important link between IL-9 and IL-9-producing T cells (termed TH9 
cells) in atopic disease and AD. Therefore, it is important to understand the underlying molecular 
mechanisms that control IL-9 production by T cells. We show here that the transcriptional regulator 
STAT3 is activated within both TH2 and TH9 cells during in vitro differentiation. Interestingly, 
genetic ablation of STAT3 in these cells resulted in an increase in the frequency of IL-9 producing 
cells in both subsets. Conversely, addition of the cytokine IL-6, a potent activator of STAT3, to TH9 
cultures virtually eliminates IL-9 production by these cells. Intriguingly, addition of less potent 
activators of STAT3 (IL-10 and IL-21) had no effect on IL-9 production in TH9 cultures. Therefore, 
therapeutic activation of STAT3, particularly by treatment with IL-6 or IL-6 analogs, may represent 
a promising avenue for preventing or treating IL-9 mediated diseases.    
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Overlapping transcriptome signatures between atherosclerotic plaque and psoriasis skin
WR Swindell,1 NL Ward,2 A Johnston1 and JE Gudjonsson1 1 Dept. of Dermatology, 
University of Michigan, Ann Arbor, MI and 2 Dept. of Dermatology, Case Western Reserve 
University, Cleveland, MI
Increased risk and accelerated atherosclerosis is a prominent co-morbidity of moderate to severe 
psoriasis. The biologic basis of this association is unclear but does not appear to be due to shared 
genetic predisposition. Using a systems biology approach, we analyzed global transcriptome data-
sets of psoriasis skin (n=163) and post-mortem samples of carotid atherosclerotic plaque (n=13 early 
stage; n=16 advanced stage). We identified increased expression of 438 genes (FC>2; FDR<0.05) 
and decreased expression of 196 genes (FC<2; FDR<0.05) in psoriasis lesions. 77% of the psoria-
sis-increased genes were also increased in advanced atherosclerotic plaque compared with early 
stage plaque (P=1.71×10-35). Likewise, 60% of the psoriasis-decreased genes were also decreased 
in advanced atherosclerotic plaque (P=0.008). Analysis of the genes increased in both psoriatic and 
advanced atherosclerotic plaque mapped to 66 Gene Ontology biological categories (P<0.001), the 
majority of which belonged to immunological processes such as inflammatory response, response 
to IFN-γ, regulation of T cell activation and antimicrobial responses. These genes tended to be spe-
cifically expressed by macrophages, monocytes, dendritic cells, and neutrophils (FDR≤1.11×10-6). 
This common psoriasis/atherosclerosis gene set had a strong overrepresentation of genes induced by 
IFN-γ (FDR=1.47×10-11), TNF, IL-17 and IL-19/IL-20/IL-24 (FDR<0.01), including the chemokines 
CCL18, CCL19; macrophage genes ADAMDEC1, FCGR1B, and IFN-response genes IFI30 and IRF8 
(P<0.001, all). These results demonstrate significant overlap in transcriptome between atheroscle-
rotic plaque and psoriatic skin, and identify key common cellular and cytokine responses involved 
in both. This innovative cross-disease analysis offers novel insight into common mechanisms by 
which skin inflammation may amplify and accelerate atherosclerosis in psoriasis patients and may 
provide guidance for prioritization of therapeutic development and treatment strategy.    
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S100A8/A9 promotes concomitant inflammation and proliferation via distinctive receptor 
oligomerization – potential relevance to atopic dermatitis
M Yamamoto-Tanaka,1,3 M Sakaguchi,2 M Miyai,1 A Motoyama,1 R Tsuboi3 and T Hibino1 1 
Shiseido Research Center, Yokohama, Japan, 2 Cell Biology, Okayama University Graduate 
School of Medicine, Okayama, Japan and 3 Dermatology, Tokyo Medical University, Tokyo, 
Japan
Although S100A8 and S100A9 are suggested to make a stable heterodimer (calprotectin) in vivo 
and play important roles in inflammation, molecular mechanisms are still obscure. Previously 
we reported a positive feedback loop between calprotectin and pro-inflammatory cytokines and 
identified extracellular matrix metalloproteinase inducer (EMMPRIN) as a receptor for S100A9. 
We also found a receptor for S100A8, neuroplastin-beta (NPTN-beta). In the present study we 
investigated physiological roles of S100 proteins and their newly discovered receptors. Calprotectin 
promoted keratinocyte proliferation as well as pro-inflammatory cytokine induction. They were 
down-regulated by the knockdown of EMMPRIM or NPTN. Double knockdown of these receptors 
markedly suppressed keratinocyte proliferation as well as pro-inflammatory cytokine induction. 
We found that NPTN was able to make a heterodimer with EMMPRIN. NPTN-beta is responsible 
for ERK phosphorylation after the stimulation by calprotectin, whereas EMMPRIN is involved in 
the p38 phosphorylation, suggesting the activation of dual pathway for the cell growth and pro-in-
flammatory cytokine induction by calprotectin. Immunohistochemical analysis demonstrated that 
NPTN and EMMPRIN were hardly detectable in the normal skin, whereas they were expressed in 
the lesional skin with atopic dermatitis (AD). Proximity ligation assay indicated the association of 
these receptors and S100 proteins in the AD. Quantitative analysis showed that corneocyte extracts 
contained 1.4 + 0.66 (normal), 7.12 + 2.58 (non-lesional AD), and 22.43 + 5.67 microgram/mg 
protein (lesional AD) of calprotectin. Collectively our results suggest that the S100A8/A9-NPTN/
EMMPRIN pathway would play an essential role for the concomitant abnormal proliferation and 
inflammation of the skin such as AD.    
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The effect of excimer laser on immunoprofiling in psoriasis
A Leon, M Malakouti, G Brown, E Levin, R Sanchez-Rodriguez, MD Rosenblum, 
M Debbaneh, E Sorenson, E Wang, R Gupta, M Huyhn, D Butler and J Koo Dermatology, 
University of California San Francisco, San Francisco, CA
Introduction: Psoriasis is an immune-mediated skin disease. There has been increasing evidence 
that inflammatory cytokines play a major role in the pathogenesis of psoriasis. These cytokines are 
also shown to be elevated in patients with psoriasis. In the past 15 years, the development of the 
excimer laser has greatly improved the deliverance of UVB to treat psoriasis. Unlike the traditional 
UVB light box, excimer laser targets only the psoriatic plaques and thus much higher doses of light 
can be delivered, resulting in greater efficacy. In this study, immunological assessment of biopsy 
specimens before and after intense laser treatment was conducted. Methods: Three patients with 
10-30% body surface area of plaque psoriasis were biopsied before and after intense excimer 
treatment. Non-lesional and lesional pre-laser biopsy specimens were analyzed for immunoprofil-
ing using flow cytometry. Post-treatment biopsy specimens were collected after patients achieved 
75% improvement in Psoriasis Assessment Severity Index (PASI-75) to compare changes in the 
immunoprofile before and after treatment with excimer laser. Results: All three patients achieved 
PASI 75 with no significant adverse events. The immunoprofile of the lesional pre-treatment and 
post-treatment biopsies were compared for changes in T cells and cytokines. After treatment with 
the excimer laser, the absolute levels of T-cells and subset of T cells producing cytokines interleukin 
17 (IL17), tumor necrosis factor-α (TNF-α), interleukin 2 (IL2), and interferon-gamma were greatly 
decreased. In fact, T-cells active in producing these cytokines were decreased relatively much 
more than T-cells not actively producing cytokines. Conclusion: Excimer laser is very effective and 
systemically safe treatment for psoriasis patients. The clinical improvement of psoriasis correlates 
with a decrease in T cells producing inflammatory cytokines within the psoriatic plaques.    
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Upregulation of co-stimulatory molecules on CD4+ T cells in the patients with pemphigus
Z Liu,1 H Yuan,1 W Zeng,2 J Zheng,1 Y Wang2 and M Pan1 1 Department of Dermatology, 
Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China and 
2 Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, 
Shanghai, China
Pemphigus is an organ-specific autoimmune blistering disease, involving skin and mucous mem-
branes. Pemphigus has two major subtypes, pemphigus vulgaris (PV) and pemphigus foliaceus (PF), 
which are caused primarily by IgG autoantibodies against desmoglein 3 and/or desmoglein 1. The 
autoantibodies play a pathogenic role in blister formation. Furthermore, the titers and subclasses 
correlate with the severity of disease activity. Besides the contribution from the B cell part, autore-
active CD4+ T cells play critical roles in disease development. Crosstalk between antigen-specific 
T cells and B cells via their co-stimulatory molecules might be important for antibody production. 
In present study, we collected 90 patients with pemphigus (PV: n=46; PF: n=44) and 30 healthy 
individuals as control. Among the patients, 24 of them were at first onset, 51 in stable stage and 15 
in remission. The activation marker CD69 and the expression of ICAM-1, ICOS, CD40L and OX40 
molecules on CD4+ T cells were detected by flow cytometry. It was shown that peripheral CD4+ 
T cells from pemphigus patients were relatively activated with higher expression of CD69 than that 
in controls (P< 0.001). The co-stimulatory molecules ICAM-1, CD40L and OX40 were obviously 
upregulated in the patients (P< 0.05). No significant differences were observed between the patients 
in different stages, except that ICOS was significantly up-regulated in newly diagnosed patients who 
didn’t get any treatment (P< 0.05). Our results showed that peripheral CD4+ T cells from pemphigus 
patients were at a relatively activated condition with higher expression of co-stimulatory molecules, 
which might play an important role in the pathogenesis of pemphigus via interacting with B cells.   
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TRPM8 agonist menthoxypropanediol reduces NGF expression and neurite outgrowth in a 
coculture model of sensory neurons and dermal fibroblasts
D Roggenkamp, AC Worthmann, M Sulzberger, L Kolbe and G Neufang Beiersdorf AG, 
Hamburg, Germany
Cooling the skin alleviates itch and is therefore a well-known treatment option for chronic pruritus 
patients. Apart from physical cooling, compounds activating the cold-sensitive calcium channel 
TRPM8 on C and Aδ nerve fibers are able to inhibit experimental or disease-related itch. However, 
TRPM8 is not only expressed on nerve fibers but also on skin cells such as dermal fibroblasts. We 
hypothesized that TRPM8 agonists partially exert their anti-itch effect by interfering with the crosstalk 
of sensory nerve endings and skin cells. In this study, we investigated the anti-inflammatory and 
anti-pruritic effects of the TRPM8 agonist menthoxypropanediol (MPD) in vitro. Several studies 
pointed to a correlation of nerve fiber sprouting and itch in chronic inflammatory skin diseases such 
as atopic dermatitis. Recently, we showed that atopic skin cells release elevated levels of NGF and 
thereby induce increased neurite outgrowth in a coculture model of sensory neurons and skin cells. 
Here, MPD reduced NGF expression in dermal fibroblasts resulting in a reduced fibroblast-induced 
neurite outgrowth in our coculture model. Furthermore, MPD decreased neuron-derived CGRP 
release indicating an impact on neurogenic inflammation. This provides evidence that TRPM8 
agonists might act anti-pruritic by counteracting itch-associated hyperinnervation and nerve fiber 
activation in chronically inflamed skin.    
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IL-6 deletion attenuates severity of psoriasis-like skin inflammation in K5-IL-17C mice
P Klenotic,1 A Johnston,2 D Diaconu,1 T McCormick1 and NL Ward1 1 Dermatology, CASE 
Western Reserve University, Cleveland, OH and 2 Dermatology, University of Michigan, 
Ann Arbor, MI
Interleukin-17C (IL-17C) is the most abundant IL-17 family member found in lesional skin of psoriasis 
patients. IL-17C treatment of primary human endothelial cells (ECs) elicits a 3.7-fold increase in 
TNFα mRNA (n=4, P<0.05) and we and others have reported that primary human keratinocytes (KCs) 
stimulated with IL-17C/TNFα respond by producing synergistic increases in key psoriasis signature 
genes. Mice genetically engineered to overexpress IL-17C in KCs (K5-IL-17C) develop a psorias-
iform skin phenotype that improves following TNFα inhibition. Interestingly, IL-17C also elicits a 
2.7-fold increase in IL-6 mRNA from ECs (P<0.05), and uninvolved and involved skin of K5-IL-17C 
mice contains significantly increased levels of IL-6 protein (42% and 480%, respectively; P<0.05). 
We hypothesized that IL-6 synergizes with IL-17C to elicit and sustain chronic skin inflammation, 
akin to IL-17C/TNFα. To address this hypothesis, we mated K5-IL-17C mice with IL-6 KO mice. 
Resultant K5-IL-17C-IL-6 KO mice showed reduced skin severity at 8-10 weeks of age compared 
to K5-IL-17C mice (40% decrease in mouse PASI; n=15, P<0.05) and significant decreases in 
circulating TNFα (64% decrease; n=4-5, P<0.035). Histological analyses of involved skin revealed 
no differences between K5-IL-17C and K5-IL-17C-IL-6 KO mice, however analyses of uninvolved 
skin revealed a significantly thinner epidermis (2-fold decrease; P<0.001) and a decrease in dermal 
angiogenesis (27%; P<0.04) in K5-IL-17C-IL-6 KO animals compared to K5-IL-17C (n=8 per group), 
as well as concomitant decreases in skin CD4+ and CD8+ T cells and F4/80+ macrophages (30%, 
50% and 51% decrease, respectively; P<0.05 for all). Taken together, these data suggest that IL-6 
may contribute to pro-inflammatory IL-17C signaling critical for sustained psoriasis pathogenesis.   
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Transcriptional snapshot of the early consequences of EGFR ablation in the epidermis
F Mascia, D Schloemann, A Michalowski and S Yuspa LCBG, NCI/NIH, Bethesda, MD
The epidermal growth factor receptor (EGFR) has a complex role in the maintenance of skin immu-
no-homeostasis as exemplified by the development of inflammatory skin lesions in cancer patients 
treated with EGFR inhibitory drugs. To gain insight into the etiology of the skin lesions, we used an 
epidermis-targeted EGFR gene knockout mouse model. The skin of knockout mice appears histolog-
ically healthy at birth but an inflammatory infiltrate is detected within the first 72 hours of life. Over 
several weeks, skin lesions develop with striking similarity to those of patients undergoing treatment 
with anti-EGFR drugs. To examine molecular changes that could reveal the primary drivers of this 
inflammatory response, we isolated total skin RNA from 6 wildtype and 6 EGFR knockout mice at 
both 24 hours and 72 hours after birth and performed microarray analysis (mouse GeneST1.0 array 
Affymetrics). Significant differences in gene expression were identified based on univariate analysis 
of variance (ANOVA) with two two-level factors, namely genotype and time. For each gene, a full 
two-way ANOVA model was fitted in Partek Genomics Suite 6.5. Five percent FDR level (q<0.05) 
was chosen as the criterion to generate significant gene lists. In a total of 96 genes the analysis 
identified a significant main effect of genotype, but not of time. Both genotype and time affected 
significantly gene expression of a total of 255 genes (additive or interactive effects). When the 
above gene list was analyzed with Ingenuity Pathway Analysis (IPA) software, the top diseases and 
bio functions highlighted were “inflammatory diseases” (16 genes, p< 0.020) and “inflammatory 
response” (22 genes, p<0.019). In molecular and cellular functions, the function “cell movement” 
grouped 31 genes of the list with p<0.021 while the canonical pathways highlighted were eicosanoid 
signaling (p<0.0038) and granulocyte adhesion and diapedesis (p<0.046). The microarray analysis 
unveiled new targets to address as therapeutic options for the anti-EGFR driven rash.    
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A meta-analysis derived atopic dermatitis (MADAD) transcriptome
DA Ewald,1,2 J Correa-Da Rosa,1 T Litman,2 J Krueger,1 E Guttman3,1 and M Suarez-Farinas1 
1 Laboratory for Investigative Dermatology, Rockefeller University, New York, NY, 2 
Molecular Biomedicine, LEO Pharma, Ballerup, Denmark and 3 Mount Sinai School of 
Medicine, New York, NY
Atopic dermatitis (AD) is the most common inflammatory skin disease, with limited treatment 
options, as complete understanding of the disease pathogenesis is not yet established. Several 
microarray experiments have been conducted on lesional (AL) and non-lesional (ANL) AD skin 
in order to develop a “genomic disease phenotype”. Although these experiments have shed light 
on the disease pathology, inter-study comparisons reveal large differences in the resulting sets of 
differentially expressed genes (DEGs), limiting the utility of direct comparisons of DEGs across 
studies. In this work we used state of the art meta-analysis models to combine four AD micro-array 
datasets from published/submitted studies. Raw data was uniformly preprocessed and batch-ad-
justment was conducted prior to the analysis. Taking into account within/cross-study variations, a 
random-effect model was applied to the 112 samples (62 AL and 50 ANL; 49 paired), to define a 
robust disease profile. This resulted in a comprehensive AD transcriptome with 623 DEGs (at FCH>2, 
adj.p-values<0.05), with 405 up- and 218 down-regulated genes in AL versus ANL samples. Our 
meta-analysis identified several Th2 and Th1-polarizing chemokines previously low or unidentified 
on arrays (CCL13, CCL5, CCL17, CXCL9), and several dendritic cell markers such as CD1B and 
CD11c/ITGAX, ICOS, a marker of T-cell activation, the local inflammatory response related IL36G, 
and a negative regulator, BATF3. Among the top DEGs we also observed previously reported key 
AD markers (i.e. S1007-8, CCL18, IL7R, CCR7). Further we assessed inter-cohort variation of known 
AD hallmark pathways to this transcriptome and identified disease hubs by co-expression network 
analysis. Our meta-analysis provides a novel and powerful insight into the AD disease pathology, 
and confirms our previous findings on disease-related pathways, providing robust candidates for 
future development of therapeutics.    
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The JAK 1/2 inhibitor baricitinib prevents and reverses alopecia areata in C3H/HeJ mice
Z Dai,1 L Xing,4 A Jabbari,1 A Christiano1,3 and R Clynes1,2,4 1 Dermatology, Columbia 
Univeristy, New York, NY, 2 Medicine, Columbia Univeristy, New York, NY, 3 Genetics 
and Development, Columbia Univeristy, New York, NY and 4 Pathology and Cell Biology, 
Columbia Univeristy, New York, NY
Alopecia areata (AA) is a T cell mediated autoimmune disease, the result of CD8 T cell attack of 
the hair follicle. In both human and mice, AA lesional skin is dominated by an IFN transcriptional 
signature, which likely contributes mechanistically to pathogenesis. To target the IFN pathway 
therapeutically we have used small molecule inhibitors of the JAK kinases, in particular JAK1 and 
JAK2, which are both downstream effector kinases of the IFN gamma receptor. Baricitinib is a JAK1/2 
inhibitor currently in clinical development for the treatment of autoimmunity, including rheumatoid 
arthritis and psoriasis, and has demonstrated an acceptable safety profile. To assess the ability of 
baricitinib to impact AA development we have used the C3H/HeJ skin graft model of AA. Systemic 
treatment with baricitinib at the time of grafting prevented the onset of AA. Moreover, in mice 
with established alopecia areata, topical baricitinib treatment reversed disease, with hair regrowth 
occurring within 4-6 weeks of beginning treatment. Baricitinib treated mice exhibited reduced CD8 
effector T cells infiltrates in the skin and reduced expression of IFN responsive genes, demonstrating 
proof-of-concept for targeted inhibition of JAK1/2 in AA. Thus, baricitinib represents a promising 
therapeutic approach in the treatment of human alopecia areata.    
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Higher prevalence of autoimmune disease observed in a cohort of patients with vitiligo
L Gill,1,2 A Zarbo,1,3 P Isedeh1 and I Hamzavi1 1 Dermatology, Henry Ford Hospital, Detroit, 
MI, 2 College of Human Medicine, Michigan State University, East Lansing, MI and 3 School 
of Medicine, Wayne State University, Detroit, MI
The purpose of this study is to describe the vitiligo patient population at Henry Ford Health Systems, 
with the ultimate goal of quantifying the burden of comorbid autoimmune disease in patients with 
vitiligo. An eleven-year retrospective chart review was conducted with a total of 1,098 patients 
included. Prevalence of autoimmune diseases in the vitiligo study population was compared to the 
general U.S. population. Out of 1,098 patients with vitiligo, 54% were female, 39% were Cauca-
sian, 35% were African American, and 26% were of other ethnicity. The age of onset of vitiligo 
ranged from infancy to 89 years, with an average age of onset of 29 years. The prevalence of certain 
autoimmune diseases was found to be higher in the vitiligo study population than the general U.S. 
population: of the study cohort, 3.8% had alopecia areata (2x higher); 0.73% had inflammatory 
bowel disease (3x higher); 0.18% had myasthenia gravis (36x higher); 0.18% had multiple sclerosis 
(3x higher); 0.55% had pernicious anemia (4x higher); 0.27% had systemic lupus erythematosus (11x 
higher); 12% percent had thyroid disease (6x higher); and 0.73% had type 1 diabetes mellitus (1.5x 
higher). Of those who were tested, 19% were found to be positive for anti-nuclear antibody, 10% 
were positive for anti-thyroglobulin antibody, and 27% were found to be positive for anti-thyroid 
peroxidase antibody. This preliminary study suggests that the prevalence of autoimmune disease is 
higher in patients with vitiligo than the general U.S. population. This study encourages physician 
inquiry about personal and family history of autoimmune disease, particularly thyroid disease, in 
patients with vitiligo, in order to diagnose comorbid diseases early in their progression.    
133
IL-2 blockade prevents the onset of alopecia areata in C3H/HeJ mice
Z Dai,1 L Xing,4 A Jabbari,1 A Christiano1,3 and R Clynes1,2,4 1 Dermatology, Columbia 
Univeristy, New York, NY, 2 Medicine, Columbia Univeristy, New York, NY, 3 Genetics 
and Development, Columbia Univeristy, New York, NY and 4 Pathology and Cell Biology, 
Columbia Univeristy, New York, NY
Alopecia areata is an autoimmune disease driven by effector cytolytic T cells (CTLs) that infiltrate 
the hair follicle. Our GWAS studies have identified the loci harboring interleukin-2 (IL-2) and its 
receptor IL-2Ra as potential disease susceptibility genes in human AA, suggesting that the IL-2 
pathway is pathogenically involved in the activation of alopecic CTLs. Interleukin-2 is a pleiotropic 
cytokine that drives T-cell growth, induces the differentiation of Treg cells, promotes the devel-
opment of naïve CD8+ T cells into effector or memory CTLs and augments NK cytolytic activity 
and increases CTL and NK cells responsiveness to IL-15. In the grafted AA C3H/HeJ mouse model, 
heterozygous IL-2+/- littermates were resistant to AA induction compared with IL-2+/+ wild-type 
littermates, thus pointing toward an involvement of IL-2 in AA pathogenesis. To assess the effect 
of inhibiting a potential IL-2 mediated response in the onset of disease in C3H/HeJ AA skin grafted 
mice, we utilized a combination of two neutralizing mAbs, S4B6 and JES6-1 recognizing different 
epitopes on the IL-2 molecule. After 12 weeks of treatment, none of the IL-2 neutralizing-treated 
mice exhibited onset of AA, whereas 80% of control mice developed AA with an average 40% 
body hair loss. Immunohistochemical staining of skin biopsies show that IL-2 neutralizing-treated 
mice have a striking decrease in MHC-I, MHC-II and ICAM-1 expression. Furthermore, immuno-
histochemistry of skin revealed a dense perifollicular and intrafollicular infiltrate of CD8+ T cells 
in control mice with AA development. Mice treated with neutralizing IL-2 antibodies did not show 
CD8+ T cell infiltrates. Collectively, our results indicate that IL-2 may be an important cytokine 
driving autoreactive effector T cells, and that blockade of the IL-2 signaling pathway may be an 
attractive therapeutic target in the treatment of AA.    
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Mass spectrometry-based proteomic analysis of pemphigus vulgaris anti-desmoglein 3 
autoantibodies
J Chen, CM Hammers, C Lin and JR Stanley Dermatology, University of Pennsylvania, 
Philadelphia, PA
In pemphigus vulgaris (PV), anti-desmoglein 3 (Dsg3) autoantibodies cause loss of keratinocyte 
adhesion with severe blistering. We analyzed the complexity of the circulating PV anti-Dsg3 auto-
antibody repertoire in patients’ sera using a mass spectrometry (MS)-based proteomic approach. 
Recombinant Dsg3 ectodomain was used to affinity purify anti-Dsg3 antibodies (Abs) from two PV 
patients (PV1 and PV3). These Abs were directly digested with either trypsin or GluC or only the 
heavy chain was digested after separation by SDS-PAGE. The resultant peptides were analyzed by 
liquid chromatography-tandem mass spectrometry. Obtained spectra (with a 1% false discovery 
rate, with individual matches requiring Xcorr>2 for Z=3, deltCN>0.1 and ppm<5 to ensure accu-
racy) were searched against previously genetically cloned (by antibody phage display) variable 
heavy chain sequences from peripheral blood mononuclear cells (PBMCs), against the constant 
regions of all immunoglobulin-isotypes, and against a human protein database. To determine if 
the genetically cloned sequences from PBMCs actually produced anti-Dsg3 circulating autoAbs 
in vivo, we determined if their genetically deduced variable heavy (VH)-CDR3 peptide sequences 
could actually be found in the MS analysis of circulating Abs. MS did detect 2 predicted VH-CDR3 
sequences from each patient’s Abs, with 50% to 100% coverage; and MS did not detect VH-CDR3 
sequences genetically predicted to be in PV1 in the PV3 Abs or vice versa. Furthermore, MS spectra 
of affinity-purified Abs from both patients also showed complement components. Finally, more 
spectra for IgG4 than IgG1 were shown in both patients, consistent with predominance of IgG4 
in PV Abs. These data demonstrate the feasibility of proteomic analysis of autoAbs, and show that 
genetic clones of VH DNA from peripheral B cells that produce anti-Dsg3 Ab in recombinant phage 
also encode circulating Abs in patients. [CMH and JC equal contributors]    
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Mast cells are key mediators of cathelicidin initiated skin inflammation in a rosacea model
Y Muto, Z Wang, M Vandenberghe, RL Gallo and A Di Nardo UCSD, San Diego, CA
MCs are a primary source of cathelicidin LL-37 (Cath LL-37), an antimicrobial peptide that has been 
a key mediator of rosacea pathogenesis. Analysis of rosacea skin in human subjects has shown 
an increase in the expression of matrix metalloproteinase-9 (MMP-9) and Chymase. Because MCs 
release MMP-9 and Chymase after Cath LL-37 challenge, we wanted to study how those proteases 
are involved in the development of rosacea-like features. After intradermal injection of LL-37, only 
MC deficient (Kitwsh-/-) mice reconstituted with wild type (WT) MCs showed an increase in Mmp9 
expression (p<0.01 in MC-reconstituted Kitwsh-/- mice when compared to Kitwsh-/- mice). MMP 
activity increased in a dose dependent fashion when Cath LL-37 was added (p<0.01). Il6 expression 
was significantly increased at early time point (p<0.001) after Cath LL-37 challenge only in WT mice 
but not in Kitwsh-/- mice. To test if those proteases released from MCs could affect keratinocytes, 
NHEK cells were co-cultured with MC supernatant. Kallikrein (KLK) and MMP protease activi-
ties in the cells were dramatically increased when NHEK cells were co-cultured with Cath LL-37 
challenged MC supernatant, demonstrating how MC activation can increase NHEK protease and 
create a self amplifying mechanism in rosacea skin. Further, we hypothesized that MC stabilizers 
could be utilized to reduce release of MMP-9, MC proteases and pro-inflammatory cytokines. 
Pre-treatment with a MC stabilizer (cromolyn) reduced Mmp9 and Cxcl2 expression (p<0.01) when 
WT mice after Cath LL-37 challenge. MMP-9 activity was significantly decreased with cromolyn 
treatment (p<0.01). Increased co-localization of MMP-9 and MC marker was also observed in Cath 
LL-37 challenged skin, but not in the skin with treatment. Thus, we speculate MCs in humans may 
play a role in amplifying rosacea inflammation and symptoms, especially erythema, flushing and 
telangiectasia. MC stabilizers could be considered a possible therapy for effective treatments for 
rosacea symptoms and prevention.    
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IKK16 inhibits activation NF-κB and reduces expression of proinflammatory chemokines 
in keratinocytes
L Li, B Flower and SH Yuspa LCBG, National Cancer Institute, Bethesda, MD
Activation of the Nuclear transcription factor κB (NF-κB) family of proteins by the action of I kappa 
B kinase (IKK) phosphorylating IkB protein is important in regulating epidermal homeostasis and 
inflammation. We have investigated the consequences of an IKK inhibitor, IKK16, on reducing the 
NF-κB mediated inflammatory response in primary mouse keratinocytes. IKK16 inhibited IL-1α 
and TNFα induced CXCL1 and CXCL2 proinflammatory chemokines that are downstream from 
NF-κB activation This dose-dependent inhibitory effect persists up to 24 hours. Similarly in a mouse 
macrophage cell line Raw, IKK16 exhibited a dose-dependent inhibition of CXCL1 and CXCL2 
expression. Immunoblotting of IkB protein demonstrated that IKK16 indirectly stabilizes IκB; the 
degradation was delayed and the recovery was faster when compared to control cells. In addition 
to reducing inflammatory chemokine transcription, fluorescence imaging has shown that IKK16 
induces cell apoptosis through the activation of Caspase-3/7. This activation of apoptosis can be 
attenuated by caspase inhibitors. However, the EC50 for apoptosis induction is much higher than 
the IC50 on cytokine-induced CXCL1 and CXCL2 expression, indicating that the effect of IKK 16 
cytokine-induced NFkB activation is independent of its ability to activate caspase 3/7. Currently, we 
are evaluating the effect of IKK 16 on inflammation of mouse skin. Our study indicates that IKK16 
is an effective inhibitor of the NF-κB signaling pathway, suggesting that IKK16 would be a suitable 
therapeutic for the treatment of skin inflammation.    
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Functional genomics defines an association of the ligand-independent CTLA4 isoform with 
alopecia areata
A Christiano,1,2 L Bian,1 M Gros,3 L Petukhova,1 Z Dai1 and R Clynes3,4 1 Dermatology, 
Columbia, New York, NY, 2 Genetics & Development, Columbia, New York, NY, 3 
Pathology & Cell Biology, Columbia, New York, NY and 4 Medicine, Columbia, New York, 
NY
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) plays a critical role in downregulating T cell 
responses. Multiple splice variant isoforms of CTLA-4 have been described, including a ligand inde-
pendent form (liCTLA-4), as well as a soluble, secreted variant (sCTLA-4). Polymorphisms around the 
CTLA-4 gene within the costimulatory locus result in differential expression of these splice variants, 
and have been associated with susceptibility to multiple autoimmune diseases, including type1 
diabetes (T1D), celiac disease (CeD), rheumatoid arthritis (RA), and alopecia areata (AA). LiCTLA-4 
is expressed in primary T cells and strongly inhibits T cell responses, but to date has only been 
described in the mouse, despite numerous attempts to identify its counterpart in human cells. Using 
splice-form specific RT-PCR, here we show that liCTLA-4 is in fact present in human cells, where it 
is expressed upon T-cell activation at the mRNA and protein levels. Functionally, over-expression of 
human liCTLA-4 inhibited T cell cytokine production, and TCR-mediated mitogen-associated protein 
kinase (MAPK) family activation in CTLA-4-deficient Jurkat cells. LiCTLA-4 is associated with T1D 
in the NOD mouse model, which expresses only 20% of liCTLA-4 compared to diabetes-resistant 
mice. To determine the relevance of liCTLA-4 in human AA, we assessed AA-associated SNPs by 
real-time PCR and found that several AA-associated SNPs showed significant association with both 
the expression and the splicing of liCTLA4. Moreover, the risk alleles predict decreased expression/
splicing (rs3087243, p=0.001 and p=0.003; and rs231775, p=0.008 and p=0.022 for expression and 
splicing, respectively). Using functional genomics, we have identified an association between the 
level of liCLTA-4 expression and susceptibility to AA. Further, establishing the existence of liCTLA-4 
in humans invites further investigation of this isoform in the human immune system.    
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Large clonal T cell populations are observed in LyP lesions and may be associated with 
increased Th17 function as compared to mycosis fungoides
L Campbell,1 R Watanabe,1 M Kadin,2 J Teague,1 TS Kupper1 and R Clark1 1 Brigham and 
Women’s Hospital, Boston, MA and 2 Roger Williams Medical Center, Providence, RI
Lymphomatoid papulosis (LyP) is a CD30+ lymphoproliferative disorder thought to represent an 
indolent, self-regressing form of CTCL. We analyzed eight lesional skin biopsies from biopsy proven 
LyP patients by high throughput TCR sequencing. Expanded T cell clones were observed in all eight 
specimens, and clonal cells made up a mean of 25% of total T cells as compared to mean 1.6% 
in healthy skin, 16% in Stage IA CTCL, 25% in Stage IB, 30% in stage IIA-IIB, and 56% in stage 
III-IV. It is not clear why clonal T cells are destroyed by the immune system in LyP but not in MF. 
Given the presence of neutrophils in LyP lesions and our finding that IL- 17 is down regulated in 
MF, we hypothesized that IL-17 production may be increased in LyP and may enhance immune 
detection. We analyzed Th1, Th2, Th17 and Th22 cytokines and transcription factors by quantitative 
RT-PCR and compared results to healthy skin and MF lesional skin. We observed that RORc, the 
gene encoding the Th17 associated transcription factor RORγt, was markedly up regulated in LyP 
specimens as compared to MF (p<0.001) and healthy skin. Levels of IL-17A were also increased in 
LyP as compared to MF. Under noninflamed conditions, a mean 34% of T cells from healthy skin 
produce IL-17; it was therefore not perhaps surprising that IL-17 from LyP was not significantly higher 
than that seen in healthy skin. Levels of the Th2 associated transcription factor GATA3 and the Th2 
cytokine IL-4 were both markedly down regulated in LyP as compared to healthy skin. IL-22 pro-
duction was lower than that observed in healthy skin, and similar to that observed in MF, although 
differences were not statistically significant. Lastly, TCR sequencing allows identification of TCRVβ 
usage. We have identified clonal cells in cryosections by immunostaining with TCRVβ antibodies. 
Direct examination of the phenotype and cytokine production by clonal cells in LyP is underway.   
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Quality of life style in Veteran patients with psoriasis
CN Young,1,2 W Nasir,2 G Messenger,2 C Hatzis2 and B Savoy1 1 Dermatology, John D 
Dingell VA Medical Center, Detroit, MI and 2 Wayne State University, Detroit, MI
Psoriasis is a chronic inflammatory immune-mediated relapsing skin disease with a prevalence 
of 1-2% in the general population and a significantly higher prevalence of 4-5% in the veteran 
population. At the John D. Dingell VA medical center in Detroit, Michigan a clinical study was 
conducted with 150 psoriasis veteran patients that looked to discover a link between psoriasis and 
metabolic syndromes, diet and lifestyle. Metabolic syndrome disorders, correlate to an up-regula-
tion in inflammation, include obesity, diabetes mellitus, dyslipidemia, heart disease, hypertension 
and stroke. The study aimed to demonstrate that by utilizing topical antioxidants, supplemental 
antioxidant pills and lifestyle modifications one can see a dramatic improvement in psoriasis. 
The aforementioned treatments all have a common mechanism of action, reducing inflammation. 
Inflammation, the etiological factor in psoriasis, may explain the reason why so many psoriasis 
patients present with accompanying metabolic syndrome disorders. This study revealed that more 
than 50% of the psoriasis patients have lifestyle-induced psoriasis. Therefore, the etiology of psoriasis 
is likely secondary to a poor diet and a sedentary lifestyle. This culminates in obesity and other 
metabolic disorders that increase the inflammatory process leading to psoriasis. While both genetics 
and lifestyle interact with one another to induce psoriasis; this study reveals that a poor lifestyle 
may be the leading etiology for the patient’s disease. By altering a patient’s lifestyle, not only has 
the patient’s psoriasis and overall health improved, the overall cost of treating these patients has 
significantly decreased. In summary, improving the quality of lifestyle may have dramatic results 
in the treatment, alleviation and possible cure of psoriasis.    
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A quantitative increase in regulatory T cells controls development of vitiligo
S Chatterjee,1 J Eby,2 AA Al-khami,1 M Soloshchenko,1 H Kang,2 N Kaur,1 OS Naga,1 
A Murali,1 MI Nishimura,3 C LePoole2 and S Mehrotra1 1 Surgery, Medical University of 
South Carolina, Charleston, SC, 2 Pathology, Loyola University, Maywood, IL and 3 Surgery, 
Loyola University, Maywood, IL
T cell cytolytic activity targeting epidermal melanocyte is shown to cause progressive depigmen-
tation and autoimmune vitiligo. Using the recently developed transgenic mice h3TA2 that carry T 
cell with a HLA-A2 restricted human tyrosinase reactive TCR and develop spontaneous vitiligo from 
an early age, we addressed the mechanism regulating autoimmune vitiligo. Depigmentation was 
significantly impaired only in IFN-γ knockout h3TA2 mice but not in TNF-α or perforin knockout 
h3TA2 mouse strains, confirming a central role for IFN-γ in vitiligo development. Additionally, the 
regulatory T cells (Treg) were relatively abundant in h3TA2-IFN-γ-/- mice, and depletion of Treg 
employing anti-CD25 antibody fully restored the depigmentation phenotype in h3TA2-IFN-γ-/- mice 
mediated in part through upregulation of pro-inflammatory cytokines as IL-17and IL-22. Further 
therapeutic potential of Treg abundance in preventing progressive depigmentation was evaluated 
by adoptively transferring purified Treg or using rapamycin. Both adoptive transfer of Treg and 
rapamycin induced lasting remission of vitiligo in mice treated at the onset of disease, or in mice 
with established disease. This leads us to conclude that reduced regulatory responses are pivotal 
to the development of vitiligo in disease-prone mice, and that a quantitative increase in the Treg 
population may be therapeutic for vitiligo patients with active disease.    
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High throughput TCR sequencing provides superior ability to diagnose, stage and follow 
patients with cutaneous T-cell lymphoma
J Teague,1 H Robins,2 L Kirsch,2 D Williamson,2 R Watanabe,1 TS Kupper1 and R Clark1 1 
Cutaneous Lymphoma Program, Dana-Farber Brigham and Women’s Cancer Center, Boston, 
MA and 2 Adaptive Biotechnologies, Seattle, WA
Diagnosis of early-stage CTCL can be challenging because skin lesions contain a mixture of both 
diverse benign and clonal malignant T cells. Currently, clonality is assessed by TCRγ PCR but this 
method is qualitative, often fails to detect clones present at low numbers, and cannot be used to 
identify malignant T cells for subsequent study by flow cytometry. High throughput sequencing of 
the TCR CDR3 variable region (HTS) is a new technique that provides comprehensive analysis of 
the total T cells in a specimen, the breadth of TCR repertoire diversity, and an exact quantification 
of individual T cell clones. We analyzed skin biopsies from 36 patients with CTCL, 4 patients with 
questionable diagnoses of CTCL and 10 healthy individuals by TCR Vγ and Vβ HTS. In all CTCL 
patients, malignant T cell clones were readily detectable by HTS, including patients negative for 
clonality by Vγ PCR. HTS provided a comprehensive picture of both the malignant T cell clones and 
benign infiltrating T cells in patients with both MF and leukemic CTCL. Individual T cell clones were 
successfully tracked in both the blood and skin over time and across multiple lesions. HTS allowed 
definitive diagnosis as CTCL (3 patients) and non-CTCL (1 patient) in 4 patients in whom diagnosis 
was unclear by both Vγ PCR and histopathology. Because of its ability to exactly quantitate malig-
nant T cell clones, HTS allowed highly accurate initial staging in blood and skin, early detection of 
disease progression and sensitive and accurate assessment of residual disease following systemic 
and skin directed therapies. Lastly, TCRVβ HTS allowed identification of malignant T cells using 
anti-TCR Vβ antibodies and flow cytometry, aiding both clinical follow-up and scientific study of 
these cells. In summary, HTS is a powerful new method for the diagnosis, staging, follow up and 
scientific study of patients with CTCL.    
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Successful treatment of discoid lupus erythematosus with tacrolimus 0.3% solution
S Ramachandran, J Shapiro and AG Franks The Ronald O. Perelman Department of 
Dermatology, New York University School of Medicine, New York, NY
Background: Traditional therapies for discoid lupus erythematosus include topical and intralesional 
corticosteroids and oral antimalarial medications. Sometimes, however, the disease can be refractory 
to these as well as other second and third line agents. We used topical tacrolimus 0.3% in two 
patients with recalcitrant discoid lupus erythematosus (DLE) of the scalp. Methods: Two patients with 
DLE of the scalp, refractory to treatment with topical and intralesional steroids and antimalarials, 
were started on topically custom-formulated tacrolimus 0.3% solution applied to affected areas twice 
daily. Results: Both patients had resolution of disease activity with a reduction in erythema, scale, 
and surface area of lesions and increased hair growth after applying tacrolimus 0.3% solution twice 
daily for several months. No adverse effects were noted. Conclusion: Although further studies are 
required, our results support the use of topical tacrolimus 0.3% solution in resistant cases of DLE, 
thereby presenting a new therapeutic option for this disease.    
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Psoriatic monocytes and skin express increased tissue factor and thrombin generation
DC Soler,1,4 A Young,1 S Churton,3 F Chao,2 AH Schmaier,2 T McCormick,1,4 KD Cooper1,3,4 
and N Korman1,3,4 1 Dermatology, Case Western Reserve University, Cleveland, OH, 2 
Hematology and Oncology, Case Western Reserve University, Cleveland, OH, 3 University 
Hospitals Case Medical Center, Cleveland, OH and 4 The Murdough Family Center for 
Psoriasis, Case Western Reserve University, Cleveland, OH
Psoriasis is a systemic, chronic immunologically mediated disease affecting primarily the skin and 
joints that is also associated with an increased risk of cardiovascular disease (CVD). The molecular 
mechanisms behind the increased risk of CVD in psoriatic patients are not known. Tissue factor (TF) 
(CD142) is an essential cofactor for physiologic hemostasis which when over-expressed leads to 
increased thrombosis. We recruited well-characterized psoriasis patients with active disease from 
the Murdough Family Center for Psoriasis Database and examined their peripheral blood monocytes 
(PBM) for CD142 expression. Using flow cytometry, we demonstrated a significant increase in TF 
expression on PBM from psoriasis patients compared to healthy controls (22% vs 5% respectively, 
n=29, p=0.03). The thrombin-generating time of CD14+ monocytic cell extracts was measured 
without added TF. Cell extracts from psoriatic patients showed increased endogenous thrombin 
potential compared to healthy controls (9,511 vs 2,116 AUC respectively, p=0.01). Immunohisto-
chemical staining of skin biopsies from the psoriatic patients showed profuse TF staining compared 
to healthy controls. Ten psoriatic patients with an average PASI of 26 and average TF expression 
on monocytes of 26% underwent treatment with a systemic agent that reduced their average PASI 
to 5 and TF expression to 7% (p=0.03). Taken together these results suggest increased PBM and 
skin expression of TF may be a contributor to increased risk of CVD in psoriatic patients through 
increased thrombin generation leading to higher risk for thrombosis..    
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Cost analysis of rituximab as an alternative first line adjuvant therapy to mycophenolate 
mofetil for moderate-to-severe pemphigus vulgaris
B Jiang, E Myers, RP Hall and AR Cardones Dermatology, Duke University Medical Center, 
Durham, NC
Pemphigus is an autoimmune blistering disorder that can be associated with significant morbidity 
and mortality. Treatment of moderate to severe disease usually requires the use of both prednisone 
and an adjuvant therapy, most commonly mycophenolate mofetil (MMF) or azathioprine. Rituximab, 
an anti-CD20 antibody, has emerged as an effective therapy for recalcitrant pemphigus, but is 
currently being used as second line adjuvant therapy. Data suggest that rituximab is more effective 
earlier in the disease course, and that patients achieve complete remission more quickly than with 
conventional therapy. This project aims to estimate the cost-effectiveness of rituximab treatment 
for pemphigus early in the disease course as compared to MMF. Efficacy data was obtained from 
prospective trials in the literature, and cost data from institutional and published resources. We 
developed a Markov model to evaluate cost effectiveness of 1 year of rituximab+steroid therapy 
versus MMF+steroid therapy. We included cost of drugs, infusions, and clinic visits in the analysis. 
We also evaluated the difference in time until steroid discontinuation as a surrogate measure of 
effectiveness. Patients on rituximab achieved disease control and were able to stop systemic ste-
roids earlier than what was reported for those receiving MMF. At 6 months, up to 86% of patients 
were off steroids when rituximab was used as adjuvant therapy versus 41% on MMF. Analysis 
predicts that more patients will be off steroids at the end of 1 year when using rituximab vs MMF. 
The estimated cost is $38,000 for each additional person who is able to be taken off steroids. 
Insufficient data on quality of life adjusted year (QALY) limited our analysis for cost effectiveness. 
In conclusion, rituximab appears to be a promising strategy as first line adjuvant therapy for pem-
phigus vulgaris. Further studies determining QALY parameters need to be done to allow for a better 
cost-effectiveness analysis.    
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CCL22 to activate Treg migration and suppress depigmentation in mice
J Eby,1 S Tully,1 W Bindeman,1 S Chatterjee,2 H Kang,1 S Mehrotra2 and C Le Poole1 1 
Pathology, Microbiology and Immunology/ Oncology Research Institute, Loyola University 
Chicago, Maywood, IL and 2 Surgery/ Hollings Cancer Center, Medical University of South 
Carolina, Charleston, SC
Before attempting repigmentation in vitiligo, ongoing autoimmune reactivity to melanocytes must 
be halted. A paucity of Tregs in vitiligo patient skin is accompanied by gradual cutaneous depig-
mentation and CTL activity against melanocytes, thus we sought a means to repopulate patient skin 
with Treg. We previously observed a marked reduction in CCL22 expression in vitiligo patient skin. 
Reduced expression of this chemokine was not associated with reduced expression of CCR4 by 
circulating patient Treg. We thus hypothesized that enhanced expression of CCL22 can promote 
Treg skin homing to suppress depigmentation. The mouse Ccl22 gene was cloned into an expres-
sion vector and resulting DNA was used to coat gold microparticles for gene gun vaccination. Two 
spontaneous depigmentation models with different kinetics of melanocyte loss were utilized in 
these investigations: the h3TA2 and Pmel-1 models expressing tyrosinase-reactive and gp100-re-
active T cell receptors, respectively. Mice were subjected to 5 gene gun vaccinations 6 days apart, 
scanned for depigmentation weekly thereafter and monitored for activation and proliferation of 
relevant T cells and for Treg infiltration to the skin. Significantly reduced depigmentation 3 weeks 
after vaccination was accompanied by >4-fold increased abundance of Tregs in the skin at the 
expense of melanocyte reactive, TCR transgenic T cells as well as reduced proliferation and 70% 
reduced IFN-gamma production in response to cognate peptide. A challenge will be to translate 
this concept into a suitable therapeutic application, as continued treatment may be necessary for 
sustained, local immunosuppression. These findings suggest that topical CCL22 may be used for 
the treatment of vitiligo.    
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Monocyte aggregates and intermediate (CD14++CD16+) monocytes that are associated with 
cardiac events are increased in human psoriatic blood
JB Golden,1,2 SG Groft,2 NL Ward,2 T McCormick2 and KD Cooper1,2,3 1 Pathology, Case 
Western Reserve University, Cleveland, OH, 2 Dermatology, Case Western Reserve 
University, Cleveland, OH and 3 VA Medical Center, Cleveland, OH
Psoriasis confers an increased risk for developing and dying of cardiovascular disease (CVD) and 
psoriasiform skin disease in mice confers increased vascular thrombosis. Recent studies demon-
strate that elevated levels of circulating intermediate monocytes (CD14++CD16+) independently 
predict MI, non-hemorrhagic stroke, and death in cardiovascular patients. We hypothesized that 
an increase of CD14++CD16+ cells in psoriasis may mechanistically link skin pathogenesis with 
CVD morbidity. We found that psoriasis patients (n=19) show an increased percentage of circulating 
CD14++CD16+ cells compared to healthy controls (n=23) (16.5%±2.7 vs. 11.9%±1.4, respec-
tively, P=.056). Furthermore, these CD14++CD16+ cells are visible by confocal microscopy in the 
dermis and as emigrating cells from blood vessels in psoriatic involved skin (n=5). Interestingly, 
further analysis of the expanded CD14++CD16+ circulating population revealed that they are 
often involved in aggregates and doublets of monocytes. Specifically, total CD14++ doublets are 
increased in psoriasis compared to control subjects (2.72%±0.58 vs. 1.09%±0.20, respectively; 
P=0.006). We used Amnis cytometry to photograph these CD14++CD16+ doublets and found that in 
addition to true CD14/CD16 doublets, CD14++CD16- and CD14++CD16+ pairs may masquerade 
as doublets. In the KC-Tie2 murine model of psoriasis, monocyte doublets were also increased, 
indicating a skin inflammation-driven process. Psoriasis-driven accumulation and aggregation of 
monocytes in circulation suggest a novel mechanistic linkage between psoriatic skin disease and 
its CVD comorbidity. Clinical utility as a biomarker of patients at risk for CVD and of therapeutics 
that modify both psoriasis and CVD is proposed.    
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DRM02, a novel PDE4 inhibitor, demonstrates activity in multiple skin inflammation models
D Hunt and HE Hofland Research, Dermira, Inc., Redwood City, CA
Cyclic adenosine monophosphate (cAMP) is a key intracellular second messenger that plays a role 
in many cellular processes, including inflammation. Increasing intracellular cAMP levels has been 
shown to have an antagonistic effect on pro-inflammatory signaling pathways. Therefore, com-
pounds that inhibit the cAMP degrading enzymes, phosphodiesterases (PDEs), especially PDE4, have 
been considered to be promising new drugs for chronic inflammatory disorders. Historically, the 
development of PDE4 inhibitors for systemic use has been hampered by dose-limiting side effects, 
including nausea and emesis, resulting in a narrow therapeutic window. Employing PDE4 thera-
peutics via a topical route of administration is a valid strategy to avoid these side effect limitations. 
DRM02, a novel small-molecule PDE4 inhibitor, has demonstrated activity in a variety of cell types 
and in vivo skin inflammation models. DRM02 suppressed expression of inflammatory mediators 
in activated T-cells, monocytes, dermal fibroblasts, and keratinocytes in vitro. Moreover, in mouse 
skin inflammation models, topically-applied DRM02 inhibited the acute inflammatory skin reaction 
instigated by phorbol ester, and the Th2-driven immune contact hypersensitivity (CHS) response 
to fluorescein isothiocynate (FITC). In the imiquimod (IMQ) skin inflammation model, which has 
been shown to be mediated via the IL-23/IL-17 axis, DRM02 profoundly suppressed skin TNF-α, 
IFN-γ, IL-17A, IL-17F, and IL-22 expression at both mRNA and protein levels. DRM02 also inhibited 
IMQ-induced increases in mRNA levels of chemokines involved in T-cell, neutrophil and/or den-
dritic cell migration, including CCL2, CCL17 (TARC), CCL20 and CXCR2. Treatment with DRM02 
in an optimized gel formulation fully suppressed development of clinical skin changes in the mouse 
evoked by repeat applications of IMQ. The pharmacology and safety profile of DRM02 suggests its 
potential to interfere in the pathogenesis of chronic inflammatory skin disorders, including psoriasis, 
atopic dermatitis, and rosacea.    
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Dermal mast cells and fibrosis: Correlation to keloid pathology
T Thekkudan,1 A Mantel,1 G Sahu,1 J Tao,2 EJ Reichenberger,2 RA Frazier3 and M Katdare1,3 
1 HUSCRI, Hampton University, Hampton, VA, 2 Reconstructive Sciences, University of 
Connecticut Health Center, Farmington, CT and 3 Dermatology, Eastern Virginia Medical 
School, Norfolk, VA
Keloids (KD) are dermal fibrotic tumors often exhibit debilitating painful and pruritic conditions. 
KD are significantly prevalent in African-Americans, Hispanics and Asians. KD pathology is char-
acterized by increased number of fibroblast, myofibroblasts, excessive deposition of extracellular 
fibrotic proteins and inflammation. Mast Cells (MC) observed in KD lesions are the major source 
of pro-inflammatory Prostaglandin H2 (PGH2) and Prostaglandin D2 (PGD2). PGH2 further gets 
metabolized into PGD2 by hematopoietic-PGD synthase (h-PGDS), whereas chemically unstable 
PGD2 either spontaneously gets converted into non-proliferative 15ΔPGJ2, or enzymatically gets 
reduced into pro-proliferative 9α11βPGF2 by aldo-keto reductase 1C3 (AKR1C3). We hypothesize 
that MC secreted PGH2 and PGD2, and pro-proliferative metabolite 9α11βPGF2, leads to discrete 
and localized fibrosis, cellular and pathological heterogeneity within KD. Archived KD samples from 
back, chest and ear were utilized to elucidate and correlate the observed pathological heterogeneity 
to active MC, together with the expression of h-PGDS, and AKR1C3 in KD lesions. We observed 
presence of abundant MC in proximity of disorganized fibroblasts, myofibroblasts, fibronectin and 
thick collagen bundles within KD lesions. In addition, immunoexpression of h-PGDS within the 
fibrotic area strongly suggest conversion of PGH2 to PGD2. The number of tryptase positive MC and 
immunopositive expression of h-PGDS, and AKR1C3 directly correlated with the extent of fibrotic 
growth and heterogeneity in the KD from back, chest and ear. Additionally, strong expression of 
extracellular matrix fibrotic proteins; fibronectin, collagen, and αSMA correlated with the presence 
of tryptase positive MC. Presence of MC and AKR1C3 indicate their significant role in KD fibrosis 
by regulating proliferation of fibroblasts via excessive secretion of PGD2 and its pro-proliferative 
metabolite 9α11βPGF2.    
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25(OH)D modifies host immune response following skin exposure to nitrogen mustard
L Au, J Meisch, L Das and KQ Lu Dermatology, Case Western Reserve University, Cleveland, 
OH
NM is a powerful alkylating agent that causes severe blistering upon contact exposure, resulting 
in epithelial injury that triggers massive inflammation. Macrophages infiltrate the injured site and 
produce inflammatory mediators like iNOS and TNF-α which further exacerbate NM-related skin 
injury. Taking advantage of the unique intracellular conversion of vitamin D3 within macrophages to 
its active form, we hypothesize that the precursor form 25-hydroxyvitamin D3 (25(OH)D), a known 
immune modulator, will control inflammation triggered by NM exposure. We observe that a single 
intraperitoneal (i.p.) dose of 25(OH)D or a pharmacological inhibitor of iNOS (1400W) given 1 
hour after NM exposure rescues mice from NM-related toxicities. Histopathological analysis of the 
NM-treated skin area reveals full thickness necrosis with fat degeneration, massive edema, and acute 
inflammation. qRT- PCR reveals a 20-fold increase in iNOS and TNF-α mRNA levels compared to 
control (n=7; p<0.0004 and p<0.0002, respectively). In contrast, the 25(OH)D (or 1400W) cohort 
had minimal infiltrating inflammatory cells and few foci of epidermal necrosis with iNOS, and 
TNF-α mRNA levels suppressed to control levels (n=7; p<0.0027 and p<0.0037, respectively). 
Longitudinal studies with NM-only group displayed non-healing wounds, an acute drop in body 
weight by 35% and a mean survival of 7-9 days (n=5), suggesting that topical NM wields far-reaching 
systemic injuries. Blood smears show marked leukopenia and anemia (13.53±4.83 vs 3.62±2.25 and 
43.13±4.06 vs 24.47±6.27, respectively; n=9; p<0.05) and a decrease in bone marrow cellularity 
in NM-exposed mice five days post NM exposure. In contrast, 25(OH)D cohort remained healthy 
with rapid skin wound recovery (n=5), unremarkable blood smears (n=9), healthy bone marrow, and 
promote survival. These findings suggest that 25(OH)D is an effective and practical countermeasure 
to prevent damaging effects of NM exposure.    
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Langerhans cells’ critical role in modulating photodamage-induced inflammation and 
immunosuppression
TH Nasti,1 JA Davis,1 M Apperson,1 Y Tsuruta,1,2 CA Elmets1,2 and L Timares1,2 1 
Dermatology, University of Alabama at Birmingham, Birmingham, AL and 2 Skin Diseases 
Research Center, University of Alabama at Birmingham, Birmingham, AL
Langerhans cells (LCs) are antigen-presenting cells (APCs) located in the epidermis of the skin. The 
role of these cells in immunosuppression and tumorigenesis has been investigated and is controver-
sial. To clarify LCs role in regulating UV–induced skin inflammation and immune suppression, we 
compared cutaneous responses to UVB exposure in C57BL/6 wild type (WT) mice versus huLang-
DTA transgenic (LC-KO) mice, in which only epidermal LCs are absent. Inflammatory responses 
were evaluated by measuring ear swelling and cytokine expression in skin following a single dose 
of UVB radiation (180mJ/cm2). UV-induced ear swelling was rapid in LC-KO mice, peaking at day 
5 versus (vs) day 7 in WT mice (400 ± 75.1 μm vs 286.67 ± 46.4 μm, Day 5, p<0.05). The reso-
lution phase in WT mice was delayed but recovery rates were similar in both strains. UV-induced 
antigen-specific suppression to the hapten DNFB was evaluated in both groups of mice (n=5). CHS 
responses in UV-treated LC-KO mice was suppressed by only 12% as compared to 65% in WT mice 
(p< 0.001), supporting LCs importance in mediating suppression. The mRNA expression level of 
anti-inflammatory cytokine IL-10 was 3-fold lower in the epidermis and 40-fold lower in the dermis 
of LC-KO as compared to WT, indicating that LCs are the main IL-10 producers in UVB treated 
skin. LC-derived IL-10 was shown to be critical for UV hapten-specific suppression, since transgenic 
mice that lack the IL-10 gene only in LCs (LC-IL10KO) developed CHS responses similar to LC-KO; 
UV-treated LC-IL10KO mice induced only partial immune suppression as compared to LC-WT mice 
(22% vs 54%, respectively. p< 0.001). LNs of UV-treated LC-KO mice contained 50% fewer CD4+ 
FoxP3+ regulatory T-cells expressing IL-10 and 2-fold more APCs producing IL-12. Thus, LCs are 
critical early responders to cutaneous photodamage, as they are the principal source of IL-10, and 
are required to suppress inflammation and skin-specific immune responses.    
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IgG1 and IgG4 subclass autoantibody responses against keratinocyte cadherins in Fogo 
Selvagem
M Maldonado,1 CR Stamey,1 DA Culton,1 P Prisayanh,1 BF Qaqish,2 V Aoki,3 G Hans Filho,4 
EA Rivitti3 and LA Diaz1 1 Dermatology, University of North Carolina, Chapel Hill, NC, 2 
Biostatistics, University of North Carolina, Chapel Hill, NC, 3 Dermatology, Universidade de 
Sao Paulo, Sao Paulo, Brazil and 4 Dermatology, Universidade Federal de Mato Grosso do 
Sul, Campo Grande, Brazil
We have previously shown that while the IgG response in Fogo Selvagem (FS) is mainly restricted 
to desmoglein 1 (Dsg1), other keratinocyte cadherins are targeted among FS patients and healthy 
controls living in the endemic region of Limao Verde, Brazil (LV controls). FS patients have a 
robust IgG4 response to Dsg1, yet the IgG subclass autoantibody response to other desmosomal 
cadherins has not been investigated. We tested over 100 sera from each group of FS patients, LV 
controls, and controls from the United States (US controls) for IgG1 and IgG4 autoantibodies to 
recombinant ectodomains of keratinocyte cadherins Dsg1, Dsg2, Dsg3, Dsg4, desmocollin (Dsc) 
1, Dsc2, Dsc3 and E-cadherin (Ecad) by ELISA. The subclass responses to all keratinocyte cadherins 
were significantly different among FS patients, LV controls and US controls with the exception of 
the IgG1 responses to E-cad and Dsg4 and IgG4 responses to Ecad, Dsg4, Dsc1 and Dsc3, which 
were similar between FS patients and LV controls. In FS patients, the IgG1 response to Dsg1 strongly 
correlates with responses to other keratinocyte cadherins, while the IgG4 response shows lower 
correlation. In LV controls, there is a strong correlation between the IgG1 and IgG4 responses to 
all keratinocyte cadherins, but particularly between Dsg1 and Ecad. No such correlation is seen 
among US controls. These findings suggest that initial subclass responses in LV controls are highly 
correlated between Dsg1 and Ecad. Among patients the correlation persists in the IgG1 response, 
but diminishes in the IgG4 response, suggesting that responses to keratinocyte cadherins become 
specific to Dsg1 at the onset of disease. Based on these findings it may be hypothesized that the 
inciting environmental antigen(s) may also crossreact with Ecad.    
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A novel role of skin activated macrophages in mediating myelosuppression
J Meisch, L Au, L Das and KQ Lu Dermatology, Case Western Reserve University, Cleveland, 
OH
Skin exposure to nitrogen mustard (NM) produces a myriad of dose-dependent toxic effects includ-
ing destructive local skin wounds to profound systemic effects such as myelosuppression. The 
mechanism of the NM-induced myelosuppression remains to be elucidated but has long been 
attributed to direct skin absorption followed by DNA-alkylation on hematopoietic precursors in 
the marrow. Utilizing a mouse NM-skin contact model, we show a skin and marrow connection 
mediated by inflammatory macrophages that is critical for NM-induced marrow toxicity. Five days 
post NM exposure, analysis of marrow isolates reveal increases in F4/80+macrophages associated 
with a 27-fold increase of iNOS expression compared to control mice (n=8; p<0.05). Concurrent 
with this increase is a decrease in hematopoietic sub-populations in the marrow as well as pancy-
topenia in the circulation (n=6; p<0.004). Given the observed rapid increase in macrophages in 
the marrow, we searched for extra-marrow reservoirs of inflammatory macrophages, as accelerated 
myeloid differentiation is less likely. In our model, skin exposure to NM result in massive dermal 
and subcutaneous infiltration of iNOS+ macrophages. Using markers specifically phagocytosed 
by macrophages (liposomal DiI or pHrodo), skin macrophages at the site of NM exposure were 
labeled and tracked into the marrow. Flow cytometric analysis of marrow cells from these mice, 5 
days post NM exposure, reveal a 13.2% increase of DiI+ F4/80+ macrophages compared to control 
(n=5; p<0.01). Confocal microscopy confirms abundant triple-colocalization of DiI+ iNOS+ F4/80+ 
macrophages in the marrow (n=3). Furthermore, imaging of whole sternal bones by Maestro revealed 
striking fluorescence (pHrodo) in NM-treated mice compared to control (n=2). Lastly, local skin 
depletion of macrophages with clodronate not only accelerates healing of wounds inflicted by NM 
but also rescues mice from myelosuppression and blood cytopenia (n=6; p<0.01). In summary, 
our observations establish a new critical role of the innate immune system in linking local tissue 
reactions with systemic pathologies following NM exposure.    
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Anti-bullous pemphigoid autoantigen BP180 antibodies exist in sera and cerebrospinal fluid 
samples of patients with stroke and dementia
J Chen,1 Y Duan,1 L Chen,1 D Li,1 B Dong,1 L Xu,1 X Qiu3 and J Rao2 1 Dermatology, Wuhan 
No.1 Hospital, Wuhan, China, 2 Neurosurgery, Union Hospital, Tongji Medical College, 
Huazhong University of Science and Technology, Wuhan, China and 3 Neurosurgery, 
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 
Wuhan, China
Bullous pemphigoid (BP) is an acquired autoimmune dermatosis that is often associated with var-
ious neurological diseases (ND) in the elderly. As a main antigen of BP, BP180 has been found to 
be present in the central nervous system. Previously, we reported that antibodies in the sera of BP 
patients with ND recognize BP180 in human brain, indicating the possibility that BP180 could act 
as a shared autoantigen of the skin and brain. However, it is not known if sera and cerebrospinal 
fluid (CSF) of ND patients without BP have autoantibodies recognizing BP180 in the human brain 
or human skin. In this study, we used Immunoblotting and BP180NC16A-ELISA to detect and 
quantify levels of anti-BP180 antibody in sera and CSF of 45 patients with stroke and dementia and 
48 controls with traumatic brain Injury . By ELISA 17.8%(8/45) sera and 17.8%(8/45) of CSF of the 
patients were positive for BP180NC16A and levels of anti-BP180 antibody were significantly higher 
than the controls. By immunoblotting 13.3%(6/45) and 24.4%(11/45) of patients’ sera recognized 
BP180 in human skin and brain, respectively, while 6.7%(3/45) and 15.6%(7/45) of patients’ CSF 
recognized BP180 in human skin and brain, respectively. These findings showed that the prevalence 
of antibodies to BP180 increased in sera and CSF of patients with stroke and dementia as compared 
to controls. This study suggests that development of anti-BP180 autoantibodies in sera and CSF may 
be associated with the elevated prevalence of BP in these neurological diseases.    
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Successful biologic therapy for bullous pemphigoid
KK Yu,1 AB Crew,1 K Messingham,2 JA Fairley2,3 and DT Woodley1,4 1 Dermatology, Keck 
School of Medicine of the University of Southern California, Los Angeles, CA, 2 Dermatology, 
Carver College of Medicine, The University of Iowa, Iowa City, IA, 3 Dermatology, Iowa 
City VA Medical Center, Iowa City, IA and 4 Dermatology, Los Angeles VA Medical Center, 
Los Angeles, CA
Bullous pemphigoid (BP) responds to a variety of immunosuppressive agents that usually control, but 
do not cure, the disease. There is growing evidence that IgE plays a crucial role in the pathogenesis 
of BP. Omalizumab, an FDA-approved monoclonal antibody for the treatment of asthma, selectively 
suppresses the activity of IgE. Therefore, we explored the therapeutic utility of IgE blockade in BP 
patients treated with omalizumab, and followed their disease up to 42 months. In this study, 6 BP 
patients, 3 of whom had failed other forms of therapy, were treated with omalizumab according 
to the asthma dosing nomogram. Five of six BP patients, including all patients who failed other 
therapy, received therapeutic benefit from systemic omalizumab (the sixth terminated treatment 
due to intercurrent illness), with control of their disease, reduced utilization of other immunosup-
pressants, inhibition of new bullae, amelioration of pruritus, and dramatic decrease in eosinophil 
counts. None of the patients had untoward side effects from omalizumab. These results provide 
additional evidence for the importance of IgE in the pathogenesis of BP and expand the therapeutic 
armamentarium against BP.    
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Standardized clinical characterization of the neutrophilic dermatoses in adult-onset auto-
inflammatory syndromes: A key step toward clarifying disease subtypes and response to 
cytokine blockade
MS Fassett,1,2 KS Leslie,1,2 LP Fox,1 K Shinkai,1 MD Rosenblum1 and AK Haemel1 1 
Dermatology, University of California-San Francisco, San Francisco, CA and 2 Dermatology, 
San Francisco General Hospital, San Francisco, CA
The UCSF inpatient dermatology service has recently cared for several patients with severe, recur-
rent adult-onset neutrophilic dermatoses and sterile inflammatory arthritis. These patients manifest 
a constellation of symptoms not well captured by currently-defined autoinflammatory syndromes, 
many of which present in childhood as the result of autosomal dominant constitutive mutations in 
the interleukin-1 signaling pathway. Therefore, we believe this patient population warrants improved 
clinical and biologic description. Three prototypic patients with symptoms of hidradenitis suppu-
rativa, pyoderma gangrenosum and suppurative arthritis will be presented as a lens into this highly 
morbid but poorly-characterized spectrum of disease. Our experience with these patients is that 
they show partial and unpredictable responses to systemic and biologic therapies such as TNF-al-
pha and interleukin-1 blockade. This suggests dysregulation of a complex network of leukocytes 
and pro-inflammatory cytokines, resulting in the neutrophil-mediated inflammation we appreciate 
clinically. Using a larger set of UCSF patients with similar neutrophilic dermatoses, we seek to 
standardize laboratory and radiographic data collection to increase accuracy in clinical description. 
We also aim to utilize flow cytometric immunophenotyping technology available at UCSF to better 
characterize patterns of inflammatory cytokine expression in these patients. We present here our 
preliminary laboratory findings, contextualized against clinical findings and historical response to 
systemic and biologic anti-inflammatory therapy.    
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Bicyclic monoterpene diol blocks keratinocyte proliferation induced by calcitonin gene-re-
lated peptide: Possible implication in skin inflammation
S Rabinovich, C Huan, SA Glick, AR Shalita and W Lee Dermatology, SUNY Downstate 
Medical Center, Brooklyn, NY
Neural calcitonin gene-related peptide (CGRP) has been shown to control local keratinocyte pro-
liferation and play an important role in skin homeostasis. We have previously shown that bicyclic 
monoterpene diol (BMTd) modulates the inflammatory signal pathways, which may contribute to 
its possible anti-pruritic and anti-inflammatory properties. In order to understand the mechanisms 
that are responsible for the cellular proliferative pathways in atopic dermatitis, in this study we 
focus on investigating the effect of CGRP and BMTd on keratinocyte (KC) proliferation. Cells were 
treated with two different concentrations of GCRP, BMTd, and GCRP and BMTd in combination. 
Using immortalized keratinocytes (hTERT), the effect of CGRP and BMTd on cell proliferation was 
studied and measured using WST-8 dye. This dye is bioreduced by cellular dehydrogenases and 
the intensity of the dye is proportional to number of living cells. Therefore this method allows for 
quantification of cell proliferation in culture. As expected, CGRP significantly enhanced prolif-
eration of KCs when compared to cells that received no treatment (p<0.05). Notably, BMTd had 
a dose-dependent negative effect on proliferation (p<0.01). Cells treated with a combination of 
CGRP and BMTd were also protected against proliferation when compared to untreated controls 
(p<0.01). There was nearly a 24-fold decrease in cell growth in the presence of CGRP and BMTd 
when compared to growth following treatment with only CGRP (p<0.01). The effects of CGRP 
and BMTd on cell cycle are currently being explored using flow cytometry. Our data indicates 
that BMTd has a potential protective role against proliferation that can attenuate the proliferative 
effect of CGRP, suggesting a novel mechanism of keratinocyte proliferation that may lead to the 
development of potential therapy.    
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Autoimmune urticaria – An indirect immunofluorescence method
B Bahrani, N Gattey and P Hull University of Saskatchewan, Saskatoon, SK, Canada
Background: An autoimmune basis is responsible for about half of all cases of chronic spontaneous 
urticaria (CSU) with specific IgG antibodies directed at the high affinity receptor sites for IgE on 
the mast cell. We have developed an indirect immunofluorescence method to demonstrate the 
presence of anti-mast cell IgG antibodies using archival skin sections from a patient with severe 
mastocytosis as well as cord-blood derived cultured mast cells. Methods: 76 patients with CSU, 
seen in the Dermatology Department, took part in this study. 34 had a positive autologous serum 
skin test (44.7%). 21 of these patients with severe symptomatic urticaria were currently receiving 
IVIG. Sections were prepared from both the skin sections and from the cultured mast cells. The 
IgGIIa receptor on the mast cells was blocked using an Anti-IgGIIa antibody. The sections were then 
incubated with serum from 76 patients with CSU and fluorescein conjugated anti-human IgG anti-
body used to label patient derived anti-IgE receptor fixed antibody. Results: Using the mastocytosis 
sections, positive indirect immunofluorescence was found in 35 (46.05%) of the patients. There 
was positive indirect immunofluorescence in 17 (50%) patients who had a positive ASST. Positive 
indirect immunofluorescence was found in 41% of patients using the cord-blood derived mast cell 
cytospin slides and in 45% of patients with a positive ASST. 60% of patients receiving IVIG were 
positive using the two substrates. If these patients are excluded then positive immunofluorescence 
was found in 49.09% using the mastocytosis slides and 44% using the cord derived mast cells. 
Conclusion: Anti-mast cell IgG antibodies were detected by indirect immunofluorescence in about 
half of CSU cases examined. Treatment with IVIG probably interfered with this but was positive in 
60% of these patients with debilitating CSU. Indirect immunofluorescence using historical masto-
cytosis pathology sections should be considered a more direct, practical and credible indicator of 
the autoimmune form of CSU. Cord derived mast cells are an alternative substrate but are more 
difficult for routine use.    
   
      
